WO2005070963A1 - Fc region variants - Google Patents
Fc region variants Download PDFInfo
- Publication number
- WO2005070963A1 WO2005070963A1 PCT/US2005/000013 US2005000013W WO2005070963A1 WO 2005070963 A1 WO2005070963 A1 WO 2005070963A1 US 2005000013 W US2005000013 W US 2005000013W WO 2005070963 A1 WO2005070963 A1 WO 2005070963A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- region
- antibody
- variant
- amino acid
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Definitions
- the present invention relates to polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants (e.g. for treating disease).
- IgG, IgM, IgD, IgA, and IgE are distinguished based on the isotypes of the heavy chain gene (gamma, mu, delta, alpha, and epsilon respectively).
- the most common isotype is IgG, and is composed of two identical heavy chain polypeptides and two identical light chain polypeptides (See, Figure 1).
- the two heavy chains are covalently linked to each other by disulfide bonds and each light chain is linked to a heavy chain by a disulfide bond (See, Figure 1).
- Each heavy chain contains approximately 445 amino acid residues, and each light chain contains approximately 215 amino acid residues.
- Each heavy chain contains four distinct domains that are generally referred to as variable domain (NH), constant heavy domain 1 (CHI), constant heavy domain 2 (CH2), and constant heavy domain 3 (CH3) (See, Figure 1).
- the CHI and CH2 domains are joined by a hinge region (inter-domain sections) that provides the Ig with flexibility.
- Each light chain contains two distinct domains that are generally referred to as the variable light (NL) and the constant light (CL).
- the variable regions of the heavy and light chains directly bind antigen and are responsible for the diversity and specificity of Igs.
- Each NL and NH has three complementarity-determining regions (CDRs, also l ⁇ iown as hyper variable regions).
- the CDRs When the NL and NH come together through interactions of the heavy and light chain, the CDRs form a binding surface that contacts the antigen. While the variable regions are involved in antigen binding, the heavy chain constant domains, primarily CH2 and CH3, are involved in non-antigen binding functions. This region, generally known as the Fc region, has many important functions. For example, the Fc region binds complement, which may trigger phagocytosis or complement dependent cytotoxicity (CDC). The Fc region also binds Fc receptors, which may trigger phagocytosis or antibody dependent cellular cytotoxicity (ADCC). The Fc region also plays a role in helping to maintain the immunoglobulin in circulation and interacts with protein A, which is commonly used to purify immunoglobulin.
- complement which may trigger phagocytosis or complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- the Fc region also binds Fc receptors, which may trigger phagocytosis or antibody dependent cellular cytotoxicity (
- the present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants, and portions thereof. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants. In some embodiments, the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 247 in the Fc region.
- ADCC antibody-dependent cell- mediated cytotoxicity
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is P247L.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 251 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is L25 IF.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 256 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is T256M.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 268 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is H268E.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 280 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is D280A.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 330 in the Fc region.
- the variant comprises an antibody (e.g. a anti- CD20 antibody).
- the amino acid modification is A330K.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 332 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is I332E.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 339 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is A339T.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates depletion of target cells (e.g. B cells) in a whole blood assay more effectively than the parent polypeptide and comprises at least one amino acid modification at position 378 in the Fc region.
- the variant comprises an antibody (e.g. an anti-CD20 antibody).
- the amino acid modification is A378D.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 440 in the Fc region.
- the variant comprises an antibody (e.g. an anti- CD20 antibody).
- the amino acid modification is S440Y.
- the present invention provides a peptide (containing the P247L amino acid modification) comprising the sequence shown in SEQ ID NO: 15.
- the present invention provides a nucleic acid sequence encoding a CH2 region with the P247L modification (e.g. SEQ ID NO:40). In some embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the P247L modification comprising SEQ ID NO: 15. In certain embodiments, the present invention provides a peptide (containing the L251F modification) with the sequence shown in SEQ ID NO: 16. In additional embodiments, the present invention provides a nucleic acid sequence encoding a CH2 region with the L251F modification (e.g. SEQ ID NO:41). In additional embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the L251F modification comprising SEQ ID NO: 16. In some embodiments, the present invention provides a peptide (containing the
- the present invention provides a nucleic acid sequence encoding a CH2 region with the T256M modification (e.g. SEQ ID NO:42). In some embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the T256M modification comprising SEQ ID NO: 17. In certain embodiments, the present invention provides a peptide (containing the H268E modification) comprising the sequence shown in SEQ ID NO:20. In additional embodiments, the present invention provides a nucleic acid sequence encoding a CH2 region with the H268E modification (e.g. SEQ ID NO:45).
- the present invention provides an amino acid sequence encoding a CH2 region with the H268E modification comprising SEQ ID NO:20.
- the present invention provides a peptide (containing the D280A amino acid modification) comprising the sequence shown in SEQ ID NO:21.
- the present invention provides a nucleic acid sequence encoding a CH2 region with the D280A modification (e.g. SEQ ID NO:46).
- the present invention provides an amino acid sequence encoding a CH2 region with the D280A modification comprising SEQ ID NO:21.
- the present invention provides a peptide (containing the A33 OK modification) comprising the sequence shown in SEQ ID NO:23.
- the present invention provides a nucleic acid sequence encoding a CH2 region with the A33 OK modification (e.g. SEQ ID NO:48). In additional embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the A33 OK modification comprising SEQ ID NO:23. In some embodiments, the present invention provides a peptide (containing the I332E amino acid modification) comprising the sequence shown in SEQ ID NO:26. In other embodiments, the present invention provides a nucleic acid sequence encoding a CH2 region with the I332E modification (e.g. SEQ ID NO:51).
- the present invention provides an amino acid sequence encoding a CH2 region with the I332E modification comprising SEQ ID NO:26. In certain embodiments, the present invention provides a peptide (containing the A339T modification) comprising the sequence showin in SEQ ID NO:29. In additional embodiments, the present invention provides a nucleic acid sequence encoding a CH2 region with the A339T modification (e.g. SEQ ID NO:54). In additional embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the A339T modification comprising SEQ ID NO:29. In some embodiments, the present invention provides a peptide (containing the
- the present invention provides a nucleic acid sequence encoding a CH2 region with the A378D modification (e.g. SEQ ID NO:55). In some embodiments, the present invention provides an amino acid sequence encoding a CH2 region with the S440Y modification comprising SEQ ID NO:30. In some embodiments, the present invention provides a peptide (containing the S440Y amino acid modification) comprising the sequence showin in SEQ ID NO: 31. In other embodiments, the present invention provides a nucleic acid sequence encoding a CH2 region with the S440Y modification (e.g. SEQ ID NO:56).
- the present invention provides an amino acid sequence encoding a CH2 region with the S440Y modification comprising SEQ ID NO:31.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 247 in the Fc region selected from P247H, P247I and P247L.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 251 in the Fc region selected from L251F.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 256 in the Fc region selected from T256M and T256P.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 268 in the Fc region selected from H268D and H268E.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 280 in the Fc region selected from D280A and D280K.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 330 in the Fc region selected from A33 OK and A33 OR.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 332 in the Fc region selected from 1332D and I332E.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 339 in the Fc region selected from A339T. In other embodiments, the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 378 in the Fc region selected from A378D.
- the present invention provides compositions comprising a variant (or a nucleic acid sequence encoding the variant) of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification at position 440 in the Fc region selected from S440Y.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 247 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 247 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%, 60%, 80%j or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 13.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 14.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 15.
- compositions comprise a nucleic acid sequence comprising SEQ ID NO:38 and/or SEQ ID NO:39 and or SEQ ID NO: 40 or the complement thereof, or sequences that bind to SEQ ID NOs:38, 39, or 40 under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:38 and/or SEQ ID NO:39 and or SEQ ID NO: 40.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO:13, 14, 15, 38, 39, or 40.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOS:l-12.
- the amino acid modification is P247H, P247I, or P247L.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 251 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 251 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%, 60%, 80%, or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 16.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:41 or the complement thereof, or sequences that bind to SEQ ID NO:41 and under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:41.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO: 16 or 41.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 1-12.
- the amino acid modification is L251F.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 256 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 256 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%, 60%, 80%, or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 17.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 18.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:42 and/or SEQ ID NO:43, or the complement thereof, or sequences that bind to SEQ ID NOs:42 or 43 under conditions of high stringency.
- the present invention provides host cells (e.g.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO:17, 18, 42, or 43.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs: 1-12.
- the amino acid modification is T256M or T256P.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 268 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 268 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%, 60%, 80%, or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 19.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:20.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:44 and/or SEQ ID NO:45, or the complement thereof, or sequences that bind to SEQ ID NOs:44 or 45 under conditions of high stringency.
- the present invention provides host cells (e.g.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO: 19, 20, 44, or 45.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells less effectively than the parent polypeptide and comprises at least one amino acid modification at position 332 in the Fc region.
- the at least one amino acid modification is I332K or I332R.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is H268D or H268E.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 280 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 280 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%o, 50%, 60%, 80%, or 90%) or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:21.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:22.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:46 and/or SEQ ID NO:47, or the complement thereof, or sequences that bind to SEQ ID NOs:46 and 47 under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:46 and/or SEQ ID NO:47.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO:21, 22, 46 and 47.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is D280A or D280K.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 330 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 330 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%), 60%, 80%, or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO: 23.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:24.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:48 and/or SEQ ID NO:49, or the complement thereof, or sequences that bind to SEQ ID NOs:48 or 49 under conditions of high stringency.
- the present invention provides host cells (e.g.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NOs:23, 24, 48 and 49.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is A33 OK or A33 OR.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 332 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 332 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region (e.g. 40%, 50%, 60%, 80%, or 90% or more of an Fc region containing the amino acid modification).
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:25.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:26.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:50 and/or SEQ ID NO:51, or the complement thereof, or sequences that bind to SEQ ID NOs:50 or 51 under conditions of high stringency.
- the present invention provides host cells (e.g.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NO:25, 26, 50, and 51.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is I332D or I332E.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 339 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 339 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:29.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:54, or the complement thereof, or sequences that bind to SEQ ID NO:54 under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:54.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NOs:29 or 54.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is A339T.
- the polypeptide variant comprises a second third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates the depletion of target cells in a whole blood assay more effectively than the parent polypeptide and comprises at least one amino acid modification at position 378 in the Fc region.
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates the depletion of target cells in a whole blood assay more effectively than the parent polypeptide and comprises at least one amino acid modification at position 378 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:30.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO:55, or the complement thereof, or sequences that bind to SEQ ID NO: 55 under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:55.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NOs:30 or 55.
- the polypeptide variant mediates mediates the depletion of target cells in a whole blood assay more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is A378D.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- the present invention provides compositions comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 440 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the present invention provides methods comprising; a) providing; i) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide and comprises at least one amino acid modification at position 440 in the Fc region, and ii) a subject with one or more symptoms of a disease; and b) administering the composition to the subject under conditions such that at least one of the symptoms is reduced.
- the variant comprises an antibody or immunoadhesin, and the subject has symptoms of an antibody or immunoadhesin responsive disease.
- the variant comprises at least a portion of the Fc region
- the polypeptide variants comprise a CH2 or CH3 region.
- the compositions comprise an amino acid sequence comprising SEQ ID NO:31.
- the compositions comprise a nucleic acid sequence comprising SEQ ID NO: 56, or the complement thereof, or sequences that bind to SEQ ID NO:56 under conditions of high stringency.
- the present invention provides host cells (e.g. CHO cells), and vectors comprising SEQ ID NO:56.
- the present invention provides a computer readable medium, wherein the computer readable medium encodes a representation of SEQ ID NOs:31 or 56.
- the polypeptide variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide.
- the polypeptide variant comprises an antibody or antibody fragment (e.g., polyclonal antibody, monoclonal antibody, chimeric antibody, humanized antibody, or Fc fragment).
- the parent polypeptide comprises a human IgG Fc region.
- the parent polypeptide comprises a human IgGl, IgG2, IgG3, or IgG4 Fc region.
- the parent polypeptide comprises an amino acid sequence selected from SEQ ID NOs:l-12.
- the amino acid modification is S440Y.
- the polypeptide variant comprises a second, third, fourth, etc. amino acid modification in the Fc region (see, e.g. Table 1).
- the variant is a CHO-expressed polypeptide.
- compositions comprise a nucleic acid sequence encoding a variant of a parent polypeptide comprising at least a portion of an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively that the parent polypeptide, and comprises at least one amino acid modification at position 247, 251, 256, 268, 280, 330, 332, 339, 378, or 440, or combinations thereof in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- compositions comprise a nucleic acid sequence encoding a variant Fc polypeptide which mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells more effectively than the parent polypeptide, wherein the variant Fc polypeptide comprises an amino acid modification at amino acid position 247, 251, 256, 268, 280, 330, 332, 339, 378, or 440, or combinations thereof.
- ADCC antibody-dependent cell-mediated cytotoxicity
- compositions comprise a nucleic acid sequence encoding a variant of a parent polypeptide comprising at least a portion of an Fc region, wherein the variant mediates the depletion of target cells in a whole blood assay more effectively than the parent polypeptide, and comprises at least one amino acid modification at position 247, 251, 256, 268, 280, 330, 332, 339, 378, or 440, or combinations thereof in the Fc region.
- the compositions comprise a nucleic acid sequence encoding a variant Fc polypeptide which mediates the depletion of target cells in a whole blood assay more effectively than the parent polypeptide, wherein the variant Fc polypeptide comprises an amino acid modification at amino acid position 247, 251, 256, 268, 280, 330, 332, 339, 378, or 440, or combinations thereof.
- the variants of the present invention, and the nucleic acid sequences encoding the variants are provided with at least one other component in a kit.
- a kit may comprise at least one type of variant, and written instructions for using the variant.
- the kit may also contain buffers, and other useful reagents.
- the present invention provides methods comprising, a) providing; i) cells expressing target antigen (CD20, for eg.), ii) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification in the Fc region, and iii) effector cells (enriched PBMCs from human donor(s), for example), and b) contacting the target cells with the composition and effector cells under conditions such that the variant binds to the target cells (e.g. via a ligand expressed on the cell surface) and c) measuring killing of the target cells (release of LDH or chromium 51, for example).
- target antigen CD20, for eg.
- a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification in the Fc region, and iii) effector cells (enriched PBMCs from human donor(s
- the present invention provides methods comprising, a) providing; i) whole blood samples containing cells expressing target antigen (B cells expressing CD20, for e.g.) and ii) a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification in the Fc region and b) contacting the target cells with the composition under conditions such that the variant binds to the target cells (e.g. via the CD20 ligand expressed on the cell surface) and c) measuring the disappearance of the target cells (Facs analysis with other B cell marker, such as CD 19, for example).
- B cells expressing CD20 for e.g.
- a composition comprising a variant of a parent polypeptide having at least a portion of an Fc region, wherein the variant comprises at least one amino acid modification in the Fc region
- the present invention provides methods of identifying dual- species improved variants, comprising; a) providing; i) target cells, ii) a composition comprising a candidate variant of a parent polypeptide having an Fc region, wherein the candidate variant comprises at least one amino acid modification in the Fc region, and wherein the candidate variant mediates target cell cytotoxicity in the presence of a first species of effector cells more effectively than the parent polypeptide, and iii) second species effector cells, and b) incubating the composition with the target cells under conditions such that the candidate variant binds the target cells thereby generating candidate variant bound target cells, c) mixing the second species effector cells with the candidate variant bound target cells, d) measuring target cell cytotoxicity (e.g.
- the method further comprises screening the parent polypeptide in the same fashion with the second species effector cells.
- steps b) and c) are performed simultaneously.
- the method further comprises step f) identifying a candidate variant as a dual-species improved variant that mediates target cell cytotoxicity in the presence of the second species effector cells more effectively than the parent polypeptide.
- the method further comprises step f) identifying a candidate variant as a dual-species improved variant that mediates target cell cytotoxicity in the presence of the second species effector cells about 1.2 times (or about 1.5 times, 5 times, or about 10 times) more effectively than the parent polypeptide (e.g. about 1.2 times more target cell lysis is observed).
- the present invention provides methods of identifying dual- species improved variants, comprising; a) providing; i) target cells, ii) a composition comprising a candidate variant of a parent polypeptide having an Fc region, wherein the candidate variant comprises at least one amino acid modification in the Fc region, iii) first species effector cells, and iv) second species effector cells, and b) incubating the composition with the target cells under conditions such that the candidate variant binds the target cells thereby generating candidate variant bound target cells, c) mixing the first species effector cells with the candidate variant bound target cells, d) measuring target cell cytotoxicity (e.g.
- the method further comprises a step to determine the ability of the parent polypeptide to mediate target cell cytotoxicity in the presence of the first species and/or the second species.
- the methods may further comprise mixing the first or second species effector cells with parent polypeptide bound target cells, and then measuring target cell cytotoxicity (e.g. determining a value such that there is a value to compare the variants against).
- the method further comprises step g) administering the dual-species improved variant to a test animal, wherein the test animal is a member of the second species.
- the method further comprises, prior to step a), a step of screening the candidate variant in an Fc receptor (FcR) binding assay.
- the FcR binding assay is an Fc neonatal receptor (FcRn) binding assay.
- the method further comprises, prior to step a), a step of screening the candidate variant in a CDC assay (See, e.g., section IN below).
- the first species of effector cells are human peripheral blood mononuclear cells (PBMCs).
- the first species of effector cells are mouse PBMCs or rat PBMCs.
- the second species of effector cells are mouse PBMCs or rat PBMCs.
- the second species of effector cells are human PBMCs.
- the present invention provides methods of identifying dual- species improved variants, comprising; a) providing; i) a composition comprising a candidate variant of a parent polypeptide having an Fc region, wherein the candidate variant comprises at least one amino acid modification in the Fc region, and wherein the candidate variant mediates CDC more effectively than the parent polypeptide, and iii) a second species source of complement, and b) incubating the composition with the second species of complement; and c) determining if the candidate variant mediates CDC more effectively than the parent polypeptide.
- the method further comprises step d) identifying a candidate variant as a dual-species improved variant.
- the target cells are human cells (e.g.
- the variant comprises an antibody, or portion thereof, specific for the target cells.
- the candidate variant mediates target cell cytoxicity in the presence of the first species of effector cells about 1.2 times more effectively than the parent polypeptide.
- step e) comprises performing a control reaction with the parent polypeptide.
- the measxiring comprises quantitating target cell death or target cell lysis.
- the target cells infected with viruses e.g. HIN, CMN, hepatitis B, or RSN, for example
- viruses e.g. HIN, CMN, hepatitis B, or RSN, for example
- microbial organisms e.g. Staphylococcus, Streptococcus, Pseudomonas, etc
- the target cells are microbial organisms (e.g. Staphylococcus, Streptococcus, Pseudomonas, etc).
- the target cells are replaced instead with viruses (e.g. HIN, CMN, hepatitis B, or RSN).
- the present invention provides compositions comprising a CD20 binding molecule, or a nucleic acid sequence encoding a CD20 binding molecule, wherein the CD20 binding molecule comprises a light chain variable region, and wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:57.
- the present invention provides compositions composition comprising a CD20 binding molecule, or a nucleic acid sequence encoding a CD20 binding molecule, wherein the CD20 binding molecule comprises a heavy chain variable region, and wherein the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO:58.
- the present invention provides compositions comprising a CD20 binding molecule, or a nucleic acid sequence encoding a CD20 binding molecule (See, e.g. Figure 16), wherein the CD20 binding molecule comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the amino acid sequence shown in SEQ ID NO:57 (See Figure 15), and wherein the heavy chain variable regin comprises the amino acid sequence shown in SEQ ID NO:58 (See Figure 15).
- the present invention provides compositions comprising a polypeptide, wherein the polypeptide comprises; i) an unmodified human framework (e.g. no alterations have been made to a naturally occurring human framework), and ii) a variant Fc region.
- the unmodified human framework is a human germline framework.
- the present invention provides compositions comprising a polypeptide, wherein the polypeptide comprises: i) at least one randomized CDR sequence and ii) a variant Fc region.
- the present invention provides compositions comprising a polypeptide, wherein the polypeptide comprises; i) an unmodified human framework (e.g. human germline framework), ii) at least one randomized CDR sequence, and iii) a variant Fc region.
- Figure 1 shows a schematic representation of an IgG molecule with the various regions and sections labeled.
- Figure 2 shows an alignment of various parental Fc amino acid sequences, including human IgGl (with non-a (SEQ ID NO:l) and a allotypes shown), human IgG2 (SEQ ID NO:2), human IgG3 (SEQ ID NO:3), human IgG4 (SEQ ID NO:4), murine IgGl (SEQ ID NO:5), murine IgG2A (SEQ ID NO:6), murine IgG2B (SEQ ID NO:7), and murine IgG3 (SEQ ID NO:8).
- human IgGl with non-a (SEQ ID NO:l) and a allotypes shown
- human IgG2 SEQ ID NO:2
- human IgG3 SEQ ID NO:3
- human IgG4 SEQ ID NO:4
- murine IgGl SEQ ID NO:5
- Figure 3 shows various amino acid sequences, including the CH2 region (SEQ ID NO:9), and CH3 region (SEQ ID NO:10) of human IgGl , as well as an f allotype (SEQ ID NO:l 1) and a, z allotype (SEQ ID NO: 12) sequences of human IgGl that include the CHI, hinge, CH2 and CH3 regions.
- Figure 4 shows the altered amino acid sequences of the variants in the context of local surrounding sequences.
- Figure 5 shows nucleotide sequences encoding parental polypeptides.
- Figure 6 shows the altered nucleic acid sequences of the variants in the context of local surrounding nucleic acid sequences.
- Figure 7A shows the results of an ADCC assay comparing the wild type Fc region with A330K, A330R, I332E and the combination of mutations at both positions 330 and 332.
- Figure 7B shows the results of an ADCC assay comparing the Fc region amino acid variants I332D and I332E to the Fc region glycan modification variant 33 (GnTIII) and the effect of amino acid plus glycan modification 33 (I332E + GnTIII) on ADCC activity.
- Figure 8 shows representative ADCC data obtained using purified variant IgG.
- Figure 9 shows ADCC activities of variable region variants with low affinity (6F1) and relatively high affinity (33 and 5) to CD20 antigen against Wil-2 (A) or SKW6.4 (B) target cell lines.
- Figure 10 shows the titration curves of Fc ⁇ RI binding to Fc-region variant IgG.
- Figure 11A, B, and C show representative CDC data obtained from titration of Fc- region variants using human complement and Ramos target cells.
- Figure 12 shows representative B cell depletion with AME-133 (variable region 33 with the I332E Fc variant sequence), Rituxan, and non-specific IgG using a whole blood sample containing the W (high affinity) genotype of the Fc ⁇ RIIIa receptor.
- Figure 13 shows representative B cell depletion with AME-133 (variable region 33 with the I332E Fc variant sequence), Rituxan, and non-specific IgG using a whole blood sample containing the FF (low affinity) genotype of the Fc ⁇ RIIIa receptor.
- Figure 14 shows representative B cell depletion with Rituxan, non-specific IgG and with variants A378D and T256P, I332E using a whole blood sample.
- Figure 15 shows the amino acid sequence of the light (SEQ ID NO: 57) and the heavy (SEQ ID NO:58) chains of AME-133 (variable region 33 with the I332E Fc variant sequence).
- Figure 16 shows the nucleotide sequence of the light (SEQ ID NO:59) and the heavy (SEQ ID NO:60) chains of AME-133 (variable region 33 with the I332E Fc variant sequence).
- the terms “subject” and “patient” refer to any animal, such as a mammal like a dog, cat, bird, livestock, and preferably a human (e.g. a human with a disease).
- the terms “nucleic acid molecule encoding,” “DNA sequence encoding,” and “DNA encoding” refer to the order or sequence of deoxyribonucleotides along a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along the polypeptide (protein) chain. The DNA sequence thus codes for the amino acid sequence.
- DNA molecules are said to have "5* ends” and "3' ends” because mononucleotides are reacted to make oligonucleotides or polynucleotides in a manner such that the 5' phosphate of one mononucleotide pentose ring is attached to the 3' oxygen of its neighbor in one direction via a phosphodiester linkage.
- an end of an oligonucleotides or polynucleoti.de referred to as the "5' end” if its 5' phosphate is not linked to the 3' oxygen of a mononucleotide pentose ring and as the "3' end” if its 3' oxygen is not linked to a 5' phosphate of a subsequent mononucleotide pentose ring.
- a nucleic acid sequence even if internal to a larger oligonucleotide or polynucleotide., also may be said to have 5' and 3' ends.
- an oligonucleotide having a nucleotide sequence encoding a polypeptide means a nucleic acid sequence comprising the coding region of a particular polypeptide.
- the coding region may be present in a cDNA, genomic DNA, or RNA form.
- the oligonucleotide or polynucleotide may be single-stranded (i.e., the sense strand) or double-stranded.
- Suitable control elements such as enhancers/promoters, splice junctions, polyadenylation signals, etc. may be placed in close proximity to the coding region of the gene if needed to permit proper initiation of transcription and/or correct processing of the primary RNA transcript.
- the coding region utilized in the expression vectors of the present invention may contain endogenous enhancers/promoters, splice junctions, intervening sequences, polyadenylation signals, etc. or a combination of both endogenous and exogenous control elements.
- the terms "complementary” or “complementarity” are used in reference to polynucleotides (i.e., a sequence of nucleotides) related by the base-pairing rules.
- the sequence “A-G-T” is complementary to the sequence “T-C- A.”
- Complementarity may be “partial,” in which only some of the nucleic acids' bases are matched according to the base pairing rules. Or, there may be “complete” or “total” complementarity between the nucleic acids.
- the degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, as well as detection methods that depend upon binding between nucleic acids.
- the term "the complement of a given sequence is used in reference to the sequence that is completely complementary to the sequence over its entire length.
- sequence A-G-T-A is "the complement" of the sequence T-C-A-T.
- homology refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity).
- a partially complementary sequence is one that at least partially inhibits a completely complementary sequence from hybridizing to a target nucleic acid and is referred to using the functional term "substantially homologous.”
- inhibitor of binding when used in reference to nucleic acid binding, refers to inhibition of binding caused by competition of homologous sequences for binding to a target sequence.
- the inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or Northern blot, solution hybridization and the like) under conditions of low stringency.
- a substantially homologous sequence or probe will compete for and inhibit the binding (i.e., the hybridization) of a completely homologous sequence to a target under conditions of * low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction.
- the absence of non-specific binding may be tested by the use of a second target that lacks even a partial degree of complementarity (e.g., less than about 30%) identity); in the absence of non-specific binding the probe will not hybridize to the second non-complementary target.
- a partial degree of complementarity e.g., less than about 30%
- low stringency conditions factors such as the length and nature (DNA, RJSIA, base composition) of the probe and nature of the target (DNA, RNA, base composition, present in solution or immobilized, etc.) and the concentration of the salts and other components (e.g., the presence or absence of formamide, dextran sulfate, polyethylene glycol) are considered and the hybridization solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the above listed conditions.
- conditions that promote hybridization under conditions of high stringency e.g., increasing the temperature of the hybridization and/or wash steps, the use of formamide in the hybridization solution, etc.).
- a nucleic acid sequence may produce multiple RNA species that are generated by differential splicing of the primary RNA transcript.
- cDNAs that are splice variants of the same gene will contain regions of sequence identity or complete homology (representing the presence of the same exon or portion of the same exon on both cDNAs) and regions of complete non-identity (for example, representing the presence of exon "A” on cDNA 1 wherein cDNA 2 contains exon "B" instead).
- the two cDNAs contain regions of sequence identity they will both hybridize to a probe derived from the entire gene or portions of the gene containing sequences found on both cDNAs; the two splice variants are therefore substantially homologous to such a probe and to each other.
- substantially homologous refers to any probe that can hybridize (i.e., it is the complement of) the single-stranded nucleic acid sequence under conditions of low stringency.
- hybridization is used in reference to the pairing of complementary nucleic acids. Hybridization and the strength of hybridization (i.e. , the strength of the association between the nucleic acids) is impacted by such factors as the degree of complementary between the nucleic acids, stringency of the conditions involved, the T m of the formed hybrid, and the G:C ratio within the nucleic acids.
- T m is used in reference to the "melting temperature.”
- the melting temperature is the temperature at which a population of double-stranded nucleic acid molecules becomes half dissociated into single strands.
- T m 81.5 + 0.41 (% G + C), when a nucleic acid is in aqueous solution at 1 M NaCl (See e.g., Anderson and Young, Quantitative Filter Hybridization, in Nucleic Acid Hybridization [1985]).
- Other references include more sophisticated computations that take structural as well as sequence characteristics into account for the calculation of T m , and in some cases the T m may be determined empirically by beginning with the calculated T m ⁇ testing small increases or decreases of temperature and examining the effect on the population of nucleic acid molecules.
- stringency is used in reference to the conditions of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted.
- stringency conditions may be altered by varying the parameters just described either individually or in concert.
- “high stringency” conditions nucleic acid base pairing will occur only between nucleic acid fragments that have a high frequency of complementary base sequences (e.g., hybridization under "high stringency” conditions may occur between homologs with about 85-100%) identity, preferably about 70-100%) identity).
- “medium stringency” conditions nucleic acid base pairing will occur between nucleic acids with an intermediate frequency of complementary base sequences (e.g., hybridization under "medium stringency” conditions may occur between homologs with about 50-70% identity).
- “High stringency conditions” when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42 °C in a solution consisting of 5X SSPE (43.8 g/1 NaCl, 6.9 g/1 NaH 2 PO 4 H 2 O and 1.85 g/1 EDTA, pH adjusted to 7.4 with NaOH), 0.5% SDS, 5X Denhardt's reagent and 100 ⁇ g/ml denatured salmon sperm DNA followed by washing in a solution comprising 0.1X SSPE, 1.0% SDS at 42 C when a probe of about 500 nucleotides in length is employed.
- “Medium stringency conditions” when used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/1 NaCl, 6.9 g/1 NaH2PO4 H2O and 1.85 g/1
- Low stringency conditions comprise conditions equivalent to binding or hybridization at 42°C in a solution consisting of 5X SSPE (43.8 g/1 NaCl, 6.9 g/1 NaH 2 PO H 2 O and 1.85 g/1 EDTA, pH adjusted to 7.4 with NaOH), 0.1 % SDS, 5X
- Denhardt's reagent [50X Denhardt's contains per 500 ml: 5 g Ficoll (Type 400, Pharmacia), 5 g BSA (Fraction V; Sigma)] and 100 g/ml denatured salmon sperm DNA followed by washing in a solution comprising 5X SSPE, 0.1% SDS at 42 C when a probe of about 500 nucleotides in length is employed.
- the following terms are used to describe the sequence relationships between two or more polynucleotides: "reference sequence”, “sequence identity”, and “percentage of sequence identity”.
- a "reference sequence” is a defined sequence used as a basis for a sequence comparison; a reference sequence may be a subset of a larger sequence, for example, as a segment of a full-length cDNA sequence given in a sequence listing or may comprise a complete gene sequence. Generally, a reference sequence is at least 20 nucleotides in length, frequently at least 25 nucleotides in length, and often at least 50 nucleotides in length (e.g.any one of SEQ ID NOs: 32-37 may be used as a reference sequence).
- two polynucleotides may each (1) comprise a sequence (i.e., a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) may further comprise a sequence that is divergent between the two polynucleotides
- sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local regions of sequence similarity.
- a “comparison window”, as used herein, refers to a conceptual segment of at least 20 contiguous nucleotide positions wherein a polynucleotide sequence may be compared to a reference sequence of at least 20 contiguous nucleotides and wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) of 20 percent or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences.
- Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman [Smith and Waterman, Adv. Appl. Math.
- sequence identity means that two polynucleotide sequences are identical (i. e. , on a nucleotide-by-nucleotide basis) over the window of comparison.
- percentage of sequence identity is calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity.
- the window of comparison is the entire length of the recited reference sequence (i.e. if SEQ ID NO:33 is recited as the reference sequence, percentage of sequence identity is compared over the entire length of SEQ ID NO:33).
- the term "probe” refers to an oligonucleotide (i.e., a sequence of nucleotides), whether occurring naturally as in a purified restriction digest or produced synthetically, recombinantly or by PCR amplification, that is capable of hybridizing to another oligonucleotide of interest.
- a probe may be single-stranded or double-stranded. Probes are useful in the detection, identification and isolation of particular gene sequences.
- any probe used in the present invention may be labeled with any "reporter molecule,” so that is detectable in any detection system, including, but not limited to enzyme (e.g., ELISA, as well as enzyme-based histochemical assays), fluorescent, radioactive, and luminescent systems. It is not intended that the present invention be limited to any particular detection system or label.
- PCR polymerase chain reaction
- This process for amplifying the target sequence consists of introducing a large excess of two oligonucleotide primers to the DNA mixture containing the desired target sequence, followed by a precise sequence of thermal cycling in the presence of a DNA polymerase.
- the two primers are complementary to their respective strands of the double stranded target sequence.
- the mixture is denatured and the primers then annealed to their complementary sequences within the target molecule.
- the primers are extended with a polymerase so as to form a new pair of complementary strands.
- the steps of denaturation, primer annealing, and polymerase extension can be repeated many times (i.e., denaturation, annealing and extension constitute one "cycle”; there can be numerous “cycles”) to obtain a high concentration of an amplified segment of the desired target sequence.
- the length of the amplified segment of the desired target sequence is determined by the relative positions of the primers with respect to each other, and therefore, this length is a controllable parameter.
- the method is referred to as the “polymerase chain reaction” (hereinafter "PCR”).
- the desired amplified segments of the target sequence become the predominant sequences (in terms of concentration) in the mixture, they are said to be "PCR amplified.”
- PCR it is possible to amplify a single copy of a specific target sequence in genomic DNA to a level detectable by several different methodologies (e.g., hybridization with a labeled probe; incorporation of biotinylated primers followed by avidin-enzyme conjugate detection; incorporation of 32p_i a beled deoxynucleotide triphosphates, such as dCTP or dATP, into the amplified segment).
- any oligonucleotide or polynucleotide sequence can be amplified with the appropriate set of primer molecules.
- isolated when used in relation to a nucleic acid, as in “an isolated oligonucleotide” or “isolated polynucleotide” refers to a nucleic acid sequence that is identified and separated from at least one contaminant nucleic acid with which it is ordinarily associated in its natural source. Isolated nucleic acid is present in a form or setting that is different from that in which it is found in nature. Isolated nucleic acid molecules therefore are distinguished from the nucleic acid molecule as it exists in natural cells.
- an isolated nucleic acid molecule includes a nucleic acid molecule contained in cells that ordinarily express the polypeptide where, for example, the nucleic acid molecule is in a chromosomal location different from that of natural cells.
- the isolated nucleic acid, oligonucleotide, or polynucleotide may be present in single-stranded or double-stranded form.
- oligonucleotide or polynucleotide When an isolated nucleic acid, oligonucleotide or polynucleotide is to be utilized to express a protein, the oligonucleotide or polynucleotide will contain at a minimum the sense or coding strand (i.e., the oligonucleotide or polynucleotide may single-stranded), but may contain both the sense and anti-sense strands (i.e., the oligonucleotide or polynucleotide may be double-stranded).
- portion when used in reference to a nucleotide sequence (as in "a portion of a given nucleotide sequence") refers to fragments of that sequence.
- the fragments may range in size from ten nucleotides to the entire nucleotide sequence minus one nucleotide (e.g., 10 nucleotides, 20, 30, 40, 50, 100, 200, etc.).
- portion when in reference to an amino acid sequence (as in "a portion of a given amino acid sequence") refers to fragments of that sequence.
- the fragments may range in size from six amino acids to the entire amino acid sequence minus one amino acid (e.g., 6 amino acids, 10, 20, 30, 40, 75, 200, etc.).
- purified or “to purify” refers to the removal of contaminants from a sample.
- antigen specific antibodies may be purified by removal of contaminating non-immunoglobulin proteins; they are also purified by the removal of immunoglobulin that does not bind to the same antigen.
- the removal of non- immunoglobulin proteins and/or the removal of immunoglobulins that do not bind a particular antigen results in an increase in the percent of antigen specific immunoglobulins in the sample.
- recombinant antigen specific polypeptides are expressed in bacterial host cells and the polypeptides are purified by the removal of host cell proteins; the percent of recombinant antigen specific polypeptides is thereby increased in the sample.
- recombinant DNA molecule refers to a DNA molecule that is comprised of segments of DNA joined together by means of molecular biological techniques.
- recombinant protein or “recombinant polypeptide” as used herein refers to a protein molecule that is expressed from a recombinant DNA molecule.
- native protein as used herein to indicate that a protein does not contain amino acid residues encoded by vector sequences; that is the native protein contains only those amino acids found in the protein as it commonly occurs in nature.
- a native protein may be produced by recombinant means or may be isolated from a naturally occurring source.
- Southern blot refers to the analysis of DNA on agarose or acrylamide gels to fractionate the DNA according to size followed by transfer of the DNA from the gel to a solid support, such as nitrocellulose or a nylon membrane.
- the immobilized , DNA is then probed with a labeled probe to detect DNA species complementary to the probe used.
- the DNA may be cleaved with restriction enzymes prior to electrophoresis. Following electrophoresis, the DNA may be partially depurinated and denatured prior to or during transfer to the solid support.
- Southern blots are a standard tool of molecular biologists (J.
- Northern blot refers to the analysis of RNA by electrophoresis of RNA on agarose gels to fractionate the RNA according to size followed by transfer of the RNA from the gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized RNA is then probed with a labeled probe to detect RNA species complementary to the probe used.
- Northern blots are a standard tool of molecular biologists (J. Sambrook, et al, supra, pp 7.39-7.52 [1989]).
- the term “Western blot” refers to the analysis of protein(s) (or polypeptides) immobilized onto a support such as nitrocellulose or a membrane.
- the proteins are run on acrylamide gels to separate the proteins, followed by transfer of the protein from the gel to a solid support, such as nitrocellulose or a nylon membrane.
- the immobilized proteins are then exposed to antibodies with reactivity against an antigen of interest.
- the binding of the antibodies may be detected by various methods, including the use of radiolabelled antibodies.
- antigenic determinant refers to that portion of an antigen that makes contact with a particular antibody (i. e., an epitope).
- antigenic determinants When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies that bind specifically to a given region or three- dimensional structure on the protein; these regions or structures are referred to as antigenic determinants.
- An antigenic determinant may compete with the intact antigen (i.e., the "immunogen” used to elicit the immune response) for binding to an antibody.
- the term "transgene” as used herein refers to a foreign, heterologous, or autologous gene that is placed into an organism by introducing the gene into newly fertilized eggs or early embryos.
- foreign gene refers to any nucleic acid (e.g., gene sequence) that is introduced into the genome of an animal by experimental manipulations and may include gene sequences found in that animal so long as the introduced gene does not reside in the same location as does the naturally-occurring gene.
- autologous gene is intended to encompass variants (e.g., polymorphisms or mutants) of the naturally occurring gene.
- transgene thus encompasses the replacement of the naturally occurring gene with a variant form of the gene.
- vector is used in reference to nucleic acid molecules that transfer DNA segment(s) from one cell to another.
- vector refers to a recombinant DNA molecule containing a desired coding sequence and appropriate nucleic acid sequences necessary for the expression of the operably linked coding sequence in a particular host organism. Nucleic acid sequences necessary for expression in prokaryotes usually include a promoter, an operator (optional), and a ribosome binding site, often along with other sequences. Eukaryotic cells are known to utilize promoters, enhancers, and termination and polyadenylation signals.
- host cell refers to any eukaryotic or prokaryotic cell
- transfection refers to the introduction of foreign DNA into cells (e.g. eukaryotic and prokaryotic cells).
- Transfection may be accomplished by a variety of means known to the art including calcium phosphate-DNA co-precipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics.
- stable transfection or "stably transfected” refers to the introduction and integration of foreign DNA into the genome of the transfected cell.
- stable transfectant refers to a cell that has stably integrated foreign DNA into the genomic DNA.
- transient transfection or “transiently transfected” refers to the introduction of foreign DNA into a cell where the foreign DNA fails to integrate into the genome of the transfected cell.
- the foreign DNA persists in the nucleus of the transfected cell for several days. During this time the foreign DNA is subject to the regulatory controls that govern the expression of endogenous genes in the chromosomes.
- transient transfectant refers to cells that have taken up foreign DNA but may have failed to integrate this DNA.
- calcium phosphate co-precipitation refers to a technique for the introduction of nucleic acids into a cell.
- composition comprising a given polynucleotide sequence refers broadly to any composition containing the given polynucleotide sequence.
- the composition may comprise an aqueous solution.
- Compositions comprising polynucleotide sequences encoding, for example, a variant Fc region or fragments thereof may be employed as hybridization probes.
- variant Fc region encoding polynucleotide sequences are typically employed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).
- salts e.g., NaCl
- detergents e.g., SDS
- other components e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.
- Test compound or “candidate compound” refer to any chemical entity, pharmaceutical, drug, and the like that can be used to treat or prevent a disease, illness, sickness, or disorder of bodily function, or otherwise alter the physiological or cellular status of a sample.
- Test compounds comprise both known and potential therapeutic compounds.
- a test compound can be determined to be therapeutic by screening using the screening methods of the present invention.
- a "known therapeutic compound” refers to a therapeutic compound that has been shown (e.g., through animal trials or prior experience with administration to humans) to be effective in such treatment or prevention.
- the term "response,” when used in reference to an assay refers to the generation of a detectable signal (e.g., accumulation of reporter protein, increase in ion concentration, accumulation of a detectable chemical product).
- the term "reporter gene” refers to a gene encoding a protein that may be assayed. Examples of reporter genes include, but are not limited to, luciferase (See, e.g., deWet et al, Mol. Cell. Biol. 7:725 [1987] and U.S.
- green fluorescent protein e.g., GenBank Accession Number U43284; a number of GFP variants are commercially available from CLONTECH Laboratories, Palo Alto, CA
- chloramphemcol acetyltransferase e.g., GenBank Accession Number U43284; a number of GFP variants are commercially available from CLONTECH Laboratories, Palo Alto, CA
- chloramphemcol acetyltransferase e.g., GenBank Accession Number U43284; a number of GFP variants are commercially available from CLONTECH Laboratories, Palo Alto, CA
- chloramphemcol acetyltransferase e.g., GenBank Accession Number U43284; a number of GFP variants are commercially available from CLONTECH Laboratories, Palo Alto, CA
- chloramphemcol acetyltransferase e.g., GenBank Accession Number U43284; a number
- computer readable medium refers to any device or system for storing and providing information (e.g., data and instructions) to a computer processor. Examples of computer readable media include, but are not limited to, DVDs, CDs, hard disk drives, magnetic tape and servers for streaming media over networks.
- computer readable medium encodes a representation" of a nucleic acid or amino acid sequence refers to computer readable medium that has stored thereon information, that when delivered to a processor, allows the sequence of the nucleic or amino acid sequence to be displayed to a user (e.g. printed out or presented on a display screen).
- processor and “central processing unit” or “CPU” are used interchangeably and refer to a device that is able to read a program from a computer memory (e.g. , ROM or other computer memory) and perform a set of steps according to the program.
- a computer memory e.g. , ROM or other computer memory
- EU index format refers to the residue numbering of the human IgGl EU antibody.
- a "parent polypeptide” is a polypeptide comprising an amino acid sequence that may be changed or altered (e.g. an amino acid substitution, addition or deletion is made) to produce a variant.
- the parent polypeptide comprises at least a portion of a naturally occurring Fc region or an Fc region with amino acid sequence modifications (e.g., additions, deletions, and/or substitutions).
- variants that are shorter or longer than the parent polypeptide are specifically contemplated.
- the parent polypeptide differs in function (e.g. effector function, binding, etc.) as compared to a variant.
- the term "variant of a parent polypeptide” refers to a peptide comprising an amino acid sequence that differs from that of the parent polypeptide by at least one amino acid modification.
- the variant comprises at least a portion of an Fc region (e.g. at least 40%, 50%, 75%, or 90% or an Fc region).
- the variant comprises an Fc region of a parent polypeptide with at least one amino acid modification.
- the term "Fc region” refers to a C-terminal region of an immunoglobulin heavy chain (e.g., as shown in Figure 1).
- the "Fc region” may be a native sequence Fc region or a variant Fc region.
- the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
- variants comprise only portions of the Fc region and can include or not include the carboxyl-terminus.
- the Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3, as shown, for example, in Figure 1.
- variants having one or more of the constant domains are contemplated.
- variants without such constant domains (or with only portions of such constant domains) are contemplated.
- the "CH2 domain” (also referred to as"C ⁇ 2"domain) generally comprises the stretch of residues that extends from about amino acid 231 to about amino acid 340 in an Fc region (e.g. in the human IgG Fc region).
- the CH2 domain is unique in that it is not closely paired with another domain. Rather, two N-linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule.
- the "CH3 domain” (also referred to as"C ⁇ 3 "domain) generally comprises the stretch of residues C-terminal to a CH2 domain in an Fc region (e.g., from about amino acid residue 341 to about amino acid residue 447 of a human IgG Fc region).
- an Fc region may possess "effector functions" that are responsible for activating or diminishing a biological activity (e.g. in a subject). Examples of effector functions include, but are not limited to: Clq binding; complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g., B cell receptor; BCR), etc.
- Such effector functions may require the Fc region to be combined with a binding domain (e.g. an antibody variable domain) and can be assessed using various assays (e.g. Fc binding assay, ADCC assays, CDC assays, target cell depletion from whole or fractionated blood samples, etc.).
- a binding domain e.g. an antibody variable domain
- assays e.g. Fc binding assay, ADCC assays, CDC assays, target cell depletion from whole or fractionated blood samples, etc.
- wild type Fc region refers to an amino acid sequence that is identical to the amino acid sequence of an Fc region commonly found in nature.
- Exemplary native sequence human Fc regions are shown in Figure 2 and include a native sequence human IgGl Fc region (f and a,z allotypes); native sequence human IgG2 Fc region; native sequence human IgG3 Fc region; and native sequence human IgG4 Fc region as well as naturally occurring variants thereof.
- Native sequence murine Fc regions are also shown in Figure 2.
- Other sequences are contemplated and are readily obtained from various web sites (e.g., NCBI's web site).
- variant Fc region refers to amino acid sequence that differs from that of a native sequence Fc region (or portions thereof) by virtue of at least one amino acid modification (e.g., substitution, insertion, or deletion), including heterodimeric variants in which the heavy chain subunit sequences may differ from one another.
- the variant Fc region has at least one amino acid substitution compared to a native sequence Fc region (e.g. from about one to about ten amino acid substitutions, and preferably from about one to about five amino acid substitutions in a native sequence Fc region).
- variant Fc regions will possess at least about 80% homology with a native sequence Fc region, preferably at least about 90% homology, and more preferably at least about 95% homology.
- the term “homology”, when used in reference to amino acid sequences, refers to the percentage of residues in an amino acid sequence variant that are identical with the native amino acid sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology.
- the term “Fc region-containing polypeptide” refers to a polypeptide, such as an antibody or immunoadhesin (see definitions below), which comprises an Fc region.
- the terms "Fc receptor” and “FcR” are used to describe a receptor that binds to an Fc region.
- Fc region e.g. the Fc region of an antibody or antibody fragment.
- the term includes the neonatal receptor, FcRn, which is responsible for the transfer of maternal IgGs to the fetus.
- ADCC antibody-dependent cell-mediated cytotoxicity
- cytotoxic cells e.g. nonspecific
- FcRs e.g. Natural Killer (NK) cells, neutrophils, and macrophages
- NK cells Natural Killer
- monocytes express Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII.
- effector cells refers to leukocytes which express one or more FcRs and perform effector functions.
- the cells express at least Fc ⁇ RJII and perform an ADCC effector function.
- leukocytes which mediate ADCC include peripheral blood mononuclear cells (PBMC), natural killer (NK) cells, monocytes, cytotoxic T cells and neutrophils.
- PBMC peripheral blood mononuclear cells
- NK natural killer
- monocytes cytotoxic T cells and neutrophils.
- the effector cells may be isolated from a native source (e.g. from blood).
- the phrase “whole blood” refers to unfractionated blood samples.
- a polypeptide variant with "altered" FcR binding affinity or ADCC activity is one which has either enhanced (i.e. increased) or diminished (i.e.
- a polypeptide variant which "displays increased binding" to an FcR binds at least one FcR with better affinity than the parent polypeptide.
- a polypeptide variant which "displays decreased binding" to an FcR binds at least one FcR with worse affinity than a parent polypeptide.
- Such variants which display decreased binding to an FcR may possess little or no appreciable binding to an FcR, e.g., 0-20% binding to the FcR compared to a parent polypeptide.
- a polypeptide variant which binds an FcR with "better affinity" than a parent polypeptide is one which binds any one or more of the above identified FcRs with higher binding affinity than the parent antibody, when the amounts of polypeptide variant and parent polypeptide in a binding assay are essentially the same, and all other conditions are identical.
- a polypeptide variant with improved FcR binding affinity may display from about 1.10 fold to about 100 fold (more typically from about 1.2 fold to about 50 fold) improvement (i.e. increase) in FcR binding affinity compared to the parent polypeptide, where FcR binding affinity is detemvined, for example, in an ELISA assay.
- amino acid modification refers to a change in the amino acid sequence of a given amino acid sequence.
- exemplary modifications include, but are not limited to, an amino acid substitution, insertion and/or deletion.
- the amino acid modification is a substitution (e.g. in an Fc region of a parent polypeptide).
- amino acid modification at a specified position (e.g. in the Fc region) refers to the substitution or deletion of the specified residue, or the insertion of at least one amino acid residue adjacent the specified residue.
- insertion "adjacent" a specified residue is meant insertion within one to two residues thereof. The insertion may be N-terminal or C-terminal to the specified residue.
- amino acid substitution refers to the replacement of at least one existing amino acid residue in a given amino acid sequence with another different “replacement” amino acid residue.
- the replacement residue or residues may be "naturally occurring amino acid residues" (i.e.
- alanine (Ala); arginine (Arg); asparagine (Asn); aspartic acid (Asp); cysteine (Cys); glutamine (Gin); glutamic acid (Glu); glycine (Gly); histidine (His); isoleucine (He): leucine (Leu); lysine (Lys); methionine (Met); phenylalanine (Phe); proline (Pro); serine (Ser); threonine (Thr); tryptophan (Trp); tyrosine (Tyr); and valine (Val).
- non-naturally occurring amino acid residue refers to a residue, other than those naturally occurring amino acid residues listed above, which is able to covalently bind adjacent amino acid residues (s) in a polypeptide chain.
- non-naturally occurring amino acid residues include norleucine, omithine, norvaline, homoserine and other amino acid residue analogues such as those described in Ellman et al. Meth. Enzym. 202: 301-336 (1991), herein incorporated by reference.
- amino acid insertion refers to the incorporation of at least one amino acid into a given amino acid sequence.
- an insertion will usually be the insertion of one or two amino acid residues.
- the insertion includes larger peptide insertions (e.g. insertion of about three to about five or even up to about ten amino acid residues.
- amino acid deletion refers to the removal of at least one amino acid residue from a given amino acid sequence.
- assay signal refers to the output from any method of detecting protein- protein interactions, including but not limited to, absorbance measurements from colorimetric assays, fluorescent intensity, or disintegrations per minute.
- Assay formats could include ELISA, facs, or other methods.
- a change in the "assay signal” may reflect a change in cell viability and/or a change in the ldnetic off-rate, the kinetic on-rate, or both.
- a “higher assay signal” refers to the measured output number being larger than another number (e.g. a variant may have a higher (larger) measured number in an ELISA assay as compared to the parent polypeptide).
- a “lower” assay signal refers to the measured ouput number being smaller than another number (e.g. a variant may have a lower (smaller) measured number in an ELISA assay as compared to the parent polypeptide).
- binding affinity refers to the equilibrium dissociation constant (expressed in units of concentration) associated with each Fc receptor-Fc binding interaction.
- the binding affinity is directly related to the ratio of the kinetic off-rate (generally reported in units of inverse time, e.g. seconds "1 ) divided by the kinetic on-rate (generally reported in units of concentration per unit time, e.g. molar /second).
- kinetic off-rate generally reported in units of inverse time, e.g. seconds "1 ) divided by the kinetic on-rate (generally reported in units of concentration per unit time, e.g. molar /second).
- the term "hinge region” refers to the stretch of amino acids in human IgGl stretching from Glu216 to Pro230 of human IgGl. Hinge regions of other IgG isotypes may be aligned with the IgGl sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions.
- the term “lower hinge region” of an Fc region refers to the stretch of amino acid residues immediately C-terminal to the hinge region (e.g. residues 233 to 239 of the Fc region of IgGl).
- Clq is a polypeptide that includes a binding site for the Fc region of an immunoglobulin.
- antibody is used in the broadest sense and specifically covers monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired biological activity.
- antibody fragments refers to a portion of an intact antibody. Examples of antibody fragments include, but are not limited to, linear antibodies; single-chain antibody molecules; Fc or Fc' peptides, Fab and Fab fragments, and multispecific antibodies formed from antibody fragments.
- the antibody fragments preferably retain at least part of the hinge and optionally the CHI region of an IgG heavy chain. In other preferred embodiments, the antibody fragments comprise at least a portion of the CH2 region or the entire CH2 region.
- the term "functional fragment" when used in reference to a monoclonal antibody is intended to refer to a portion of the monoclonal antibody that still retains a functional activity.
- a functional activity can be, for example, antigen binding activity or specificity.
- Monoclonal antibody functional fragments include, for example, individual heavy or light chains and fragments thereof, such as NL, NH and Fd; monovalent fragments, such as Fv, Fab, and Fab'; bivalent fragments such as F(ab') ; single chain Fv (scFv); and Fc fragments.
- monovalent fragments such as Fv, Fab, and Fab'
- bivalent fragments such as F(ab') ; single chain Fv (scFv); and Fc fragments.
- humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
- donor antibody such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity.
- Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
- humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are generally made to further refine antibody performance.
- the humamzed antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a nonhuman immunoglobulin and all or substantially all of the FR residues are those of a human immunoglobulin sequence.
- the humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Pat. 5,225,539 to Winter et al. (herein incorporated by reference).
- the term "hypervariable region" refers to the amino acid residues of an antibody which are responsible for antigen-binding.
- the hypervariable region comprises amino acid residues from a "complementarity determining region" or "CDR" (i.e. residues 24-34 (LI), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (HI), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD. (1991)) and/or those residues from a "hypervariable loop" (i.e.
- immunoadhesin designates antibody-like molecules which combine the binding domain of a heterologous "adhesin” protein (e.g. a receptor, ligand or enzyme) with an immunoglobulin constant domain.
- a heterologous "adhesin” protein e.g. a receptor, ligand or enzyme
- immunoadhesins comprise a fusion of the adhesin amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site (antigen combining site) of an antibody (i.e. is "heterologous") with an immunoglobulin constant domain sequence.
- ligand binding domain refers to any native receptor or any region or derivative thereof retaining at least a qualitative ligand binding ability of a corresponding native receptor.
- the receptor is from a cell-surface polypeptide having an extracellular domain that is homologous to a member of the immunoglobulin supergenefamily.
- receptors which are not members of the immunoglobulin supergenefamily but are nonetheless specifically covered by this definition, are receptors for cytokines, and in particular receptors with tyrosine kinase activity (receptor tyrosine kinases), members of the hematopoietin and nerve growth factor receptor superfamilies, and cell adhesion molecules (e.g. E-, L-, and P- selectins).
- receptor binding domain refers to any native ligand for a receptor, including cell adhesion molecules, or any region or derivative of such native ligand retaining at least a qualitative receptor binding ability of a corresponding native ligand.
- antibody-immunoadhesin chimera comprises a molecule that combines at least one binding domain of an antibody with at least one immunoadhesin.
- examples include, but are not limited to, the bispecific CD4-IgG chimeras described in Berg et al., PNAS (USA) 88:4723-4727 (1991) and Charnow et al, J. Immunol., 153:4268 (1994), both of which are hereby incorporated by reference.
- an "isolated" polypeptide is one that has been identified and separated and/or recovered from a component of its natural environment.
- the isolated polypeptide is purified (1) to greater than 95% by weight of polypeptides as determined by the Lowry method, and preferably, more than 99% by weight, (2) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (3) to homogeneity by SDS-page under reducing or nonreducing conditions using Coomassie blue, or silver stain.
- Isolated polypeptide includes the polypeptide in situ within recombinant cells since at least one component of the polypeptide's natural environment will not be present. Ordinarily, however, isolated polypeptide will be prepared by a least one purification step.
- treatment refers to both therapeutic treatment and prophylactic or preventative measures. Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented.
- disorder refers to any condition that would benefit from treatment with a polypeptide variant, including chronic and acute disorders or diseases (e.g. pathological conditions that predispose a patient to a particular disorder). In certain embodiments, the disorder is cancer.
- cancer and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia.
- cancers include squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung, squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney cancer, liver cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma and various types of head and neck cancer.
- the phrase "HER2-expressing cancer” is one comprising cells which have HER2 receptor protein (e.g., Genebank accession number X03363) present at their cell surface, such that an anti-HER2 antibody is able to bind to the cancer.
- the term "label” refers to a detectable compound or composition that is conjugated directly or indirectly to a polypeptide.
- the label may itself be detectable (e.g., radioisotope labels or fluorescent labels) or, in the case of an enzymatic label, may catalyze chemical alteration of a substrate compound or composition which is detectable.
- control element refers to a genetic element that controls some aspect of the expression of nucleic acid sequences.
- a promoter is a regulatory element that facilitates the initiation of transcription of an operably linked coding region.
- Other regulatory elements include splicing signals, polyadenylation signals, termination signals, etc.
- Control elements that are suitable for prokaryotes include a promoter, optionally an operator sequence, and a ribosome binding site.
- Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
- nucleic acid is "operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
- "operably linked" means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading frame. However enhancers, for example, do not have to be contiguous. Linking may be accomplished, for example, by ligation at convenient restriction sites.
- oligonucleotide adaptors or linkers may be used in accordance with conventional practice.
- the expressions "cell,” “cell line,” and “cell culture” are used interchangeably and all such designations include progeny.
- the words “transformants” and “transformed cells” include the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content due to deliberate or inadvertent mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. Where distinct designations are intended, it will be clear from the context.
- analyte refers to a substance that is to be analyzed.
- the preferred analyte is an Fc region containing polypeptide that is to be analyzed for its ability to bind to an Fc receptor.
- the term “receptor” refers to a polypeptide capable of binding at least one ligand.
- the preferred receptor is a cell-surface or soluble receptor having an extracellular ligand-binding domain and, optionally, other domains (e.g. transmembrane domain, intracellular domain and/or membrane anchor).
- a receptor to be evaluated in an assay described herein may be an intact receptor or a fragment or derivative thereof (e.g.
- a fusion protein comprising the binding domain of the receptor fused to one or more heterologous polypeptides).
- the receptor to be evaluated for its binding properties may be present in a cell or isolated and optionally coated on an assay plate or some other solid phase or labeled directly and used as a probe.
- the phrase "CHO-expressed polypeptide” refers to a polypeptide that has been recombinantly expressed in Chinese Hamster Ovary (CHO) cells.
- antibody responsive disease refers to any disease or medical condition that is shown to be treatable, at least in part, with antibody therapy.
- diseases and medical conditions include, but are not limited to, lymphoma (shown to be treatable with RITUXAN), infectious disease (shown to be treatable with SYNAGIS), kidney transplant (ZENAPAX has shown to be helpful), Crohn's disease and rheumatoid arthritis (shown to be treatable with REMICADE), breast carcinoma (shown to be treatable with HERCEPTIN), and colon cancer (shown to be treatable with EDRECOLOMAB).
- infectious disease shown to be treatable with SYNAGIS
- kidney transplant ZENAPAX has shown to be helpful
- Crohn's disease and rheumatoid arthritis shown to be treatable with REMICADE
- breast carcinoma shown to be treatable with HERCEPTIN
- colon cancer shown to be treatable with EDRECOLOMAB
- immunoadhesin responsive disease refers to any disease or medical condition that is shown to be treatable, at least in part, with immunoadhesin therapy.
- a polypeptide variant that "mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of human effector cells more effectively" than a parent antibody is one which in vitro or in vivo is substantially more effective at mediating ADCC, when the amounts of polypeptide variant and parent antibody used in the assay are essentially the same.
- ADCC antibody-dependent cell- mediated cytotoxicity
- Such a variant causes a higher amount of target cell lysis in a given ADCC assay than the parent polypeptide in an identical ADCC assay.
- Such variants may be identified, for example, using an ADCC assay, but other assays or methods for determining ADCC activity may also be employed (e.g. animal models).
- the polypeptide variant is from about 1.2 fold, 1.5 fold, 50 fold, 100 fold, about 500 fold, or about 1000 fold more effective at mediating ADCC than the parent polypeptide.
- a polypeptide variant that "mediates antibody-dependent B cell depletion from whole blood more effectively" than a parent antibody is one which in vitro or in vivo is substantially more effective at mediating depleting B cells, when the amounts of polypeptide variant and parent antibody used in the assay are essentially the same. For example, such a variant causes a higher degree of B cell depletion in a given assay than the parent polypeptide in an identical assay.
- such a variant may deplete B cells to the same extent but at lower concentrations than are required of the parent polypeptide in an identical assay.
- Such variants may be identified, for example, using an ADCC assay, but other assays or methods for determining ADCC activity may also be employed (e.g. animal models).
- the enhancement in depletion relative to the parent polypeptide is independent of the genotype of the FcRJIIa genotype at position 158 (V or F) and the FcRIIa genotype at position 131 (H or R), and the polypeptide variant is from about 1.2 fold, 1.5 fold, 50 fold, 100 fold, about 500 fold, or about 1000 fold more effective at mediating B cell depletion than the parent polypeptide.
- symptoms of an antibody or immunoadhesin responsive disease refers to those symptoms generally associated with a particular disease.
- the symptoms normally associated with Crohn's disease include: abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, dehydration, anemia, distention, fibrosis, inflamed intestines and malnutrition.
- the phrase "under conditions such that the symptoms are reduced” refers to any degree of qualitative or quantitative reduction in detectable symptoms of any antibody or immunoadhesin responsive disease, including but not limited to, a detectable impact on the rate of recovery from disease (e.g.
- the rate of weight gain or the reduction of at least one of the symptoms normally associated with the particular disease (e.g., if the antibody or immunoadhesin responsive disease were Crohn's disease, a reduction in at least one of the following symptoms: abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, dehydration, anemia, distention, fibrosis, inflamed intestines and malnutrition).
- the antibody or immunoadhesin responsive disease were Crohn's disease, a reduction in at least one of the following symptoms: abdominal pain, diarrhea, rectal bleeding, weight loss, fever, loss of appetite, dehydration, anemia, distention, fibrosis, inflamed intestines and malnutrition).
- the present invention provides polypeptide Fc region variants and oligonucleotides encoding Fc region variants. Specifically, the present invention provides compositions comprising novel Fc region variants, methods for identifying useful Fc region variants, and methods for employing Fc region variants for treating disease.
- Antibody Fc Regions As described above, antibodies have regions, primarily the CH2 and CH3 regions, that are involved in non-antigen binding functions. Together, these regions are generally known as the Fc region, and have several effector functions mediated by binding of effector molecules.
- the effector functions mediated by the antibody Fc region can be divided into two categories: (1) effector functions that operate after the binding of antibody to an antigen (these functions involve, for example, the participation of the complement cascade or Fc receptor (FcR)-bearing cells); and (2) effector functions that operate independently of antigen binding (these functions confer, for example, persistence in the circulation and the ability to be transferred across cellular barriers by transcytosis). For example, binding of the CI component of complement to antibodies activates the complement system.
- Fc receptor Fc receptor
- IgG gamma receptors
- IgE eta receptors
- IgA alpha receptors
- IgM mu receptors
- Fc receptors Fc receptors
- ADCC antibody-dependent cell-mediated cytotoxicity
- FcRs are defined by their specificity for immunoglobulin isotypes; Fc receptors for IgG antibodies are referred to as Fc ⁇ R, for IgE as Fc ⁇ R, for IgA as Fc ⁇ R and so on. Three subclasses of Fc ⁇ R have been identified: Fc ⁇ RI (CD64), Fc ⁇ RII (CD32) and Fc ⁇ RIII (CD16). Because each Fc ⁇ R subclass is encoded by two or three genes, and alternative RNA spicing leads to multiple transcripts, a broad diversity in Fc ⁇ R isoforms exists.
- the three genes encoding the Fc ⁇ RI subclass are clustered in region lq21.1 of the long arm of chromosome 1; the genes encoding Fc ⁇ RII isoforms (Fc ⁇ RIIA, Fc ⁇ RIIB and Fc ⁇ RIIC) and the two genes encoding Fc ⁇ RIII (Fc ⁇ RIIIA and Fc ⁇ RIIIB) are all clustered in region lq22.
- Fc ⁇ RII Fc ⁇ RIIA, Fc ⁇ RIIB and Fc ⁇ RIIC
- Fc ⁇ RIIIA and Fc ⁇ RIIIB are all clustered in region lq22.
- Fc ⁇ RIIIB is found only on neutrophils
- Fc ⁇ RIIIA is found on macrophages, monocytes, natural killer (NK) cells, and a subpopulation of T-cells.
- Fc ⁇ RIIIA is present on NK cells, one of the cell types implicated in ADCC.
- Human Fc ⁇ RIIIA (CD 16) receptor has a common polymorphism at position 158 in its extracellular domain encoding either a phenylalanine or valine at this position.
- the V allele of Fc ⁇ RIIIA has higher affinity to human IgGl than the F allele.
- the VI 58 allele also mediates ADCC more efficiently.
- a genetic polymorphism is also present in human Fc ⁇ RIIA (CD32) receptor at position 131 in its extracellular domain encoding either a histidine (H) or arginine (R) at this position.
- the polymorphism at position 131 has been found to affect its ability to bind to human IgG.
- Recent data also show a correlation between the Fc ⁇ RIIA position 131 polymorphism and clinical response to Rituxan. Patients homozygous for the HI 31 allele had a significantly higher response rate than the other 2 groups.
- Fc ⁇ RI, Fc ⁇ RII and Fc ⁇ RIII are immunoglobulin superfamily (IgSF) receptors; Fc ⁇ RI has three IgSF domains in its extracellular domain, while Fc ⁇ RII and Fc ⁇ RIII have only two IgSF domains in their extracellular domains.
- Another type of Fc receptor is the neonatal Fc receptor (FcRn).
- FcRn is structurally similar to major histocompatibility complex (MHC) and consists of an ⁇ - chain noncovalently bound to ⁇ 2-microglobulin.
- the present invention provides polypeptide variants, nucleic acid sequences encoding the polypeptide variants, and methods for generating polypeptide variants.
- the polypeptide variants of the present invention differ from a parent polypeptide by at least one amino acid modification.
- the "parent”, “wild type”, “starting” or “nonvariant” polypeptide preferably comprises at least a portion of an antibody Fc region, and may be prepared using techniques available in the art for generating polypeptides comprising an Fc region or portion thereof.
- the parent polypeptide is an antibody.
- the parent polypeptide may, however, be any other polypeptide comprising at least a portion of an Fc region (e.g.
- a variant Fc region may be generated (e.g. according to the methods disclosed herein) and can be fused to a heterologous polypeptide of choice, such as an antibody variable domain or binding domain of a receptor or ligand.
- the parent polypeptide comprises an Fc region or functional portion thereof.
- the Fc region of the parent polypeptide will comprise a native sequence Fc region, and preferably a human native sequence Fc region.
- the Fc region of the parent polypeptide may have one or more pre-existing amino acid sequence alterations or modifications from a native sequence Fc region.
- the Clq binding activity of the Fc region may have been previously altered or the Fc ⁇ R binding affinity of the Fc region may have been altered.
- the parent polypeptide Fc region is conceptual (e.g. mental thought or a visual representation on a computer or on paper) and, while it does not physically exist, the antibody engineer may decide upon a desired variant Fc region amino acid sequence and generate a polypeptide comprising that sequence or a DNA encoding the desired variant Fc region amino acid sequence.
- a nucleic acid encoding an Fc region of a parent polypeptide is available and this nucleic acid sequence is altered to generate a variant nucleic acid sequence encoding the Fc region variant.
- Nucleic acid encoding a variant of the parent polypeptide may be prepared by methods known in the art using the guidance of the present specification for particular sequences. These methods include, but are not limited to, preparation by site-directed (or oligonucleotide-mediated) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared nucleic acid encoding the polypeptide. Site-directed mutagenesis is a preferred method for preparing variants. This technique is well known in the art (see, e.g., Carter et al. Nucleic Acids Res. 13: 4431-4443 (1985) and Kunkel et. al., Proc. Natl. Acad. Sci.
- the starting DNA is altered by first simultaneously hybridizing one or multiple oligonucleotide(s) encoding the desired mutation(s) to a single strand of such starting DNA. After hybridization, a DNA polymerase is used to synthesize an entire second strand, using the hybridized oligonucleotide(s) as a primer, and using the single strand of the starting DNA as a template and a DNA ligase is used to ligate the second strand to form a circular, double- stranded DNA.
- oligonucleotide encoding the desired mutation is incorporated in the resulting double-stranded DNA.
- PCR mutagenesis is also suitable for making amino acid sequence variants of the starting polypeptide (see, e.g., Vallette et al., Nuc. Acids Res. 17: 723-733 (1989), hereby incorporated by reference).
- primers that differ slightly in sequence from the corresponding region in a template DNA can be used to generate relatively large quantities of a specific DNA fragment that differs from the template sequence only at the positions where the primers differ from the template.
- the starting material is the plasmid (or other vector) comprising the starting polypeptide DNA to be mutated.
- the codon(s) in the starting DNA to be mutated are identified.
- the plasmid DNA is cut at these sites to linearize it.
- a double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures, wherein the two strands of the oligonucleotide are synthesized separately and then hybridized together using standard techniques.
- This double-stranded oligonucleotide is referred to as the cassette.
- This cassette is designed to have 5' and 3' ends that are compatible with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid.
- This plasmid now contains the mutated DNA sequence.
- the desired amino acid sequence encoding a polypeptide variant can be determined, and a nucleic acid sequence encoding such amino acid sequence variant can be generated synthetically.
- the amino acid sequence of the parent polypeptide may be modified in order to generate a variant Fc region with altered Fc receptor binding affinity or activity in vitro and/or in vivo and/or altered antibody-dependent cell-mediated cytotoxicity (ADCC) activity in vitro and/or in vivo.
- the amino acid sequence of the parent polypeptide may also be modified in order to generate a variant Fc region with altered complement binding properties and/or circulation half-life.
- Substantial modifications in the biological properties of the Fc region may be accomplished by selecting substitutions that differ significantly in their effect on altering (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site, or the bulk of the side chain, (d) interaction with carbohydrate, or (e) flexibility of domain movement.
- Naturally occurring residues are divided into classes based on common side-chain properties: (1) hydrophobic: norleucine, met, ala, val, leu, ile; (2) neutral hydrophilic: cys, ser, thr; (3) acidic: asp, glu; (4) basic: asn, gin, his, lys, arg; (5) residues that influence chain orientation: gly, pro; and (6) aromatic: trp, tyr, phe.
- Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.
- Conservative substitutions will entail exchanging a member of one of these classes for another member of the same class.
- one can engineer an Fc region variant with altered activity effector function(s) and pharmacokinetics).
- a modification comprises one or more of the Fc region residues identified herein (See, e.g, Example 2, and WO0042072, herein incorporated by reference for all purposes).
- no more than one to about ten Fc region residues will be deleted or substituted.
- the Fc regions herein comprising one or more amino acid modifications will preferably retain at least about 80%), and preferably at least about 90%, and most preferably at least about 95%, of the parent Fc region sequence or of a native sequence human Fc region.
- Fc region variants may display enhanced or diminished FcR binding and/or ADCC activity relative to the partent molecule.
- one may evaluate a co-crystal structure of a polypeptide comprising a binding region of an FcR (e.g. the extracellular domain of the FcR of interest) and the Fc region into which the amino acid residue(s) are to be inserted (see, e.g., Sondermann et al.
- a variant Fc region which (a) mediates antibody-dependent cell- mediated cytotoxicity (ADCC) in the presence of human effector cells more or less effectively and/or (b) mediates complement-dependent cytotoxicity (CDC) in the presence of human complement more or less effectively and/or (c) binds an Fc gamma receptor (Fc ⁇ R) or Fc neonatal receptor (FcRn) with the desired affinity at different pHs than the parent polypeptide.
- ADCC antibody-dependent cell- mediated cytotoxicity
- CDC complement-dependent cytotoxicity
- Fc ⁇ R Fc gamma receptor
- FcRn Fc neonatal receptor
- Such Fc region variants will generally comprise at least one amino acid modification in the Fc region.
- the parent polypeptide Fc region is a human Fc region, e.g.
- the parent polypeptide in order to generate an Fc region with improved ADCC activity, preferably has pre-existing ADCC activity (e.g., the parent polypeptide comprises a human IgGl or human IgG3 Fc region).
- a variant with improved ADCC mediates ADCC substantially more effectively than an antibody with a native sequence IgGl or IgG3 Fc region (e.g. P247L and I332E variants).
- amino acid modification(s) are introduced into the CH2 and/or CH3 domains of a Fc region.
- Useful amino acid positions for modification in order to generate a variant IgG Fc region with altered ADCC activity include any one or more of amino acid positions: 247, 251, 256, 268, 269, 270, 272, 276, 278, 280, 283, 285, 286, 289, 290, 292, 293, 294, 295, 296, 298, 300 301, 303, 305, 307, 309, 330, 331, 332, 333, 334, 335, 337, 338, 339, 340, 360, 373, 376, 416, 419, 430, 434, 435, 437, 438 ,439, or 440 of the Fc region.
- the parent Fc region used as the .
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 247 in the Fc region.
- the amino acid modification is P247L.
- the amino acid modification is P247I or P247H
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 251 in the Fc region.
- the amino acid modification is L251F.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 256 in the Fc region.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the amino acid modification isT256M or T256P.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 268 in the Fc region.
- the amino acid modification is H268D or H268E.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 280 in the Fc region.
- the amino acid modification is D280A or D280K.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 330 in the Fc region.
- the amino acid modification is A33 OK or A33 OR.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 332 in the Fc region.
- the amino acid modification is I332D, I332E, I332K, or I332R.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 339 in the Fc region.
- the amino acid modification is A339T.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 378 in the Fc region.
- the amino acid modification is A378D.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant mediates antibody-dependent cell-mediated cytotoxicity (ADCC) in the presence of effector cells, and comprises at least one amino acid modification at position 440 in the Fc region.
- the amino acid modification is S440Y.
- polypeptide variants described above may be subjected to further modifications, depending on the desired or intended use of the polypeptide.
- modifications may involve, for example, further alteration of the amino acid sequence (substitution, insertion and/or deletion of amino acid residues), carbohydrate modifications, fusion to heterologous polypeptide(s) and/or covalent modifications.
- Such further modifications may be made prior to, simultaneously with, or following, the amino acid modification(s) disclosed above which result in an alteration of Fc receptor binding and/or ADCC activity.
- the starting polypeptide of particular interest herein is one that binds to Clq and displays complement dependent cytotoxicity (CDC).
- Amino acid substitutions described herein may serve to alter the ability of the starting polypeptide to bind to Clq and/or modify its complement dependent cytotoxicity function (e.g. to reduce and preferably abolish these effector functions).
- polypeptides comprising substitutions at one or more of the described positions with improved Clq binding and/or complement dependent cytotoxicity (CDC) function are contemplated herein.
- the starting polypeptide may be unable to bind Clq and/or mediate CDC and may be modified according to the teachings herein such that it acquires these further effector functions.
- polypeptides with pre-existing Clq binding activity may be modified such that one or both of these activities are enhanced.
- Amino acid modifications that alter Clq and/or modify its complement dependent cytotoxicity function are described, for example, in WO0042072, which is hereby incorporated by reference.
- one can design an Fc region or portion thereof with altered effector function e.g., by modifying CDC activity and/or ADCC activity.
- glycosylation sites that are not present in the polypeptide.
- this may be achieved indirectly, by altering amino acids other than the glycosylation site or by engineering the cells.
- Glycosylation of polypeptides is typically either N-linked or O-linked.
- N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue.
- the peptide sequences asparagine-X-serine and asparagine-X-threonine, where X is any amino acid except proline, are the recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain.
- O-linked glycosylation refers to the attachment of one of the sugars N- aceylgalactosamine, galactose, or xylose to a hydroxyamino acid, most commonly serine or threonine, although 5-hydroxyproline or 5-hydroxylysine may also be used.
- Addition of glycosylation sites to the polypeptide is conveniently accomplished by altering the amino acid sequence such that it contains one or more of the above-described tripeptide sequences (for N-linked glycosylation sites).
- the alteration may also be made by the addition of, or substitution by, one or more serine or threonine residues to the sequence of the original polypeptide (for O-linked glycosylation sites).
- An exemplary glycosylation variant has an amino acid substitution of residue Asn 297 of the heavy chain.
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant comprises at least one surface residue amino acid modification (See, e.g., Deisenhofer, Biochemistry, 28;20(9):2361-70, April 1981, and WO0042072, both of which are hereby incorporated by reference).
- the present invention provides compositions comprising a variant of a parent polypeptide having an Fc region, wherein the variant comprises at least one non-surface residue amino acid modification.
- the present invention comprises a variant of a parent polypeptide having an Fc region, wherein the variant comprises at least one surface amino acid modification and at least one non-surface amino acid modification.
- the variants of the present comprise two or more amino acid modifications (e.g. substitutions). Such combination variants may be produced, for example, by selecting two or more of the amino acid modifications detailed above.
- Table 1 below provides exemplary combinations of two or more amino acid substitutions. For example, the first row of Table 1 shows possible combinations of P247H with other amino acid substitutions at postions 251, 256, 268, 280, 330, 332, 339, 378 and 440 (e.g. this row shows combinations of two, three, four, five, six, seven, eight, nine, and ten amino acid modifications). Table 1.
- the combination variants shown in Table 1 and other combination variants may be tested for a given activity (e.g. FcR binding activity, ADCC activity, and CDC activity) in a variety of assays (See, Section IV. below).
- useful combination variants may be identified.
- the combination variants of the present invention have one amino acid modification that increases ADCC activity, and one amino acid modification that increases neonatal Fc receptor (FcRn) binding affinity (e.g., at pH 6.0, but not at pH 7.0 or 7.4).
- the combination variants of the present invention have one surface amino acid modification, and one non-surface amino acid modification. Additional combination variants may be generated by combining two or more of the amino acid modifications described herein, or at least one of the amino acid modifications described herein with those described in WO0042072.
- the present invention provides various assays for screening Fc region variants. Screening assays may be used to find or confirm useful variants. For example, combination variants (See Table 1) may be screened to find variants with altered FcR binding, and/or altered ADCC and/or altered CDC activity (e.g. increased or decreased ADCC or CDC activity) and/or modified ability to deplete target cells (B cells, for eg.) from whole blood. Also, as described below, the assays of the present invention may be employed to find or confirm variants that have beneficial therapeutic activity in a subject (e.g. such as a human with symptoms of an antibody or immunoadhesin responsive disease).
- a subject e.g. such as a human with symptoms of an antibody or immunoadhesin responsive disease.
- the variants of the present invention are antibodies that essentially retain the ability to bind antigen (via an unmodified antigen binding region or modified antigen binding region) compared to the nonvariant (parent) polypeptide (e.g. the binding capability is preferably no worse than about 20 fold or no worse than about 5 fold of that of the nonvariant polypeptide).
- the binding capability of the polypeptide variant to antigen may be determined using techniques such as ELISA, fluorescence activated cell sorting (FACS) analysis, or radioimmunoprecipitation (RIA), for example.
- Fc receptor (FcR) binding assays may be employed to evaluate the variants of the present invention. For example, binding of Fc receptors such as Fc ⁇ RI, Fc ⁇ RIIa, Fc ⁇ RIIb, Fc ⁇ RIII, FcRn, etc., can be measured by titrating polypeptide variant and measuring bound polypeptide variant using an antibody which specifically binds to the polypeptide variant in an ELISA format (see Examples below).
- a variant that comprises an antibody may be screened in a standard ELISA assay to determine binding to an FcRn at pH 6.0 and pH 7.0 or 7.4.
- a solid surface coated with streptavidin or Neutravidin may be used to capture biotin labeled FcRn from any species, such as mouse or human.
- the capture receptor can be incubated with variant polypeptides (antibodies) diluted in buffers at pH 6.0 or pH 7.0.
- a molecule specific for human antibodies is added (e.g. goat (Fab')2 anti-human-Fab conjugated to an enzyme).
- a substrate may be added in order to determine the amount of binding of the variant polypeptide to the immobilized FcRn at pH 6.0 or pH 7.0 or 7.4.
- the results of this assay can be compared to the parent (non- variant) polypeptide's ability to bind the same FcR.
- the components for carrying out an ELISA (e.g. with FcRn ) to screen variants are packaged in a kit (e.g. with instructions for use).
- An antibody dependent cellular cytotoxicity (ADCC) assay may also be employed to screen the variants of the present invention. ADCC assays may be performed in vitro or in vivo.
- an in vitro ADCC assay may be performed using varying effector:target ratios.
- An exemplary ADCC assay could use a target cell line expressing any of the following target antigens: CD20, CD22, CD33, CD40, CD63, EGF receptor, her-2 receptor, prostate-specific membrane antigen, Lewis Y carbohydrate, GD and GD 3 gangliosides, lamp-1, CO-029, L6, and ephA2. Effector cells may be obtained from a healthy donor (e.g. on the day of the experiment) and PBMC purified using Histopaque (Sigma).
- Target cells are then preincubated with an IgG variant at, for example, 0.1 - 1,000 ng/ml for about 30 minutes prior to mixing with effector cells at effecto ⁇ target ratios of, for example, 40:1, 20:1 and 10:1.
- ADCC activity may then be measured colorimetrically using a Cytotoxicity Detection Kit (Roche Molecular Biochemicals) for the quantitation of cell death and lysis based upon the measurement of lactate dehydrogenase (LDH) activity released from the cytosol of damaged cells into the supernatant.
- ADCC activity may also be measured, for Chromium 51 loaded target cell assays, by measuring the resulting Chromium 51 released.
- Antibody independent cellular cytoxicity can be determined by measuring the LDH activity from target and effector cells in the absence of antibody. Total release may be measured following the addition of 1 %> Triton X-l 00 to the mixture of target and effector cells. Incubation of the target and effector cells may be performed for an optimized period of time (0.54-18 hours) at 37 C in 5.0 % CO 2 and then be followed by centrifugation of the assay plates. The supernatants may then be transferred to 96 well plates and incubated with LDH detection reagent for 30 minutes at 25°C. The sample absorbance may then be measured at 490 nm using a microplate reader.
- the percent cytoxicity of anti-CD20 and variants can then be compared directly with equal amount of RITUXAN to provide a measurement of relative effectiveness.
- An exemplary ADCC assay could employ SKW6.4 cells over-expressing the CD20 antigen (e.g. purchased from the American Type Culture Collection) as the source of target cells. Many variations of this assay are known in the art (See, e.g., Zuckerman et al, CRC CritRev Microbiol 1978;7(l):l-26, herein incorporated by reference).
- Useful effector cells for such assays includes, but is not limited to, natural killer (NK) cells, macrophages, and other peripheral blood mononuclear cells (PBMC).
- NK natural killer
- PBMC peripheral blood mononuclear cells
- ADCC activity of the polypeptide variants of the present invention may be assessed in vivo, e.g., in a animal model such as that disclosed in Clynes et al. PNAS (USA) 95:652-656 (1998), herein incorporated by reference).
- the variants of the present invention may also be screened for complement activation.
- a complement dependent cytotoxicity (CDC) assay may be performed (See, e.g. Gazzano-Santoro et al., J. Immunol. Methods, 202:163 (1996), herein incorporated by reference).
- CDC complement dependent cytotoxicity
- various concentrations of the polypeptide variant and human complement may be diluted with buffer.
- Cells which express the antigen to which the polypeptide variant binds may be diluted to a density of ⁇ 1 x 10 6 cells/ml.
- Mixtures of polypeptide variant, diluted human complement and cells expressing the antigen may be added to a flat bottom tissue culture 96 well plate and allowed to incubate for 2 hours at 37°C and 5% CO 2 to facilitate complement mediated cell lysis.
- 50 ul of alamar blue (Accumed International) may then be added to each well and incubated overnight at 37°C.
- the absorbance may be measured using a 96-well fluorimeter with excitation at 530 nm and emission at 590 nm. The results may be expressed in relative fluorescence units (RFU).
- sample concentrations may be computed from a standard curve and the percent activity as compared to nonvariant polypeptide may be reported for the polypeptide variant of interest.
- the variants of the present invention do not activate complement.
- a polypeptide variant displays about 0-10% CDC activity in this assay compared to a control antibody having a nonmutated IgGl Fc region.
- the variant does not appear to have any CDC activity (e.g. above background) in the above CDC assay.
- the variants of the present invention are found to have enhanced CDC compared to a parent polypeptide (e.g., displaying about two-fold to about 100-fold (or greater) improvement in CDC activity in vitro or in vivo when the IC50 values are compared).
- the variants of the present invention may also be screened for depletion of target cells in a whole blood assay.
- various concentrations of the polypeptide variant with CD20 target specificity can be screened for the depletion of B cells in a whole blood assay using facs (Vugmeyster et al., 2003 Cytometry 52A, 101-109).
- Freshly drawn blood is incubated with varying concentrations of polypeptide variant at 37°C and 5% CO for 4 hours (time can be varied).
- red blood cells are lysed per manufacturer's directions with an ammonium chloride reagent (Beckton-Dickinson cat. #555899) and B cells are detected by facs using a fluorescent- labeled antibody specific for B cells (anti-CD 19, for example).
- the results may be expressed as % depletion of B cells relative to either an untreated sample or a sample incubated with an irrelevant (non-depleting) antibody.
- the variant depletes B cells more effectively than the parental polypeptide.
- a variant may deplete B cells, for example, to about two-fold or greater extent, and preferably about five-fold or more.
- a variant may display greater potency in depleting B cells.
- a variant may deplete the same percentage of B cells relative to parental polypeptide, but utilize about five-fold less, and preferably about 10-fold less antibody.
- Target cell depletion mediated by variants may be about 5-fold to about 100-fold, and preferably from about 5-fold to about 1000-fold improved compared to the parent polypeptide.
- the variants of the present invention may also be screened in vivo. Any type of in vivo assay may be employed. A particular example of one type of assay is provided below.
- This exemplary assay allows for preclinical evaluation of Fc variants in vivo.
- a variant to be tested may be incorporated into the Fc region of a particular antibody known to have some activity.
- a variant may be incorporated into the Fc region of an anti-CD20 IgG by mutagenesis. This allows a parental IgG and Fc variant IgG to be compared directly with RITUXAN (known to promote tumor regression).
- the preclinical evaluation may be done in 2 phases (a phannacokinetic and pharmacodynamic phase).
- the goal of the Phase I pharmacokinetic studies is to determine if there are differences in the clearance rate between an Fc variant IgG and the antibody with known in vivo activity (e.g. RITUXAN). Differences in clearance rate may cause differences in the steady-state level of IgG in serum. As such, if differences in steady-state concentrations are detected these should be normalized to enable accurate comparisons to be made.
- the goal of the Phase II pharmacodynamic studies is to determine the effect of the Fc mutations upon, in this case, tumor growth. Previous studies with RITUXAN used a single dose which completely inhibited tumor growth. Because this does not allow quantitative differences to be measured, a dose range should be employed.
- Phase I pharmacokinetic comparison of an Fc variant, the wild type parental Fc, and RITUXAN may be performed in the following manner.
- 40 ⁇ g per animal may be injected intravenously and the plasma level of the IgG quantitated at 0, .25, .5, 1, 24, 48, 72, 96, 120, 168, and 336 hrs.
- the data may be fitted, for example, using a pharmacokinetic program (WinNonLin) using a zero lag two compartment pharmacokinetic model to obtain the clearance rate.
- Pharmacokinetic experiments may be performed in non-tumor bearing mice with, for example, a minimum of 5 mice per time point.
- An animal model may be employed for the next phase in the following manner.
- the right flank of CB17-SCID mice may be implanted with 10 6 Raji cells subcutaneously.
- Intravenous bolus of the Fc variant, the wild type Fc, and RITUXAN may be commenced immediately after implantation and continued until the tumor size is greater than 2 cm in diameter. Tumor volume may be determined every Monday,
- RITUXAN may be perfomied in the following manner. Based on published data, RITUXAN at 10 ⁇ g/g weekly completely inhibited tumor growth in vivo (Clynes et al., Nat. Med. 2000 Apr;6(4):443-6, 2000, herein incorporated by reference). Therefore, a weekly dose range of 10 ⁇ g/g, 5 ⁇ g/g, 1 ⁇ g/g, 0.5 ⁇ g/g, and 0 ⁇ g/g may be tested.
- the steady state plasma level at which tumor growth rate is inhibited by 50% may be graphically determined by the relationship between steady state plasma level and effectiveness. The steady state plasma level may be calculated as described above.
- ⁇ may be adjusted accordingly for each Fc variant and the Fc wild type depending on their pharmacokinetic properties to achieve comparable steady state plasma level as RITUXAN.
- Statistical improved pharmakodynamic values of the Fc variant in comparison to the parental polypeptide (e.g. Fc wild type) and RITUXAN will generally indicate that Fc variant confers improved activity in vivo. Additional pharmacodynamic comparison of the Fc variants, the wild type Fc, and RITUXAN may be performed in cynomolgous monkeys as described previously (Reff et al, Blood 83, 435-445, 1994).
- a dose response for depletion of peripheral B cells and lymph node B cells may be used to compare the relative potencies of the Fc variants with wild type Fc and Rituxan admimstered intravenously and/or subcutaneously.
- Statistical improved pharmakodynamic values of the Fc variant in comparison to the parental polypeptide (e.g. Fc wild type) and RITUXAN will generally indicate that Fc variant confers improved activity in vivo.
- the variants of the present invention are screened such that variants that are useful for therapeutic use in at least two species are identified.
- Such variants are referred to herein as "dual-species improved variants", and are particularly useful for identifying variants that are therapeutic in humans, and also demonstrate (or are likely to demonstrate) efficacy in an animal model.
- the present invention provides methods for identifying variants that have a strong chance of being approved for human clinical testing since animal model data will likely support any human testing applications made to governmental regulatory agencies (e.g. U.S. Food and Drug Administration) .
- dual-species improved variants are identified by first performing an ADCC assay using human effector cells to find improved variants, and then performing a second ADCC assay using mouse, rat, or non-human primate effector cells to identify a sub-set of the improved variants that are dual-species improved variants.
- the present invention provides methods for identifying dual-species improved variants, comprising; a) providing; i) target cells, ii) a composition comprising a candidate variant of a parent polypeptide having at least a portion of an Fc region, wherein the candidate variant comprises at least one amino acid modification in the Fc region, and wherein the candidate variant mediates target cell cytotoxicity in the presence of a first species (e.g.
- the method further comprises step e) determining if the candidate variant mediates target cell cytotoxicity in the presence of the second species effector cells more effectively than the parent polypeptide.
- the method further comprises step f) identifying a candidate variant as a dual-species improved variant that mediates target cell cytotoxicity in the presence of the second species effector cells more effectively than the parent polypeptide.
- the dual- species variants identified are then screened in vivo in one or more animal assays.
- dual-species improved variants are identified by first performing a whole blood assay using human blood to find improved variants, and then performing a second whole blood assay using mouse, rat, or non-human primate blood to identify a sub-set of the improved variants that are dual-species improved variants.
- the present invention provides methods for identifying dual-species improved variants, comprising; a) providing; i) target cells, ii) a composition comprising a candidate variant of a parent polypeptide having at least a portion of an Fc region, wherein the candidate variant comprises at least one amino acid modification in the Fc region, and wherein the candidate variant mediates target cell depletion in the presence of a first species (e.g. human) blood more effectively than the parent polypeptide, and iii) second species (e.g.
- a first species e.g. human
- second species e.g.
- the method further comprises step e) determining if the candidate variant mediates target cell depletion in the presence of the second species blood more effectively than the parent polypeptide.
- the method further comprises step f) identifying a candidate variant as a dual-species improved variant that mediates target cell depletion in the presence of the second species blood more effectively than the parent polypeptide.
- the dual-species variants identified are then screened in vivo in one or more animal assays.
- dual-species improved variants are identified by performing any of the assays above using human components (e.g. human cells, human Fc receptors, etc.) to identify improved variants, and then running the same assay (or a different assay) with non-human animal components (e.g. mouse cells, mouse Fc receptors, etc.).
- human components e.g. human cells, human Fc receptors, etc.
- non-human animal components e.g. mouse cells, mouse Fc receptors, etc.
- An exemplary process for identifying dual-species improved variants is a follows.
- a nucleic acid sequence encoding at least a portion of an IgG Fc region is mutated such that the amino acid sequence expressed has at least one amino acid change, thereby generating a variant.
- This expressed IgG variant is then characterized in an ADCC assay using human PBMCs or a subset (NK cells or macrophages, for example). If enhanced ADCC activity is found, then the variant is screened in a second ADCC assay using mouse or rat PBMCs. Alternatively, or in addition, an assay can be performed with the variant for binding to cloned rodent receptors or cell lines. Finally, if the variant is found to be improved in the second assay, making it a dual-improved variant, then the variant is screened in vivo in mice or rats.
- variant Fc Region Containing Molecules may be part of larger molecules.
- the larger molecules may be, for example, monoclonal antibodies, polyclonal antibodies, chimeric antibodies, humamzed antibodies, bispecific antibodies, immunoadhesins, etc. As such, it is evident that there is a broad range of applications for the variant Fc regions of the present invention.
- the variant Fc region containing molecule is an antibody.
- Techniques for producing antibodies are described below.
- the antibody is directed against an antigen of interest.
- the antigen is a polypeptide and administration of the antibody to a mammal suffering from a disease or disorder can result in a therapeutic benefit in that mammal.
- antibodies directed against nonpolypeptide antigens may also be employed.
- antigens include, but are not limited to, molecules such as renin; a growth hormone, including human growth hormone and bovine growth hormone; growth hormone releasing factor; parathyroid hormone; thyroid stimulating hormone; lipoproteins; alpha- 1- antitrypsin; insulin A-chain; insulin B-chain; proinsulin; follicle stimulating hormone; calcitonin; luteinizing hormone; glucagon; clotting factors such as factor VIIIC, factor IX, tissue factor (TF), and von Willebrands factor; anti-clotting factors such as Protein C; atrial natriuretic factor; lung surfactant; a plasminogen activator, such as urokinase or human urine or tissue-type plasminogen activator (t-PA); bombesin; thrombin; hemopoietic growth factor; tumor necrosis factor-alpha and -beta; enkephalinase; RANTES (regulated on activation normally T-cell expressed and secreted); human macrophage
- CD4, CD8, CD 19 and CD20 CD4, CD8, CD 19 and CD20; erythropoietin; osteoinductive factors; immunotoxins; a bone morphogenetic protein (BMP); an interferon such as interferon- alpha, -beta, and-gamma; colony stimulating factors (CSFs), e.
- BMP bone morphogenetic protein
- CSFs colony stimulating factors
- ILs interleukins
- IL-1 interleukins
- superoxide dismutase superoxide dismutase
- T-cell receptors surface membrane proteins
- decay accelerating factor viral antigen such as, for example, a portion of the AIDS envelope; transport proteins; homing receptors; addressins; regulatory proteins; integrins such as GDI 1 a, GDI 1 b, CD1 lc, CD18, an ICAM, VLA-4 and VCAM; a tumor associated antigen such as HER2, HER3 or HER4 receptor; a member of an apoptosis pathway; and fragments of any of the above-listed polypeptides.
- ILs interleukins
- superoxide dismutase superoxide dismutase
- T-cell receptors surface membrane proteins
- decay accelerating factor viral antigen such as, for example, a portion of the AIDS envelope
- transport proteins homing receptors
- addressins regulatory proteins
- integrins
- Preferred antigens include, but are not limited to, CD proteins such as CD3, CD4, CDS, CD19, CD20 and CD34; members of the ErbB receptor family such as the EGF receptor, HER2, HER3 or HER4 receptor; cell adhesion molecules such as LFA-1, Macl, pl50.95, VLA-4, ICAM-1, VCAM, a4/p7 integrin, and (Xv/p3 integrin including either a or subunits thereof (e.g.
- anti-CD I la, anti-CD 18 or anti-CDl lb antibodies growth factors such as VEGF; tissue factor (TF); alpha interferon (a-IFN); an interleukin, such as IL-8; IgE; blood group antigens; flk2/flt3 receptor; obesity (OB) receptor; mpl receptor; CTLA-4; protein C etc.
- Soluble antigens or fragments thereof, optionally conjugated to other molecules can be used as immunogens for generating antibodies.
- transmembrane molecules such as receptors, fragments of these (e.g. the extracellular domain of a receptor) can be used as the immunogen.
- cells expressing the transmembrane molecule can be used as the immunogen.
- Such cells can be derived from a natural source (e.g. cancer cell lines) or may be cells which have been transformed by recombinant techniques to express the transmembrane molecule.
- a natural source e.g. cancer cell lines
- Other antigens and forms thereof useful for preparing antibodies will be apparent to those in the art.
- polyclonal Antibodies The present invention provides polyclonal antibodies with variant Fc regions.
- a human immunoglobulin repertoire containing modified Gl constant regions may be transplanted into immunoglobulin-inactivated mice, resulting in mice expressing an IgG repertoire containing modified Fc regions (see e.g. Mendez, M et al, Nature Genetics 15:146 (1997), herein incorporated by reference).
- Polyclonal antibodies are preferably raised in animals by multiple subcutaneous (sc) or intraperitoneal (ip) injections of the relevant antigen and an adjuvant. It may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized (e.g.
- a general immunization protocol for a rabbit and mouse are as follows.
- Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining, for example, 100 ⁇ g or 5 ⁇ g of the protein or conjugate (e.g. for a rabbit or mouse respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermally at multiple sites.
- 100 ⁇ g or 5 ⁇ g of the protein or conjugate e.g. for a rabbit or mouse respectively
- 3 volumes of Freund's complete adjuvant injecting the solution intradermally at multiple sites.
- the animals are boosted with 1/5 or 1/10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sites.
- Seven to fourteen days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus.
- the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent.
- Conjugates also can be made in recombinant cell culture as protein fusions.
- aggregating agents such as alum are suitably used to enhance the immune response.
- Monoclonal antibodies may be made in a number of ways, including using the hybridoma method (e.g. as described by Kohler et al, Nature, 256: 495, 1975, herein incorporated by reference), or by recombinant DNA methods (e.g., U. S. Patent No.
- hybridoma a mouse or other appropriate host animal, such as a hamster or macaque monkey, is immunized to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the protein used for immunization.
- lymphocytes may be immunized in vitro. Lymphocytes then are fused with myeloma cells using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell.
- the hybridoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, parental myeloma cells.
- the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells.
- HAT medium hypoxanthine, aminopterin, and thymidine
- Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium.
- preferred myeloma cell lines are murine myeloma lines, such as those derived from MOPC-21 and MPC-11 mouse tumors available from the Salk Institute Cell Distribution Center, San Diego, California USA, and SP-2 or X63-Ag8-653 cells available from the American Type Culture Collection, Rockville, Maryland USA.
- Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (e.g., Kozbor, J. Immunol., 133: 3001 (1984), herein incorporated by reference). Culture medium in which hybridoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen.
- the binding specificity of monoclonal antibodies produced by hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).
- RIA radioimmunoassay
- ELISA enzyme-linked immunoabsorbent assay
- the clones may be subcloned by limiting dilution procedures and grown by standard methods. Suitable culture media for this purpose include, for example, D-MEM or RPMI-1640 medium.
- the hybridoma cells may be grown in vivo as ascites tumors in an animal.
- the monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
- DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the monoclonal antibodies).
- the hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as E.
- antibodies or antibody fragments are isolated from antibody phage libraries generated using the techniques described in, for example, McCafferty et al, Nature, 348: 552554 (1990). Clackson et al, Nature, 352:624-628 (1991) and Marks et al, J. Mol. Biol, 222: 581-597 (1991) describe the isolation of murine and human antibodies, respectively, using phage libraries.
- non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen- combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
- non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen- combining site of an antibody to create a chimeric bivalent antibody comprising one antigen-combining site having specificity for an antigen and another antigen-combining site having specificity for a different antigen.
- a humanized antibody comprises human antibody amino acid sequences together with amino acid residues that are not from a human antibody.
- the human sequences in a humanized antibody comprise the framework regions (FRs) and the sequences or residues that are not from a human antibody comprise one or more complementarity-determining regions (CDRs).
- FRs and CDRs can be defined based on amino acid residue numbering in the heavy and light chain variable regions.
- complementarity determining region, or CDR is intended to mean the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. These regions have been defined by Kabat et al. (I. Biol. Chem.
- variable region when used in reference to an antibody variable region is intended to mean all amino acid residues outside the CDR regions within the variable region of an antibody. Therefore, a variable region framework is between about 100-120 amino acids in length but is intended to reference only those amino acids outside of the CDRs.
- framework region is intended to mean each domain of the framework that is separated by the CDRs.
- framework region 1 corresponds to the domain of the variable region encompassing amino acids 1-30
- region 2 corresponds to the domain of the variable region encompassing amino acids 36- 49
- region 3 corresponds to the domain of the variable region encompassing amino acids 66-94
- region 4 corresponds to the domain of the variable region from amino acid 103 to the end of the variable region.
- the framework regions for the light chain are similarly separated by each of the light chain variable region CDRs.
- the framework boundaries are separated by the respective CDR termini as described above.
- the residues in a humanized antibody that are not from a human antibody may be residues or sequences imported from or derived from another species (including but not limited to mouse), or these sequences may be random amino acid sequences (e.g. generated from randomized nucleic acid sequences), which are inserted into the humanized antibody sequence.
- the human amino acid sequences in a humanized antibody are preferably the framework regions, while the residues which are not from a human antibody (whether derived from another species or random amino acid sequences) preferably correspond to the CDRs.
- one or more framework regions may contain one or more non-human amino acid residues.
- the altered or modified framework region In cases of alterations or modifications (e.g. by introduction of a non-human residue) to an otherwise human framework, it is possible for the altered or modified framework region to be adjacent to a modified CDR from another species or a random CDR sequence, while in other embodiments, an altered framework region is not adjacent to an altered CDR sequence from another species or a random CDR sequence.
- the framework sequences of a humamzed antibody are entirely human (i.e. no framework changes are made to the human framework).
- the framework sequences of a humanized antibody are entirely human germline (i.e. no framework changes are made to the human germline framework).
- Non-human amino acid residues from another species, or a random sequence are often referred to as "import" residues, which are typically taken from an "import” variable domain.
- Humanization can be essentially performed following the method of Winter and co-workers (e.g., ones et al, Nature, 321: 522-525 (1986); Riechmann et al, Nature, 332: 323-327 (1988); Nerhoeyen et al., Science, 239: 1534-1536 (1988), all of which are hereby incorporated by reference), by substituting rodent (or other mammal) CDRs or CDR sequences for the corresponding sequences of a human antibody.
- antibodies wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species may also be generated (e.g. 4,816,567, hereby incorporated by reference).
- humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies, or, as noted above, in which CDR sequences have been substituted by random sequences.
- methods for conferring donor CDR binding affinity onto an antibody acceptor variable region framework are described in WO 01/27160 Al, herein incorporated by reference and in US applications 09/434,870 and 09/982,464, all of which are herein incorporated by reference.
- variable domains both light and heavy
- sequence of the variable domain of a rodent antibody to be humamzed is screened against the entire library of known human variable-domain sequences.
- the human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibody (e.g., Sims et al, I. Immunol., 151: 2296 (1993), and Chothia et al, I. Mol. Biol., 196: 9O1 (1987), both of which are hereby incorporated by reference).
- FR human framework
- Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup of light or heavy chains.
- the same framework may be used for several different humanized antibodies (e.g., Carter et al, Proc. Natl. Acad. Sci. USA, 89: 4285 (1992); Presta et al, I. Immunol., 151: 2623 (1993), both of which are hereby incorporated by reference).
- there is no need to "pre-select" a particular human antibody framework i.e. there is no need to select a human framework with the closest homology or sequence identity to a given candidate antibody to be humanized.
- a common or universal human framework may be used to accept one or more non-human CDRs.
- a single universal, fully human framework is used as the framework for all antibodies to be humamzed, regardless of its homology to the framework sequence(s) of the candidate antibodies.
- humanized antibodies may be generated without making any changes in the framework region.
- This universal, fully human framework can then accept one or more CDR sequences.
- the one or more CDR sequences are CDR sequences from an antibody from another species (e.g. mouse or rat) which have been modified in comparison to the corresponding CDR in the intact antibody from the other species (i.e. there is simultaneous introduction of the CDR and modification of the CDR being introduced into the universal human framework).
- the modification corresponds to one or more amino acid changes (in the modified CDR) in comparison to the corresponding CDR in the intact antibody from the other species.
- all amino acid residues in the CDR are included in a library, while in other embodiments, not all of the CDR amino acid residues are included in a library.
- the one or more CDR sequences are random sequences, which substitute for CDR sequences.
- antibodies are humamzed with retention of high affinity for the antigen and other favorable biological properties.
- the affinity of the humanized antibody for the antigen is higher than the affinity of the corresponding non-humanized, intact antibody or fragment or portion thereof (e.g. the candidate rodent antibody).
- humanized antibodies are prepared by a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models of the parental and humanized sequences.
- Three-dimensional immunoglobulin models are commonly available and are familiar to those skilled in the art.
- Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
- FR residues can be selected and combined from the recipient and import sequences so that the desired antibody characteristic, such as increased affinity for the target antigen (s), is achieved.
- the CDR residues are directly and most substantially involved in influencing antigen binding.
- a variety of specific methods may be employed to introduce antibody CDRs (or random sequences substituting for antibody CDRs) into antibody frameworks (see, for example, US applications 09/434,879 and 09/982,464).
- overlapping oligos may be used to synthesize an antibody gene, or portion thereof (for example, a gene encoding a humanized antibody).
- mutagenesis of an antibody template may be carried out using the methods of Kunkel (infra), for example to introduce a modified CDR or a random sequence to substitute for a CDR.
- light and heavy chain variable regions are humanized separately, and then co-expressed as a humanized variable region.
- humanized variable regions make-up the variable region of an intact antibody.
- the Fc region of the intact antibody comprising a humanized variable region has been modified (e.g. at least one amino acid modification has been made in the Fc region).
- an antibody that has been humamzed with randomized CDR and no framework changes may comprise at least one amino acid modification in the Fc region.
- transgenic animals e.g., mice
- mice that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production are employed.
- JH antibody heavy-chain joining region
- Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (See, e.g., Jakobovits et al, Proc. Natl. Acad. Sci. USA, 90: 2551 (1993), and lakobovits et al, Nature, 362: 255-258 (1993), both of which are hereby incorporated by reference).
- Human antibodies can also be derived from phage-display libraries (e.g., Hoogenboom et al, I. Mol.
- the present invention provides methods for generating humanized antibodies (and antibody fragments) that comprise at least one amino acid modification in the Fc region (as compared to a parental polypeptide having an Fc region). Discussed below are additional methods for generating such humanized antibodies. The present invention also provides compositions comprising the antibodies and antibody fragments generated by these methods. Importantly, the humanization methods discussed below, and other huminization methods (e.g. discussed above), may be combined with the Fc variants of the present invention. In this regard, humanized antibodies with altered, unique Fc regions may be constructed according to the present invention.
- a method of constructing a population of altered heavy chain variable region encoding nucleic acids comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing a) first oligonucleotides encoding portions of the framework regions of the acceptor heavy chain variable region, wherein the portions of the framework regions when compared to the second reference sequence are unmodified; and b) a population of second oligonucleotides, each encoding i) at least a portion of a first complementarity-determining region that has been modified, the first complementarity-determining region selected from the group consisting of HCD 1 , HCDR2 and
- the representation of first and second reference sequences is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing comprises chemically synthesizing.
- the acceptor is human.
- the treating of step D) comprises extension by a polymerase.
- a method of constructing a population of altered light chain variable region encoding nucleic acids comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- ,- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a) first oligonucleotides encoding portions of the framework regions of the acceptor light chain variable region, wherein the portions of the framework regions when compared to the second reference sequence are unmodified; and b) a population of second oligonucleotides, each encoding i) at least a portion of a first complementarity-determining region that has been modified, the first complementarity-determining region selected from the group consisting of LCDR1 , LCDR2
- the representation of first and second reference sequences is in electronic form.
- the method further comprises the step of (E) co-expressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing comprises chemically synthesizing.
- the acceptor is human.
- the treating of step D) comprises extension by a polymerase.
- a method of constructing a population of altered heavy chain variable region encoding nucleic acids comprising: A) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) thxee complementarity- determining regions as defined by the combined definitior S of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; B) synthesizing a) a population of first oligonucleotides, each encoding at least a portion of a first complementarity-determimng region selected from the group consisting of HCDR1, HCDR2 and HCDR3, wherein the modified first complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity determining regions of the first reference sequence; and b) second oligonucleotides
- the representation of first and second reference sequences is in electronic form.
- the method futrther comprises the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so .as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing comprises chemically synthesizing.
- the acceptor is human.
- the treating of step D) comprises extension by a polymerase.
- a method of constructing a population of altered light chain variable region encoding nucleic acids comprising: A) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; B) synthesizing a) a population of first oligonucleotides, each encoding at least a portion of a first complementarity-determining region selected from the group consisting of LCDR1, LCDR2 and LCDR3, wherein the modified first complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity determining regions of the first reference sequence; and b) second oligonucleotides encoding i) portions of the framework regions of the acceptor
- the representation of first and second reference sequences is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing comprises chemically synthesizing.
- the acceptor is human.
- the treating of step D) comprises extension by a polymerase.
- a method of constructing a population of altered heavy chain variable region encoding nucleic acids comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions, the second reference sequence comprising a heavy chain variable region; b) synthesizing a population of altered heavy chain variable region antibody gene sequences, wherein the framework regions of the altered heavy chain variable regions are identical to the framework regions of the second reference sequence and at least a first CDR of the altered antibody variable regions has been modified, wherein the modified first CDR comprises a different amino acid at one or more positions when compared to the corresponding donor CDR of the first reference sequence.
- the representation of first and second reference sequences is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the acceptor is human.
- the synthesizing involves the use of overlapping oligonucleotides.
- the CDRs are defined by the Kabat definition.
- a method of constructing a population of altered light chain variable region encoding nucleic acids comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- detemiining regions; the second reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a population of altered light chain variable region antibody gene sequences, wherein the framework regions of the altered light chain variable regions are identical to the framework regions of the second reference sequence and at least a first CDR of the altered antibody light chain variable region has been modified, wherein the modified first CDR comprises a different amino acid at one or more positions when compared to the conesponding donor CDR of the first reference sequence.
- the representation of first and second reference sequences is in electronic form.
- the method further comprisies the step of (E) coexpressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the acceptor is human.
- the synthesizing involves the use of overlapping oligonucleotides .
- a method of constructing a population of altered heavy chain variable region encoding nucleic acids comprising: a) providing a representation of a reference amino acid sequence, the reference sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing a population of altered heavy chain variable region antibody gene sequences, wherein the framework regions of the altered heavy chain variable regions are identical to the framework regions of the reference sequence and at least a first CDR of the altered antibody variable regions comprises a random amino acid sequence.
- the representation of the reference sequence is in electronic form.
- the method further comprising the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the acceptor is human.
- the synthesizing involves the use of overlapping oligonucleotides.
- the CDRs are defined by the Kabat definition.
- a method of constructing a population of altered light chain variable region encoding nucleic acids comprising: a) providing a representation of a reference amino acid sequence, the reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a population of altered light chain variable region antibody gene sequences, wherein the framework regions of the altered light chain variable regions are identical to the framework regions of the reference sequence and at least a first CDR of the altered antibody light chain variable regions comprises a random amino acid sequence.
- the representation of the reference sequence is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the acceptor is human.
- the synthesizing involves the use of overlapping oligonucleotides.
- the CDRs are defined by the Kabat definition.
- a method of constructing a population of altered heavy chain variable region encoding nucleic acids comprising: a) providing a representation of a reference amino acid sequence, the reference sequence comprising the sequence of a human acceptor heavy chain variable region comprising framework regions; b) synthesizing a population of altered heavy chain variable region antibody gene sequences, wherein the framework regions of the altered heavy chain variable regions are identical to the framework regions of the human reference sequence and at least a first CDR of the altered antibody variable regions comprises a random amino acid sequence.
- the representation of the human reference sequence is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing involves the use of overlapping oligonucleotides.
- the CDRs are defined by the Kabat definition.
- a method of constructing a population of altered light chain variable region encoding nucleic acids comprising: a) providing a representation of a reference amino acid sequence, the reference sequence comprising the sequence of a human acceptor light chain variable region comprising framework regions; b) synthesizing a population of altered light chain variable region antibody gene sequences, wherein the framework regions of the altered light chain variable regions are identical to the framework regions of the human reference sequence and at least a first CDR of the altered antibody light chain variable regions comprises a random amino acid sequence.
- the representation of the reference sequence is in electronic form.
- the method further comprises the step of (E) coexpressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing involves the use of overlapping oligonucleotides.
- the CDRs are defined by the Kabat definition.
- one or more framework regions are modified simultaneously with the introduction of one or more modified CDRs.
- the modified frameworks are adjacent to the modified CDRs.
- the present invention provides methods of constructing a population of altered heavy chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing a) a first population of oligonucleotides, comprising oligonucleotides encoding a modified heavy chain variable region framework region, or portion thereof, wherein the heavy chain variable region framework region, or portion thereof, contains a plurality of changed amino acids at one or more positions when compared to the acceptor framework region reference sequence, wherein the framework positions that are changed are selected from among the acceptor framework positions of the second reference sequence that differ at the corresponding position compared to the donor
- the representation of first and second reference sequences is in electronic form.
- the methods further comprise the step of (e) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the synthesizing comprises chemically synthesizing.
- the acceptor is human.
- the one or more of the diverse population of altered heteromeric variable regions are part of an antibody comprising an Fc region, wherein the Fc region comprises at least one amino acid modification as compared to a parental polypeptide having an Fc region.
- the present invention provides methods of constructing a population of altered light chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a) a first population of oligonucleotides, comprising oligonucleotides encoding a modified light chain variable region framework region, or portion thereof, wherein the light chain variable region framework region, or portion thereof, contains a plurality of changed amino acids at one or more positions when compared to the acceptor framework region reference sequence, wherein the framework positions that are changed are selected from among the acceptor framework positions of the second reference sequence that differ at the corresponding position compared to the donor
- the representation of first and second reference sequences is in electronic form.
- the methods further comprise the step of (e) coexpressing the population of altered light chain variable region encoding nucleic acids with a heavy chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the methods comprise a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing a) a first population of oligonucleotides, comprising oligonucleotides encoding a modified heavy chain variable region framework region, or portion thereof, wherein the heavy chain variable region framework region, or portion thereof, contains a plurality of changed amino acids at one or more positions when compared to the acceptor framework region reference sequence, wherein the framework positions that are changed are selected from among the acceptor framework positions of the second reference sequence that differ at the corresponding position compared to the donor framework positions of the first reference sequence; and b) a second population of oligonucleotides
- the present invention provides methods of constructing a population of altered light chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a) a first population of oligonucleotides, comprising oligonucleotides encoding a modified light chain variable region framework region, or portion thereof, wherein the light chain variable region framework region, or portion thereof, contains a plurality of changed amino acids at one or more positions when compared to the acceptor framework region reference sequence, wherein the framework positions that are changed are selected from among the acceptor framework positions of the second reference sequence that differ at the corresponding position compared to the
- portions of adjacent framework regions which are capable of hybridizing to the first population of oligonucleotides and c) mixing the first and second populations of oligonucleotides so as to create overlapping oligonucleotides; and d) extending the overlapping oligonucleotides with a DNA polymerase under conditions such that a population of altered light chain variable region encoding nucleic acids is constructed.
- one or more modifications are introduced into the framework, simultaneously with the introduction of one or more modified CDRs.
- the modified CDRs may comprise one or more amino acid alterations in comparison with the corresponding CDR of a reference sequence.
- the methods of constructing a population of altered heavy chain variable region encoding nucleic acids comprises: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing i) a first population of oligonucleotides, each encoding at least one modified complementarity-determining region, wherein the modified complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity-determining region amino acid reference sequence; and ii) a second population of oligonucleotides, comprising oligonucleotides encoding modified portions of a heavy chain variable region framework, the modified portion containing a
- the representation of first and second reference sequences is in electronic form.
- the methods further comprise the step of (e) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the acceptor is human.
- the present invention provides methods constructing a population of altered light chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing i) a first population of oligonucleotides, each encoding at least one modified complementarityrdetermining region, wherein the modified complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity-determining region amino acid reference sequence; and ii) a second population of oligonucleotides, comprising oligonucleotides encoding modified portions of a light chain variable region framework, the modified portion
- the antibodies or antibody fragments comprising an Fc variant and an altered heavy chain variant region may be generated.
- the present invention provides methods of constructing a population of altered heavy chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; b) synthesizing A) first oligonucleotides encoding portions of the framework regions of the acceptor heavy chain variable region, wherein the portions of the framework regions when compared to the second reference sequence are unmodified; and B) a population of second oligonucleotides, each encoding i) at least a portion of a first complementarity-determimng
- the methods further comprise the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the present invention provides methods of constructing a population of altered light chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determimng regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; b) synthesizing a) first oligonucleotides encoding .ap ⁇
- first complementarity-determining region selected from the group consisting of LCDR1 , LCDR2 and LCDR3, wherein the modified first complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity determining regions of the first reference sequence and ii) one or more portions of unmodified framework regions which are capable of hybridizing to the first oligonucleotides; c) mixing the first oligonucleotides with the population of second oligonucleotides as to create overlapping oligonucleotides; and d) treating the overlapping oligonucleotides under conditions such that a population of altered light chain variable region
- the present invention provides methods of constructing a population of altered heavy chain variable region encoding nucleic acids, comprising: A) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor heavy chain variable region comprising framework regions; B) synthesizing a) a population of first oligonucleotides, each encoding at least a portion of a first complementarity-determining region selected from the group consisting of HCDRl, HCDR2 and HCDR3, wherein the modified first complementarity-determining region comprises a different amino acid at one or more positions when compared to the corresponding donor complementarity determining regions of the first reference sequence; and b) second oligonucleotides encoding i) portions of the framework regions
- the methods further comprise the step of (E) coexpressing the population of altered heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the present invention provides methods of constructing a population of altered light chain variable region encoding nucleic acids, comprising: A) providing a representation of first and second reference amino acid sequences, the first reference sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) framework regions and ii) three complementarity- determining regions as defined by the combined definitions of Kabat and Chothia; the second reference sequence comprising the sequence of an acceptor light chain variable region comprising framework regions; B) synthesizing a) a population of first oligonucleotides, each encoding at least a portion of a first complementarity-determining region selected from the group consisting of LCDR1, LCDR2 and LCDR3, wherein the modified first complementarity-
- the present invention provides methods of improving the binding affinity of a mutated humanized antibody variable region, comprising: a) providing a nucleic acid sequence encoding a first mutated humanized antibody variable region, the mutated variable region comprising (i) a wild type human antibody framework, (ii) three non-human heavy chain complementarity determining regions, and (iii) three non-human light chain complementarity determining regions, wherein the complementarity determining regions are defined by the combined definitions of Kabat and Chothia, wherein at least one of the light chain complementarity determining regions is a mutation-containing light chain complementarity determimng region comprising at least one different amino acid at at least one position when compared to the corresponding wild type non-human complementarity determining region, and wherein the first mutated antibody variable region has a higher binding affinity than the conesponding non-mutated antibody variable region; b) mutating the nucleic acid sequence encoding the first mutated antibody variable region under conditions such
- the mutation-containing light chain complementarity determining region of the first mutated humamzed antibody variable region is complementarity determimng region 3 (LCDR3).
- at least one of the non-human heavy chain complementarity determining regions of the first mutated humanized antibody variable region comprises a mutation, such that a different amino acid is encoded at at least one position when compared to the corresponding wild type non-human complementarity determimng region.
- the heavy chain complementarity determining region mutation is in HCDR3.
- the present invention provides methods of of simultaneously modifying at least one complementarity-determining region (CDR) and at least one framework region (FR) while constructing a population of altered heavy chain variable region encoding nucleic acids, comprising: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor heavy chain variable region, the donor variable region comprising i) four framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor heavy chain variable region comprising four framework regions, as defined by the combined definitions of Kabat and Chothia; b) synthesizing i) for every framework region to be modified, a population of oligonucleotides, each encoding a modified framework region, or portion thereof, the modified framework region, or portion thereof, containing a plurality of changed amino acids at one or more positions when compared to the conesponding framework region in
- the representation of first and second reference sequences is in electronic form.
- the framework region to be modified is selected from the group consisting of HFR1, HFR2 and HFR3.
- the complementarity-determining region to be modified is HCDR3.
- the method further comprises the step of e) coexpressing the population of heavy chain variable region encoding nucleic acids with a light chain variable region encoding nucleic acid so as to produce a diverse population of altered heteromeric variable regions.
- the method further comprises the step of e) coexpressing the population of heavy chain variable region encoding nucleic acids with a population of light chain variable region encoding nucleic acids so as to produce a diverse population of altered heteromeric variable regions.
- the methods of simultaneously modifying at least one complementarity-determining region (CDR) and at least one framework region (FR) while constructing a population of altered light chain variable region encoding nucleic acids are employed, wherein said method comprises: a) providing a representation of first and second reference amino acid sequences, the first reference amino acid sequence comprising the sequence of a donor light chain variable region, the donor variable region comprising i) four framework regions and ii) three complementarity-determining regions as defined by the combined definitions of Kabat and Chothia; the second reference amino acid sequence comprising the sequence of an acceptor light chain variable region comprising four framework regions, as defined by the combined definitions of Kabat and Chothia; b) synthesizing i) for every framework region to be modified,
- the methods further comprise the step of e) coexpressing the population of light chain variable region encoding nucleic acids with a population of heavy chain variable region encoding nucleic acids so as to produce a diverse population of altered heteromeric variable regions.
- Multispeci ⁇ c antibodies The present invention provides multispecific antibodies comprising a variant Fc region. Multispecific antibodies have binding specificities for at least two different antigens. While such molecules normally will only bind two antigens (i.e. bispecific antibodies, BsAbs), antibodies with additional specificities such as trispecific antibodies are encompassed by this expression when used herein.
- BsAbs include, but are not limited to, those with one ann directed against a tumor cell antigen and the other arm directed against a cytotoxic trigger molecule such as anti-Fc ⁇ RI/anti- CD 15, anti- pi 85HER2/FcyRIII (CD16), anti-CD3/anti-malignant B-cell (1D10), anti- CD3/antipl85HER2, anti-CD3/anti-p97, anti-CD3/anti-renal cell carcinoma, anti- CD3/anti-ONCAR-3, antiCD3/L-Dl (anti-colon carcinoma), anti-CD3/anti-melanocyte stimulating hormone analog, anti EGF receptor/anti-CD3, anti-CD3/anti-CAMAl, anti- CD3/anti-CD19, anti-CD3/MoN18, anti-neural cell adhesion molecule ( ⁇ CAM)/anti- CD3, anti-folate binding protein (FBP)/anti-CD3, anti-pan carcinoma associated antigen (AMOC-3 l)/anti-CD3; BsAbs with one arm which bind
- BsAbs for use in therapy of infectious diseases such as anti-CD3/anti-herpes simplex virus (HSN), anti-T- cell receptor: CD3 complex/anti-influenza, anti-FcyR/anti-HIN; BsAbs for tumor detection in vitro or in vivo such as anti-CEA/anti-EOTUBE, anti-CEA/anti-DPTA, anti- pi 85HER2/anti-hapten; BsAbs as vaccine adjuvants; and BsAbs as diagnostic tools such as anti-rabbit IgG/anti-femtin, anti-horse radish peroxidase (HRP)/anti-hormone, anti- somatostatin/anti-substance P, anti-HRP/anti-FITC, anti-CEA/anti-p-galactosidase.
- HRP herpes simplex virus
- trispecific antibodies examples include, but are not limited to, anti-CD3/anti-CD4/anti- CD37, anti-CD3/anti-CD5/anti-CD37 and anti-CD3/anti-CD8/anti-CD37.
- Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g. F (ab') 2 bispecific antibodies). Methods for making bispecific antibodies are known in the art. Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobulin heavy chain-light chain pairs, where the two chains have different specificities (e.g., Millstein et al, Nature, 305: 537-539 (1983), herein incorporated by reference).
- CHI first heavy-chain constant region
- the bispecific antibodies are composed of a hybrid immunoglobulin heavy chain with a first binding specificity in one arm, and a hybrid immunoglobulin heavy chain-light chain pair (providing a second binding specificity) in the other arm (see, e.g., WO 94/04690, herein incorporated by reference).
- the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers which are recovered from recombinant cell culture.
- Bispecific antibodies also include cross-linked or "heteroconjugate" antibodies.
- one of the antibodies in the heteroconjugate can be coupled to avidin, the other to biotin.
- B. Immunoadhesin Molecules The present invention also provides iinmunoadhesin molecules comprising a variant Fc region.
- One type of immunoadhesin design combines the binding domain(s) of the adhesin (e.g.
- nucleic acid encoding the binding domain of the adhesin will be fused C-terminally to nucleic acid encoding the N-terminus of an immunoglobulin constant domain sequence, however N-terminal fusions are also possible.
- the encoded chimeric polypeptide will retain at least functionally active hinge, CH2 and CH3 domains of the constant region of an immunoglobulin heavy chain.
- Fusions are also made to the C-terminus of the Fc portion of a constant domain, or immediately N-terminal to the CHI of the heavy chain or the conesponding region of the light chain.
- the precise site at which the fusion is made is not critical; particular sites are well known and may be selected in order to optimize the biological activity, secretion, or binding characteristics of the immunoadhesin.
- the adhesin sequence is fused to the N-terminus of the variant Fc region of immunoglobulin Gi. It is possible to fuse the entire heavy chain constant region to the adhesin sequence.
- a sequence beginning in the hinge region just upstream of the papain cleavage site which defines IgG Fc chemically i.e.
- the adhesin amino acid sequence is fused to (a) the hinge region and CH2 and CH3 or (b) the CHI, hinge, CH2 and CH3 domains, of an IgG heavy chain.
- the immunoadhesins are bispecific.
- the adhesin sequences can be inserted between immunoglobulin heavy chain and light chain sequences, such that an immunoglobulin comprising a chimeric heavy chain is obtained.
- the adhesin sequences may be fused to the 3' end of an immunoglobulin heavy chain in each arm of an immunoglobulin, either between the hinge and the CH2 domain, or between the CH2 and CH3 domains (see, e.g., Hoogenboom et al, Mol. Immunol. 28:1027-1037 (1991), herein incorporated by reference).
- an immunoglobulin light chain might be present either covalently associated to an adhesin-immunoglobulin heavy chain fusion polypeptide, or directly fused to the adhesin.
- DNA encoding an immunoglobulin light chain is typically coexpressed with the DNA encoding the adhesin- immunoglobulin heavy chain fusion protein.
- the hybrid heavy chain and the light chain will be covalently associated to provide an immunoglobulin-like structure comprising two disulfide-linked immunoglobulin heavy chain-light chain pairs.
- Methods suitable for the preparation of such structures are, for example, disclosed in U. S. Patent No. 4,816,567, herein incorporated by reference.
- immunoadhesins are constructed by fusing the cDNA sequence encoding the adhesin portion in-frame to an immunoglobulin cDNA sequence.
- fusion to genomic immunoglobulin fragments can also be used. Generally, the latter type of fusion requires the presence of Ig regulatory sequences for expression.
- cDNAs encoding IgG heavy chain constant regions can be isolated based on published sequences from cDNA libraries derived from spleen or peripheral blood lymphocytes, by hybridization or by polymerase chain reaction (PCR) techniques.
- PCR polymerase chain reaction
- the cDNAs encoding the "adhesin" and the immunoglobulin parts of the immunoadhesin may be inserted in tandem into a plasmid vector that directs efficient expression in the chosen host cells.
- the present invention also provides nucleic acid sequences encoding Fc region variants, as well as compositions, vectors, and host cells comprising nucleic acid sequences encoding Fc region variants.
- the present invention also provides recombinant methods for producing Fc region variants. Generally, for recombinant production of variants, nucleic acid encoding the variant is isolated and inserted into a vector. Host cells may be transfected with the vector, thereby allowing the nucleic acid sequence to be amplified, and/or the variant peptide produced. Nucleic acid sequences encoding the peptide variants of the present invention may be isolated and sequenced using conventional procedures (e.g.
- the nucleic acid sequence encoding the variant is operably linked to other elements, such as a signal sequence (e.g. secretory signal sequences), an origin of replication, at least one marker gene, an enhancer, a promoter, or a transcription terminator.
- a signal sequence e.g. secretory signal sequences
- host cells are stably transfected with nucleic acid encoding a variant to generate a cell line expressing a particular variant.
- the variants are expressed in CHO, NSO, Sp2/0, PER.C6, or HEK293 cells. Recombinant methods are well known in the art.
- Nucleic acid sequences may be mutated such that variant Fc regions may be produced.
- a nucleic acid sequence encoding a parental Fc region e.g. SEQ ID NO:32
- nucleic acid sequences encoding at least a portion of a parental Fc region may be mutated to produce amino acid sequences comprising at least a portion of an Fc region variant.
- SEQ ID NO: 32 may be mutated, such that at least one amino acid sequence results (See, e.g., SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56).
- codon-based synthesis is employed to generate mutated sequences.
- codon-based synthesis examples include, for example, those described in U.S. Patents 5,264,563, 5,523,388 and 5,808,022, all of which are hereby incorporated by reference. Briefly, codon-based synthesis may be performed by sequentially coupling monomers on separate supports to form at least two different tuplets. The coupling may be performed in separate reaction vessels, then mixing the supports from the reaction vessels, and dividing the mixed supports into two or more separate reaction vessels, and repeating the coupling, mixing and dividing steps one or more times in the reaction vessels, ending with a mixing or dividing step. Additionally, the oligonucleotides can be cleaved from the supports. VII.
- the present invention provides therapeutic formulations comprising the variants described herein. It is not intended that the present invention be limited by the particular nature of the therapeutic composition.
- such compositions can include a polypeptide variant (or portion thereof), provided together with physiologically tolerable liquids, gels, solid earners, diluents, adjuvants and excipients, and combinations thereof (See, e.g, Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980), herein incorporated by reference).
- polypeptide variants may be used together with other therapeutic agents, including, but not limited to, salicylates, steroids, immunosuppressants, antibodies or antibiotics.
- Particular therapeutic agents which may be used with the variants of the present invention include, but are not limited to, the following agents: azobenzene compounds (US Pat. No. 4,312,806, incorporated herein by reference), benzyl-substituted rhodamine derivatives (US Pat. No. 5,216,002, incorporated herein by reference), zinc L- carnosine salts (US Pat. No. 5,238,931, incorporated herein by reference), 3-phenyl-5- carboxypyrazoles and isothiazoles (US Pat. No. 5,294,630, incorporated herein by reference), IL-10 (US Pat. No. 5,368,854, incorporated herein by reference), quinoline leukotriene synthesis inhibitors (US Pat. No.
- Polypeptide variants may be used together with agents which reduce the viability or proliferative potential of a cell.
- Agents which reduce the viability or proliferative potential of a cell can function in a variety of ways including, for example, inhibiting DNA synthesis, inhibiting cell division, inducing apoptosis, or inducing non-apoptotic cell killing.
- cytotoxic and cytostatic agents include but are not limited to, pokeweed antiviral protein, abrin, ricin, and each of their A chains, doxorubicin, cisplastin, iodine-131, yttrium-90, fhenium-188, bismuth-212, taxol, 5- fluorouracil VP-16, bleomycin, methotrexate, vindesine, adriamycin, vincristine, vinblastine, BCNU, mitomycin and cyclophosphamide and certain cytokines such as TNF- ⁇ and TNF- ⁇ .
- cytotoxic or cytostatic agents can include, for example, radionuclides, chemotherapeutic drugs, proteins, and lectins.
- Therapeutic compositions may contain, for example, such normally employed additives as binders, fillers, earners, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions typically contain l%-95% of active ingredient, preferably 2%-70% active ingredient.
- the polypeptide variants of the present invention can also be mixed with diluents or excipients which are compatible and physiologically tolerable.
- Suitable diluents and excipients are, for example, water, saline, dextrose, glycerol, or the like, and combinations thereof.
- the compositions may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, stabilizing or pH buffering agents.
- the therapeutic compositions of the present invention are prepared either as liquid solutions or suspensions, as sprays, or in solid forms.
- Oral formulations usually include such normally employed additives such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain l%-95% of active ingredient, preferably 2%-70%.
- binders such as binders, fillers, carriers, preservatives, stabilizing agents, emulsifiers, buffers and excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like.
- These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations, or powders, and typically contain l
- -Ill- Additional formulations which are suitable for other modes of administration, such as topical administration, include salves, tinctures, creams, lotions, transdermal patches, and suppositories.
- traditional binders, earners and excipients may include, for example, polyalkylene glycols or triglycerides.
- a topical delivery method is described in U.S. Pat. No. 5,834,016 (incorporated herein by reference).
- Other liposomal delivery methods may also be employed (See, e.g., US Pat. Nos. 5,851,548 and 5,711,964, both of which are herein incorporated by reference).
- the formulations may also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.
- Sustained-release preparations may also be prepared. Suitable examples of sustained release preparations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide variant, which matrices are in the form of shaped articles, e.g., films, or microcapsule.
- sustained-release matrices include, but are not limited to, polyesters, hydrogels (for example, poly (2-hydroxyethyl- methacrylate), or poly (vinylalcohol)), polylactides, copolymers of L-glutamic acid and y ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D- (-)-3- hydroxybutyric acid.
- polyesters for example, poly (2-hydroxyethyl- methacrylate), or poly (vinylalcohol)
- polylactides copolymers of L-glutamic acid and y ethyl-L-glutamate
- non-degradable ethylene-vinyl acetate non-degradable ethylene
- polymers such as ethylene-vinyl acetate and lactic acid- glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.
- the polypeptide variants of the present invention may be used to treat a subject. Such treatment may be administered to a subject with a disease, or may be administered prophylactically to a subject (e.g. to a subject predisposed to a disease).
- Example of conditions that may be treated include, but are not limited to, cancer (e.g. where the polypeptide variant binds the HER2 receptor, CD20 or vascular endothelial growth factor (VEGF)); allergic conditions such as asthma (with an anti-IgE antibody); and LFA-1- mediated disorders (e.g.
- polypeptide variant is an anti-LFA-1 or anti-ICAM-1 antibody
- the variants used to treat subjects comprise antibodies or immunoadhesins.
- the diseases treated are antibody or immunoadhesin responsive diseases.
- antibody responsive diseases include diseases and medical conditions such as: lymphoma (shown to be treatable with RITUXAN, an anti-CD20 antibody), infectious disease (shown to be treatable with SYNAGIS, an antibody directed to the F protein of respiratory syncytial virus), kidney transplant (ZENAPAX, an anti-IL-2 receptor antibody, has shown to be helpful), Crohn's disease and rheumatoid arthritis (shown to be treatable with REMICADE, an anti-TNF alpha antibody), breast carcinoma (shown to be treatable with OERCEPTIN, an anti- HER2 antibody), and colon cancer (shown to be treatable with EDRECOLOMAB, an anti- 17-1 A antibody).
- a polypeptide variant with improved ADCC activity is employed in the treatment of diseases or disorders where destruction or elimination of tissue or foreign microorganisms is desired.
- the variant may be used to treat cancer; inflammatory disorders; infections (e.g. bacterial, viral, fungal or yeast infections); and other conditions (such as goiter) where removal of tissue is desired.
- the polypeptide variant has diminished ADCC activity (e.g. the I332R or I332K variant).
- Such variants may h»e used to treat diseases or disorders where an Fc region-containing polypeptide with long half-life is desired, but the polypeptide preferably does not have undesirable effector func ⁇ ion(s).
- the Fc region-containing polypeptide may be an anti-tissue factor (TF) antibody; anti-IgE antibody; and anti-integrin antibody (e.g. an anti- ⁇ 4 ⁇ 7 antibody ⁇ ).
- TF tissue factor
- anti-IgE antibody anti-integrin antibody
- the desired mechanism of action of such Fc region-containing polypeptides may be to block ligand-receptor binding pairs.
- the Fc-region containing polypeptide with diminished ADCC activity may be an agonist antibody.
- polypeptide variants of the present invention may be admimstered by any suitable means, including parenteral, subcutaneous, topical, intraperitoneal, intrapulmonary, and intranasal, and, intralesional administration (e.g. for local immunosuppressive treatment).
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the polypeptide variant is suitably administered by pulse infusion, particularly with declining doses of the polypeptide variant.
- the dosing is given by injections, most preferably intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
- polypeptide variant For the prevention or treatment of disease, the appropriate dosage of polypeptide variant will depend on the type of disease to be treated, the severity and course of the disease, whether the polypeptide variant is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the polypeptide variant, and the discretion of the attending physician.
- the polypeptide variant is suitably admimstered to the patient at one time or over a series of treatments. For example, depending on the type and severity of the disease, about 1 ⁇ g/kg to
- 15 mg/kg (e.g., 0.120 mg/kg) of polypeptide variant is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
- a typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned above.
- the treatment is sustained until the symptoms are sufficiently reduced or eliminated. The progress of this therapy is easily monitored by conventional techniques and assays, and may be used to adjust dosage to achieve a therapeutic effect.
- a therapeutically effective amount of a polypeptide variant to be administered is the dosage level required for a patient such that the symptoms of the disease being treated are reduced.
- the polypeptide variant need not be, but is optionally formulated with one or more agents cunently used to prevent or treat the disorder in question.
- the effective amount of such other agents depends on the amount of polypeptide variant present in the formulation, the type of disorder or treatment, and other factors discussed above.
- variants, and nucleic acid sequences encoding variants, of the present invention may be used in many ways.
- variants of the present invention may be used in drug screening assays.
- candidate compounds may be evaluated for their ability to alter or interfere with Fc effector functions by contacting a variant with the candidate compound and determining binding of the candidate compound to the variant.
- the variant may be immobilized using methods known in the art such as binding a GST-variant fusion protein to a polymeric bead containing glutathione.
- a chimeric gene encoding a GST fusion protein is constructed by fusing DNA encoding the variant of interest to the DNA encoding the carboxyl terminus of GST (See e.g.
- the fusion construct is then transformed into a suitable expression system (e.g., E. coli XA90) in which the expression of the GST fusion protein can be induced with isopropyl- ⁇ -D-thiogalactopyranoside (IPTG). Induction with IPTG should yield the fusion protein as a major constituent of soluble, cellular proteins.
- IPTG isopropyl- ⁇ -D-thiogalactopyranoside
- the fusion proteins can be purified by methods known to those skilled in the art, including purification by glutathione affinity chromatography. Binding of the candidate compound to the variant is conelated with the ability of the compound to disrupt the one or more effector functions.
- either the variant or a selected FcR is immobilized using methods known in the art, such as adsorption onto a plastic microtiter plate or specific binding of a GST-fusion protein to a polymeric bead containing glutathione.
- GST-variant is bound to glutathione-Sepharose beads.
- the immobilized variant is then contacted with an Fc receptor and a candidate compound. Unbound peptide is then removed and the complex solubilized and analyzed to determine the amount of bound labeled peptide.
- a decrease in binding is an indication that the candidate compound inhibits the interaction of variant with the Fc receptor.
- This screening method is particularly useful with variants of the present invention that show an increased level of Fc receptor binding (e.g.
- a variation of this method allows for the screening of compounds that are capable of disrupting a previously-formed variant/Fc receptor complex.
- a complex comprising a variant bound to an Fc receptor is immobilized as described above and contacted with a candidate compound.
- the dissolution of the complex by the candidate compound conelates with the ability of the compound to disrupt or inhibit the interaction between the variant being tested and the Fc receptor being.
- compounds with therapeutic potential e.g. in humans
- compounds useful in treating human disease, such as autoimmune diseases may be identified (e.g. compounds useful in treating human disease, such as autoimmune diseases).
- Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to variant peptides and is described in detail in WO 84/03564, incorporated herein by reference. Briefly, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are then reacted with variant peptides and washed. Bound variant peptides are then detected by methods well known in the art. Another technique uses antibodies directed to variant peptides. Such antibodies capable of specifically binding to variant peptides compete with a test compound for binding to a given variant. In this manner, the antibodies can be used to detect the presence of any peptide that shares one or more antigenic determinants of the variant peptide.
- the present invention contemplates many other means of screening compounds.
- the examples provided above are presented merely to illustrate a range of techniques available.
- One of ordinary skill in the art will appreciate that many other screening methods can be used.
- the present invention contemplates the use of cell lines transfected with nucleic acid encoding at least one Fc region variant for screening compounds for activity, and in particular to high throughput screening of compounds from combinatorial libraries (e.g., libraries containing greater than 10 ⁇ compounds).
- the cell lines of the present invention can be used in a variety of screening methods.
- the variants of the present invention may be used as an affinity purification agent.
- the variant may be immobilized on a solid phase such a Sephadex resin or filter paper, using methods well known in the art.
- the immobilized variant is then contacted with a sample containing the antigen to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the antigen to be purified, which is bound to the immobilized polypeptide variant. Finally, the support is washed with another suitable solvent, such as glycine buffer, pH 5.0, that will release the antigen from the polypeptide variant.
- a suitable solvent such as glycine buffer, pH 5.0
- the polypeptide variant may also be useful in diagnostic assays (e.g., for detecting expression of an antigen of interest in specific cells, tissues, or serum).
- the variant will typically be labeled with a detectable moiety (such labels are also useful in the Fc region assays described above).
- radioisotopes e.g., S, C, I, H, and I
- Fluorescent labels e.g. rare earth chelates (europium chelates) or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, Lissamine, phycoerythrin and Texas Red
- enzyme-substrate labels see, e.g., U. S. Patent No.
- luciferase luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, ⁇ -galactosidase, glucoamylase, lysozyme, saccharide oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (such as uricase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like).
- HRPO horseradish peroxidase
- alkaline phosphatase alkaline phosphatase
- ⁇ -galactosidase glucoamylase
- lysozyme saccharide oxidases
- glucose oxidase galact
- enzyme-substrate combinations include, for example: (i) horseradish peroxidase (HRPO) with hydrogen peroxidase as a substrate, wherein the hydrogen peroxidase oxidizes a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3', 5,5'-tetramethyl benzidine hydrochioride (TMB)); (ii) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and (iii) -D-galactosidase (R- D-Gai) with a chromogenic substrate or fluorogenic substrate.
- HRPO horseradish peroxidase
- OPD orthophenylene diamine
- TMB 3,3', 5,5'-tetramethyl benzidine hydrochioride
- AP alkaline phosphatase
- R- D-Gai -D-galactosidase
- the variants of the present invention may also be used for in vivo diagnostic assays.
- the polypeptide variant is labeled with a radionuclide so that the antigen or cells expressing it can be localized using immunoscintiography.
- EXAMPLE 1 Screening Variants in ADCC Assays This example describes how variants were screened in an ADCC assay. All variants screened were anti-CD20 antibodies (based on variable region specificity). i. PBMC (peripheral blood mononuclear cell) isolation About 50 mL of peripheral blood is obtained from a healthy donor and diluted 1 :2 with phosphate buffered saline (PBS), pH 7.0. The solutions are mixed by gently swirling the tube. About 12 mL of Histopaque-1077 (Sigma Cat. No.
- PBS phosphate buffered saline
- the resuspended PBMCs are split into two T-175 culture flasks, and 30 mL of RPMI containing 10% FBS is added to each followed by incubation overnight in a 37°C 5% CO 2 incubator. The following day the nonadherent PBMCs are collected in 50 mL Falcon tubes, centrifuged as above and resuspended in RPMI containing 1% FBS lacking phenol red. A small portion of the resuspended cells are diluted 10-fold and counted using a hemocytometer. The remaining PBMCs are placed in the incubator until needed. ii.
- Target cell line (these are specific for anti-CD20 ADCC assays) Wil.2 and SKW6.4 CD20-ex ⁇ ressing B-cell lines were obtained from ATCC and grown as recommended. One day before use, the cells are split 2-fold. The next day the cell number is adjusted to 4 X 10 5 cells/mL and 50 ⁇ L aliquots (20,000 cells/well) added to a 96-well tissue culture plate. iii. IgG dilutions Prior to screening, IgG variants are expressed and quantitated using a standard enzyme-linked immunosorbent assay (ELISA). For primary single-point ADCC screening IgG variants are diluted to 40 ng/mL in RPMI media containing 1% FBS lacking phenol red.
- ELISA enzyme-linked immunosorbent assay
- the final IgG concentration in the assay will be diluted by 4-fold (i.e. 10 ng/mL final concentration). Fifty microliter aliquots of IgG are added to the target cells and incubated for about 15 minutes at 37°C prior to adding the effector cells to the opsonized target cells. When IgG titrations are performed, IgG concentration is varied in the range from about .0001 to 1 ⁇ g/mL. IgG dilutions are prepared using a 96-well microtiter plate by diluting the samples in RPMI containing 1% FBS lacking phenol red. The diluted IgG samples are then added to the assay plate containing the target cells. iv.
- Effector cells The concentration of the PBMCs are adjusted so that the effector-to-target ratio is in the range of 10-20: 1 (i.e. 2-4 X 10 6 cells/mL).
- One hundred microliters of the resuspended PBMCs are added to each well of the opsonized target cells. The plates are incubated at 37°C in the presence of 5% CO 2 for 3-4 hours.
- LDH Lactate-dehydrogenase-release detection
- Target cell lysis is measured by detecting the release of lactate dehydrogenase enzyme from the cytoplasm of damaged cells into the culture supernatant. Following incubation of the opsonized target cells with the effector cells, the assay plates are centrifuged at 2000 m for 5 minutes. About 75 ⁇ L of the cell culture supernatant is carefully removed while the pelleted cells and debris are avoided. This supernatant is added directly to a microtiter plate and to this is added 75 ⁇ L of LDH detection reagent (Roche Cat. No. 1 644 793).
- the plate is then incubated for approximately 15-30 minutes and the absorbance read at 490 nm using a Molecular Devices Vmax Kinetic Microplate Reader.
- Data Analysis All single-point ADCC screening assays are performed in duplicate. Each assay plate contains controls for spontaneous target lysis, spontaneous effector plus target lysis in the absence of IgG and target cell total lysis. Target cell total lysis is achieved by addition of 1% Triton X-100 to the target cells. Three wild type controls are included on each assay plate and the ADCC assay signal averaged. The background value, obtained from the spontaneous lysis controls, is subtracted from each sample. The background value, obtained from the diluted IgG, is subtracted from each sample.
- the data are converted from absorbance values to percentage of specific-lysis based upon the spontaneous and total lysis controls.
- the percentage of the Fc variant activity is normalized relative to the averaged wild type controls. The percentage of the normalized activity for duplicate assay plates are averaged and the standard deviation between individual assay plates calculated for each sample.
- Figure 7A shows representative ADCC data obtained following titration of IgG variants.
- SKW6.4 cells were opsonized using both single and double amino acid Fc-region IgG variants followed by addition of PBMCs at a ratio of 15 : 1.
- the assay plate was incubated at 37°C in the presence of 5% CO 2 for 3 hours, followed by centrifugation. A portion of the supernatant was collected and transfened to a microtiter plate and the LDH activity in the supernatant detected by addition of an equal volume of LDH substrate. Following color development the absorbance was read at 490 nm.
- FIG. 7B shows that the activity of the 1332 variant can be further enhanced with altered glycosylation (by increasing bisecting GlcNAc content, for eg)-
- Figure 8 shows representative ADCC data obtained using purified IgG.
- the plot shows percentage cytotoxicity versus IgG concentration for a non-specific IgG, wild type anti-CD20 and Fc-region variants I332D and I332E.
- the data show that the ADCC activity of the I332D and I332E variants are enhanced compared to the wild type.
- the target cells used in this experiment were SKW6.4 and an effector-to-target ratio of 15:1 was used in a standard 3 hour ADCC assay.
- Figure 9 shows the same type of ADCC activity, except a lower affinity variable region is employed (AME 6F1 instead of AME 33). This figure demonstrates that ADCC activity with this particular anti-CD20 specificity and the Wil-2 and SKW6.4 cell lines is independent of variable region affinity.
- Figure 10 shows Fc gamma RI receptor binding.
- the extracellular portion of the human Fc gamma RI receptor (CD64) with a C-terminal 6-his tag added in place of the putative transmembrane domain was expressed in HEK-293 A cells and purified using a Ni-column.
- the receptor was coated overnight at 4°C on an ELISA plate and the plate was subsequently blocked using Superblock. After blocking and washing, IgG dilutions were prepared and added to the receptor-coated plate followed by incubation at 37°C for 2 hours. Unbound IgG was removed by washing and bound antibody detected using a 1:1000 of an anti-human Kappa alkaline phosphatase conjugated secondary antibody.
- IgG was detected by addition of the phosphatase substrate (phenolphthalein monophosphate) (PPMP) ( BL Scientific) with absorbance determined colorimetrically at 560 nm with a VMAX microplate reader (Molecular Devices, Sunnyvale, CA). Data are plotted as log IgG concentration versus absorbance.
- PPMP phenolphthalein monophosphate
- VMAX microplate reader Molecular Devices, Sunnyvale, CA
- Example 2 Screening Variants for B Cell Depletion in Whole Blood Assay This example describes screening variants for B cell depletion in a whole blood assay.
- Fc ⁇ RIIA Genotyping Genomic DNA was isolated from peripheral blood samples using the QiaAmp kit (Qiagen, Cat No. 51104). Fc ⁇ RIIA was amplified by PCR using the primers (5' GGAAAATCCCAGAAATTCTCGC y - SEQ ID NO:61) and (5' CAACAGCCTGAC TACCTATTACGCGGG 3' - SEQ ID NO:62). PCR products were purified using a
- MinElute PCR purification kit (Qiagen, Cat No. 28006) and digested with the restriction enzyme, BstUI, at 60°C for 12 hours. Digested samples were analyzed on 3% agarose gels. All PCR products cut at an internal BstUI site independent of the H or R genotype. Products that possess the R allele cut at an additional BstUI site. This results in the H/H genotype being identified by one fragment of 337bp, H/R being identified by two fragments of 337 bp and 316 bp and R/R identified by one fragment of 316bp. ii. Fc ⁇ RIIIA Genotyping Genomic DNA was isolated from peripheral blood samples using the QiaAmp kit (Qiagen, Cat No.
- Fc ⁇ RIIIA was amplified from genomic DNA by PCR using the primers (5' ATATTTACAGAATGGCA 3' - SEQ ID NO:63) and (5' GGTGATGT TCACAGTCTCTGAAGACACATTTTTACTGTCAA 3 ' - SEQ ID NO:64J.
- PCR products were purified using a MinElute PCR purification kit (Qiagen, Cat No. 28006) and digested with the restriction enzyme, Hindi, at 37°C for 16 hours. Digested samples were analyzed on 3% NuSieve agarose gels. Hindi cuts the V allele but not the F allele.
- F/F gives one fragment of 148bp
- F/V gives three fragments of 148, 109, and 39bp
- V/V gives two fragments of 109 and 39bp.
- Tubes were incubated for four hours at 37°C and then stained with fluorescein-anti-CD45 (to identify leucocytes) (BD, cat#555482) and phycoerythrin-anti-CD19 (to identify B cells) (BD, cat#555413) for 30 minutes at room temperature. Red cells were lysed by the addition of BD PharmLyse, (BD, cat#555899), samples were washed and resuspended in FACS buffer for analysis on a Becton Dickinson FACSort flow cytometer. Immediately before analysis, propidium iodide (PI), 0.1 ⁇ g/ml final concentration, was added to the samples to discriminate between live and dead cells.
- PI propidium iodide
- Controls included cells that had been incubated with FACS buffer alone, unstained and single-color stained samples. Each sample was set up in triplicate and 10,000 Pi-negative events falling within the lymphocyte forward/side scatter (FSCSSC) gate were collected. Data was analyzed using WinMDI software. For analysis, live lymphocytes were identified on the basis of positive staining with CD45, PI negativity and FSC/SSC characteristics. In each sample the percentage of CD 19+ cells with these characteristics was identified. Data was expressed as mean % CD 19+ cells plus/minus 1 standard deviation. Alternatively, to facilitate comparison between donors, data was expressed as % of initial CD 19+ cells remaining i.e.
- FSCSSC lymphocyte forward/side scatter
- FIG. 12 shows representative B cell depletion data demonstrating that the I332E variant depeletes B cells more potently and to a greater extent than Rituxan in a whole blood sample containing the VV (high affinity) genotype of the Fc ⁇ RIIIa receptor.
- Figure 13 shows representative B cell depletion data demonstrating that the I332E variant depeletes B cells more potently and to a greater extent than Rituxan in a whole blood sample containing the FF (low affinity) genotype of the Fc ⁇ RIIIa receptor. Similar results are obtained when the assay is performed with whole blood displaying the VF (heterozygous) genotype for the Fc ⁇ RIIIa receptor or with HH, HR, or RR genotypes of the Fc ⁇ RIIa receptor (Table 3).
- Figure 14 shows representative B cell depletion data demonstrating that variant A378D unexpectedly depeletes B cells more potently and to a greater extent than variants with equal or greater activity in in vitro ADCC and CDC assays.
- Example 3 Affinity Determination of Variant This examples describes how the affinity (Kd) of the interaction between Fc ⁇ RIIIa (FF genotype) and wild type, or parental, Fc and variant I332E was determined.
- Kd affinity of the interaction between Fc ⁇ RIIIa
- Fc ⁇ RIIIa/IgG Kd analysis Human Fc ⁇ RIIIa(158F) soluble extracellular domain was expressed in 293 cells and purified by Ni-NTA resin binding to its engineered 6-histidine tag.
- One tube of Azlactone beads (Sapidyne) was coupled with lmg of Fc ⁇ RIII(158F) in sodium bicarbonate buffer pH 9.3.
- Example 4 Characterization of CDC Activity of Variants This example descibes how the CDC activity of various Fc region variants was determined. . Assay This assay was canied out using human complement (Quidel Corp., cat#Al 13) on
- Ramos (RA #1) cell (ATCC Catalog No. CRL-1596). Ramos cells were cultured in Gibco RPMI1640 media containingl0% FBS at 37°C and 5% CO2. The day before the assay, cells were seeded at 1 x 10 6 cells in a T175 flask. The following day, the cells were resuspended to 3.57 x 10 5 cells/ml in RPMI 1640 without phenol red containing 1% FBS. Distribute 70 ⁇ l cells per well to a Costar 3917 flat bottom plate. For titration curve, variant IgG was prepared in a 3-fold serial dilution in RPMI 1640 media.
- transiently expressed IgG variant in culture supernatant was normalized to 1 ⁇ g/ml in mock media.
- Thirty microliter of variant IgG (i.e. 200 ng/ml final concentration) and 50 ⁇ l of human complement (Quidel Corp., cat#A113) 1:5 diluted in RPMI1640 + 1% FBS was added to the target cell andmixed well by gentle pipetting.
- the plates were incubated at 37°C in the presence of 5% CO 2 for 1.5 hours. After addition of 15 ⁇ l/well of Alamar Blue (Serotec, cat#BUF012B) the incubation continued overnight.
- the fluorescence signal was measured by PerkinElmer's EnVision 2100 multilabel reader with excitation at 560 nm and emission at 590 nm.
- Figure 11 A, B, and C shows representative CDC data obtained following titration of IgG variants.
- Ramos cells were lysed using both single and double amino acid Fc-region IgG variants and human complement.
- the assay plate was incubated at 37°C in the presence of 5% CO 2 for 1.5 hours, followed by addition of 15 ⁇ l of Alamar blue and overnight incubation. The fluorescence signal was measured and plotted against the IgG concentrations.
- Example 5 Characterization of Binding to FcRn This Example describes assays for Fc neonatal receptor (FcRn) binding to variant IgG.
- FcRn Fc neonatal receptor binding to variant IgG.
- a U-bottom 96-well ELISA plate was coated (Costar) with 50 ⁇ l/well of 2 ⁇ g/ml Neutravidin (Pierce Biotechnology, Cat#31000) in 50 mM Carbonate buffer (pH 9.3) at 4°C overnight. Unbound NeutraAvidin was removed and the plate was washed three times with PBST (PBS containing 0.1% Tween 20). 50 ⁇ l/well biotin-labeled soluble FcRn at 2.5 ⁇ g/ml in PBS was applied and incubated at room temperature for 1 hr.
- PBST PBS containing 0.1% Tween 20
- variant IgG was prepared by a 3-fold serial dilution in FcRn-binding buffer (100 mM NaPO 4 , 0.05% Tween-20 at different pH (from 6.0 to 7.4).
- FcRn-binding buffer 100 mM NaPO 4 , 0.05% Tween-20 at different pH (from 6.0 to 7.4).
- transient expressed variant IgG in culture supernatant was normalized to final concentration of 50 ng/ml (200 ng/ml for pH 7.4 binding) and pH adjusted with FcRn binding buffer to 6.0.
- FcRn-binding buffer at conespondingly pH was used to wash the plate and to dilute reagents.
- the binding reaction was carried out at room temperature for 1 hr. After three washes, bound IgG was detected by goat (Fab')2 anti-human-Fab-HRP conjugate for 1 hr.
- HRP activity was developed in Pierce's HRP substrate (Turbo TMB-ELISA, Cat#34022) for 5-30 minutes. Reaction was stopped by addition of 50 ⁇ l of 2 M H 2 SO and the absorbance at 450nm was read with a VMAX microplate reader (Molecular Devices).
- patients presenting with stage II to IV disease according to the Ann- Arbor classification, having at least one measurable disease site, and low tumor burden according to the GELF criteria could be treated with a total of four approximately 375 mg/m 2 doses of an anti- CD20-I332E Fc variant or with RITUXAN administered by intravenous infusion (days 1, 8, 15, and 22).
- the primary efficacy end point is the objective response rate, ie, the proportion of patients achieving either complete remission (CR), unconfirmed CR (Cru), or partial response (PR) according to criteria recently proposed by an international expert committee.
- Clinical response may be evaluated at month two (M2).
- Patients may also be evaluated for progression at 1 year (Ml 2).
- the objective response rates at M2 and Ml 2 for patients treated with RITUXAN or anti-CD20-I332E can be compared such that the improved ADCC activities provided by I332E variants may be quantified.
- This same example could be repeated with other anti-CD20 variants (eg., I332D, P247L A330K, A339T, A378D, or combinatorial as shown in Table 1).
- the enhanced potency of the variants may permit different routes of administration, less frequent injections, and/or admimsfration of smaller doses.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steering Control In Accordance With Driving Conditions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL05704868T PL1706424T3 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
CA2552788A CA2552788C (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
JP2006549330A JP4762156B2 (en) | 2004-01-12 | 2005-01-10 | Fc region variant |
KR1020067013897A KR101149242B1 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
AU2005206473A AU2005206473B2 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
EP05704868A EP1706424B1 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
CN2005800049248A CN1918178B (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
BRPI0506771-5A BRPI0506771A (en) | 2004-01-12 | 2005-01-10 | antibody and pharmaceutical composition |
AT05704868T ATE437184T1 (en) | 2004-01-12 | 2005-01-10 | VARIANTS OF THE FC REGION |
DK05704868T DK1706424T3 (en) | 2004-01-12 | 2005-01-10 | FC region variants |
US10/584,692 US20080089892A1 (en) | 2004-01-12 | 2005-01-10 | Fc Region Variants |
EA200601313A EA009746B1 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
SI200530808T SI1706424T1 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
DE602005015542T DE602005015542D1 (en) | 2004-01-12 | 2005-01-10 | VARIANTS OF FC REGION |
IL176674A IL176674A (en) | 2004-01-12 | 2006-07-03 | Fc region variants |
NO20063624A NO339745B1 (en) | 2004-01-12 | 2006-08-10 | Antibody and pharmaceutical preparation. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53576404P | 2004-01-12 | 2004-01-12 | |
US60/535,764 | 2004-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005070963A1 true WO2005070963A1 (en) | 2005-08-04 |
Family
ID=34806962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/000013 WO2005070963A1 (en) | 2004-01-12 | 2005-01-10 | Fc region variants |
Country Status (21)
Country | Link |
---|---|
US (1) | US20080089892A1 (en) |
EP (2) | EP1706424B1 (en) |
JP (1) | JP4762156B2 (en) |
KR (1) | KR101149242B1 (en) |
CN (1) | CN1918178B (en) |
AT (1) | ATE437184T1 (en) |
AU (1) | AU2005206473B2 (en) |
BR (1) | BRPI0506771A (en) |
CA (1) | CA2552788C (en) |
CY (1) | CY1109382T1 (en) |
DE (1) | DE602005015542D1 (en) |
DK (1) | DK1706424T3 (en) |
EA (1) | EA009746B1 (en) |
ES (1) | ES2328369T3 (en) |
IL (1) | IL176674A (en) |
NO (1) | NO339745B1 (en) |
PL (1) | PL1706424T3 (en) |
PT (1) | PT1706424E (en) |
SI (1) | SI1706424T1 (en) |
UA (1) | UA86605C2 (en) |
WO (1) | WO2005070963A1 (en) |
Cited By (287)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
WO2006020114A2 (en) * | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006105338A3 (en) * | 2005-03-31 | 2007-03-29 | Xencor Inc | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
WO2007080274A1 (en) * | 2005-12-16 | 2007-07-19 | Lfb Biotechnologies | Antibody characterization test |
WO2007119796A1 (en) * | 2006-04-14 | 2007-10-25 | Medical And Biological Laboratories Co., Ltd. | Mutant polypeptide having effector function |
WO2008008482A2 (en) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
WO2008032833A1 (en) * | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
EP1991572A2 (en) * | 2006-02-17 | 2008-11-19 | Syntonix Pharmaceuticals, Inc. | Peptides that block the binding of igg to fcrn |
WO2009054435A1 (en) | 2007-10-24 | 2009-04-30 | Otsuka Chemical Co., Ltd. | Polypeptide having enhanced effector function |
JP2009095249A (en) * | 2007-10-12 | 2009-05-07 | Igaku Seibutsugaku Kenkyusho:Kk | Antibody improved in effector function |
WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
EP2119780A1 (en) * | 2007-01-24 | 2009-11-18 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
WO2010001908A1 (en) | 2008-06-30 | 2010-01-07 | 協和発酵キリン株式会社 | Anti-cd27 antibody |
US7659374B2 (en) | 2004-08-16 | 2010-02-09 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010074266A1 (en) | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | Anti-cd4 antibody |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
US7863419B2 (en) | 2003-08-22 | 2011-01-04 | Biogen Idec Ma Inc. | Antibodies having altered effector function and methods for making the same |
WO2011053982A2 (en) | 2009-11-02 | 2011-05-05 | University Of Washington | Therapeutic nuclease compositions and methods |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
WO2011108502A1 (en) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | Modified antibody composition |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039595B2 (en) | 2000-10-06 | 2011-10-18 | Kyowa Hakko Kirin Co., Ltd. | Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation |
EP2377527A1 (en) | 2007-01-22 | 2011-10-19 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8133982B2 (en) | 2004-05-10 | 2012-03-13 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
WO2012064627A2 (en) | 2010-11-08 | 2012-05-18 | Genentech, Inc. | Subcutaneously administered anti-il-6 receptor antibody |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
WO2012142515A2 (en) | 2011-04-13 | 2012-10-18 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
WO2012149440A2 (en) | 2011-04-29 | 2012-11-01 | University Of Washington | Therapeutic nuclease compositions and methods |
US8309690B2 (en) | 2005-07-01 | 2012-11-13 | Medimmune, Llc | Integrated approach for generating multidomain protein therapeutics |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2012176779A1 (en) | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | Anti-erbb3 antibody |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
US8409568B2 (en) | 2005-10-14 | 2013-04-02 | Medimmune, Llc | Mutant antibody Fc domains and fusion proteins thereof |
WO2013047729A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule inducing immune response to target antigen |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013004842A3 (en) * | 2011-07-06 | 2013-04-04 | Genmab A/S | Antibody variants and uses thereof |
WO2013047752A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule for promoting loss of antigens |
WO2013081143A1 (en) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Drug containing carrier into cell for forming immune complex |
WO2013085972A1 (en) | 2011-12-05 | 2013-06-13 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
EP2604628A2 (en) | 2007-12-21 | 2013-06-19 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013100120A1 (en) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
WO2013147153A1 (en) | 2012-03-29 | 2013-10-03 | 株式会社未来創薬研究所 | Anti-lamp5 antibody and utilization thereof |
WO2013148296A1 (en) | 2012-03-28 | 2013-10-03 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
WO2013169657A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
WO2013175427A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V. | Il-6 binding molecules |
WO2013180200A1 (en) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | Target-tissue-specific antigen-binding molecule |
WO2013180201A1 (en) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | Antigen-binding molecule for eliminating aggregated antigens |
WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
WO2013185114A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
US8618252B2 (en) | 2003-11-12 | 2013-12-31 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014007303A1 (en) | 2012-07-06 | 2014-01-09 | 学校法人 聖マリアンナ医科大学 | Therapeutic method and remedy for htlv-1-associated myelopathy patients |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
EP2703011A2 (en) | 2007-05-07 | 2014-03-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US8679491B2 (en) | 1999-04-09 | 2014-03-25 | Kyowa Hakko Kirin Co., Ltd. | Method of modulating the activity of functional immune molecules |
EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
US8697071B2 (en) | 2005-08-10 | 2014-04-15 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2014088040A1 (en) | 2012-12-06 | 2014-06-12 | 国立大学法人 金沢大学 | Method for treating mesothelioma |
WO2014097648A1 (en) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective |
WO2014108198A1 (en) | 2013-01-10 | 2014-07-17 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
WO2014164534A2 (en) | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US8871907B2 (en) * | 2004-05-31 | 2014-10-28 | Korea Prime Pharm Co., Ltd | Glycosylated immunoglobulin and immunoadhesin comprising the same |
WO2014208482A1 (en) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
WO2015066557A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease molecules with altered glycosylation and methods |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
WO2015083764A1 (en) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
WO2015085210A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
WO2015106052A1 (en) | 2014-01-10 | 2015-07-16 | Biogen Ma Inc. | Factor viii chimeric proteins and uses thereof |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
WO2015143271A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2016046301A1 (en) | 2014-09-26 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
WO2016061286A2 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
US9376672B2 (en) | 2009-08-24 | 2016-06-28 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
US9657106B2 (en) | 2003-03-03 | 2017-05-23 | Xencor, Inc. | Optimized Fc variants |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
AU2012313670B2 (en) * | 2011-09-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
US9708408B2 (en) | 2006-12-08 | 2017-07-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibiting |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
WO2017136358A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
US9737599B2 (en) | 2006-06-26 | 2017-08-22 | Macrogenics, Inc. | Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017161173A1 (en) | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
WO2017196663A1 (en) | 2016-05-09 | 2017-11-16 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
US9822181B2 (en) | 2013-08-23 | 2017-11-21 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9845363B2 (en) | 2013-08-13 | 2017-12-19 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof |
WO2018005954A2 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US9889197B2 (en) | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
US9932400B2 (en) | 2013-08-23 | 2018-04-03 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
WO2018102760A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
WO2018101448A1 (en) | 2016-11-30 | 2018-06-07 | Kyowa Hakko Kirin Co., Ltd. | Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody |
WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
WO2018139404A1 (en) | 2017-01-24 | 2018-08-02 | 協和発酵キリン株式会社 | Therapeutic or prophylactic agent and treatment or prevention method for radiation sickness |
WO2018146317A1 (en) * | 2017-02-10 | 2018-08-16 | Genmab B.V. | Polypeptide variants and uses thereof |
WO2018151821A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
US10064952B2 (en) | 2014-10-09 | 2018-09-04 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
WO2018159845A1 (en) | 2017-03-02 | 2018-09-07 | 学校法人 聖マリアンナ医科大学 | Preventive or therapeutic agent for htlv-1-associated myelopathy using low-dose anti-ccr4 antibody |
US10100116B2 (en) | 2006-06-26 | 2018-10-16 | Macrogenics, Inc. | FcγRIIB-specific antibodies and methods of use thereof |
WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2018213097A1 (en) | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
WO2018218056A1 (en) | 2017-05-25 | 2018-11-29 | Birstol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP2925350B1 (en) | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
WO2019032898A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
WO2019040674A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
US10279021B2 (en) | 2014-03-14 | 2019-05-07 | Dana-Faber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
WO2019118873A2 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
EP3505179A1 (en) | 2012-01-12 | 2019-07-03 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
US10344092B2 (en) | 2013-08-09 | 2019-07-09 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
WO2019160829A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US10421798B2 (en) | 2012-02-15 | 2019-09-24 | Bioverativ Therapeutics Inc. | Factor VIII compositions and methods of making and using same |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
WO2019195126A1 (en) | 2018-04-02 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
EP3557260A1 (en) | 2012-12-21 | 2019-10-23 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
WO2019222682A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
WO2019236417A1 (en) | 2018-06-04 | 2019-12-12 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
WO2020010117A2 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Fgf21 formulations |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
EP3620472A1 (en) | 2013-08-13 | 2020-03-11 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
EP3632462A1 (en) * | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
US10618965B2 (en) | 2011-02-25 | 2020-04-14 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020142740A1 (en) | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
WO2020154293A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
WO2020180733A1 (en) | 2019-03-01 | 2020-09-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020189748A1 (en) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
US10793633B2 (en) | 2011-09-30 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
WO2020206063A1 (en) | 2019-04-03 | 2020-10-08 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
WO2020254197A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
WO2021011681A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
EP3789399A1 (en) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
US10947269B2 (en) | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
US10995148B2 (en) | 2014-03-19 | 2021-05-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
WO2021174034A1 (en) | 2020-02-28 | 2021-09-02 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2021202235A1 (en) | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021222935A2 (en) | 2020-04-28 | 2021-11-04 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
US11168125B2 (en) | 2003-05-06 | 2021-11-09 | Bioverativ Therapeutics Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
US11186638B2 (en) | 2011-09-12 | 2021-11-30 | Genzyme Corporation | Anti-αβTCR antibody |
WO2022006153A1 (en) | 2020-06-29 | 2022-01-06 | Resolve Therapeutics, Llc | Treatment of sjogren's syndrome with nuclease fusion proteins |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2022076952A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022098870A1 (en) | 2020-11-04 | 2022-05-12 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
WO2022147196A2 (en) | 2020-12-31 | 2022-07-07 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
WO2022155324A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
US11401348B2 (en) | 2009-09-02 | 2022-08-02 | Xencor, Inc. | Heterodimeric Fc variants |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
WO2022204564A2 (en) | 2021-03-25 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
WO2022204155A1 (en) | 2021-03-23 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2023004074A2 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
US11578141B2 (en) * | 2011-04-20 | 2023-02-14 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
US11642398B2 (en) | 2013-03-15 | 2023-05-09 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
EP4223783A2 (en) | 2012-09-12 | 2023-08-09 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
US11820830B2 (en) | 2004-07-20 | 2023-11-21 | Xencor, Inc. | Optimized Fc variants |
US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
US11932685B2 (en) | 2007-10-31 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024112711A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
US12049512B2 (en) | 2011-07-06 | 2024-07-30 | Genmab B.V. | Antibody variants and uses thereof |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090215639A1 (en) * | 2005-04-26 | 2009-08-27 | Bioren, Inc. | Method of Producing Human IgG Antibodies with Enhanced Effector Functions |
US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
RU2549695C2 (en) * | 2009-12-21 | 2015-04-27 | Ридженерон Фармасьютикалз, Инк. | FCγR HUMANISED MICE |
TWI667346B (en) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
EP2598168A4 (en) * | 2010-07-28 | 2014-03-26 | Merck Sharp & Dohme | Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor |
JP2013537416A (en) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | Monomer polypeptide containing mutant Fc region and method of use |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
CA2830254C (en) | 2011-03-16 | 2019-09-10 | Amgen Inc. | Fc variants |
KR20200120743A (en) * | 2011-07-06 | 2020-10-21 | 젠맵 비. 브이 | Antibody variants and uses thereof |
ES2749349T3 (en) | 2011-11-07 | 2020-03-19 | Medimmune Llc | Multispecific and multivalent binding proteins and uses thereof |
CN118005782A (en) | 2013-10-02 | 2024-05-10 | 免疫医疗有限责任公司 | Neutralizing anti-influenza a antibodies and uses thereof |
GEP20237479B (en) | 2013-10-18 | 2023-03-27 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
KR20230104764A (en) | 2013-11-11 | 2023-07-10 | 추가이 세이야쿠 가부시키가이샤 | Antigen-binding molecule containing modified antibody variable region |
TWI740809B (en) | 2014-11-11 | 2021-10-01 | 日商中外製藥股份有限公司 | Database of antigen-binding molecules containing altered antibody variable regions |
EP3633371A1 (en) | 2014-12-18 | 2020-04-08 | F. Hoffmann-La Roche AG | Assay and method for determining cdc eliciting antibodies |
TWI831538B (en) | 2014-12-19 | 2024-02-01 | 日商中外製藥股份有限公司 | ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT Fc REGIONs, AND METHODS OF USE |
US11952422B2 (en) | 2017-12-05 | 2024-04-09 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137 |
JP2018138022A (en) * | 2018-02-23 | 2018-09-06 | ゲンマブ ビー.ブイ. | Human igg1 fc region variants and uses thereof |
CN113227134A (en) | 2018-12-05 | 2021-08-06 | 株式会社梅花治疗 | Fc region variants of antibodies |
CN111909268B (en) * | 2019-05-07 | 2022-04-19 | 北京天成新脉生物技术有限公司 | anti-TNF-alpha humanized monoclonal antibody TCX060 with low immunogenicity and low ADCC/CDC function and application thereof |
GB201910900D0 (en) | 2019-07-31 | 2019-09-11 | Scancell Ltd | Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof |
TW202140553A (en) | 2020-01-13 | 2021-11-01 | 美商威特拉公司 | Antibody molecules to c5ar1 and uses thereof |
EP4166574A1 (en) | 2020-06-10 | 2023-04-19 | Bica Therapeutics Inc. | Fusion protein containing erythropoietin polypeptide |
CN114644708B (en) | 2020-12-18 | 2023-06-27 | 珠海泰诺麦博生物技术有限公司 | Respiratory syncytial virus specific binding molecules |
MX2023008302A (en) | 2021-01-13 | 2023-09-25 | Visterra Inc | Humanized complement 5a receptor 1 antibodies and methods of use thereof. |
Citations (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4312806A (en) | 1981-03-02 | 1982-01-26 | G. D. Searle & Co. | Method and compounds for treating inflammatory bowel disease |
EP0227110A2 (en) * | 1985-12-26 | 1987-07-01 | Teijin Limited | Human immunoglobulin G FC region protein and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
WO1992016562A1 (en) * | 1991-03-12 | 1992-10-01 | Lynxvale Limited | Humanised antibodies having modified allotypic determinants |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5238931A (en) | 1990-07-06 | 1993-08-24 | Zeria Pharmaceutical Co., Ltd. | Inflammatory bowel disease preventive and curative agent containing zinc l-carnosine salt as active ingredient |
US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
WO1994029351A2 (en) * | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5506213A (en) | 1986-02-03 | 1996-04-09 | The Scripps Research Institute | Adminstration of 2'-halo-2'-deoxy adenosine to treat inflammatory bowel disease |
US5569680A (en) | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
US5792795A (en) | 1995-05-15 | 1998-08-11 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US5834021A (en) | 1994-08-12 | 1998-11-10 | Speirs; Christopher J. | Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease |
US5834016A (en) | 1996-04-04 | 1998-11-10 | Cilag Ag | Liposome-based topical vitamin D formulation |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2001027160A1 (en) | 1999-10-14 | 2001-04-19 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2004063351A2 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP2345671B8 (en) * | 2002-09-27 | 2023-01-11 | Xencor, Inc. | Optimized fc variants and methods for their generation |
-
2005
- 2005-01-10 EP EP05704868A patent/EP1706424B1/en active Active
- 2005-01-10 CA CA2552788A patent/CA2552788C/en active Active
- 2005-01-10 AU AU2005206473A patent/AU2005206473B2/en not_active Ceased
- 2005-01-10 EP EP09155531A patent/EP2154157A3/en not_active Withdrawn
- 2005-01-10 BR BRPI0506771-5A patent/BRPI0506771A/en not_active Application Discontinuation
- 2005-01-10 KR KR1020067013897A patent/KR101149242B1/en active IP Right Grant
- 2005-01-10 US US10/584,692 patent/US20080089892A1/en not_active Abandoned
- 2005-01-10 CN CN2005800049248A patent/CN1918178B/en active Active
- 2005-01-10 SI SI200530808T patent/SI1706424T1/en unknown
- 2005-01-10 AT AT05704868T patent/ATE437184T1/en active
- 2005-01-10 UA UAA200607634A patent/UA86605C2/en unknown
- 2005-01-10 EA EA200601313A patent/EA009746B1/en unknown
- 2005-01-10 DK DK05704868T patent/DK1706424T3/en active
- 2005-01-10 JP JP2006549330A patent/JP4762156B2/en not_active Expired - Fee Related
- 2005-01-10 PT PT05704868T patent/PT1706424E/en unknown
- 2005-01-10 ES ES05704868T patent/ES2328369T3/en active Active
- 2005-01-10 DE DE602005015542T patent/DE602005015542D1/en active Active
- 2005-01-10 WO PCT/US2005/000013 patent/WO2005070963A1/en active Application Filing
- 2005-01-10 PL PL05704868T patent/PL1706424T3/en unknown
-
2006
- 2006-07-03 IL IL176674A patent/IL176674A/en active IP Right Grant
- 2006-08-10 NO NO20063624A patent/NO339745B1/en not_active IP Right Cessation
-
2009
- 2009-09-18 CY CY20091100968T patent/CY1109382T1/en unknown
Patent Citations (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4312806A (en) | 1981-03-02 | 1982-01-26 | G. D. Searle & Co. | Method and compounds for treating inflammatory bowel disease |
US4683202B1 (en) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0227110A2 (en) * | 1985-12-26 | 1987-07-01 | Teijin Limited | Human immunoglobulin G FC region protein and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683195B1 (en) | 1986-01-30 | 1990-11-27 | Cetus Corp | |
US5506213A (en) | 1986-02-03 | 1996-04-09 | The Scripps Research Institute | Adminstration of 2'-halo-2'-deoxy adenosine to treat inflammatory bowel disease |
US5091178A (en) | 1986-02-21 | 1992-02-25 | Oncogen | Tumor therapy with biologically active anti-tumor antibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
WO1988007089A1 (en) * | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5238931A (en) | 1990-07-06 | 1993-08-24 | Zeria Pharmaceutical Co., Ltd. | Inflammatory bowel disease preventive and curative agent containing zinc l-carnosine salt as active ingredient |
US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
US5808022A (en) | 1990-08-24 | 1998-09-15 | Ixsys Incorporated | Oligonucleotides having random riplets |
WO1992016562A1 (en) * | 1991-03-12 | 1992-10-01 | Lynxvale Limited | Humanised antibodies having modified allotypic determinants |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1994004690A1 (en) | 1992-08-17 | 1994-03-03 | Genentech, Inc. | Bispecific immunoadhesins |
US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
WO1994029351A2 (en) * | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
US5834021A (en) | 1994-08-12 | 1998-11-10 | Speirs; Christopher J. | Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease |
US5569680A (en) | 1995-02-13 | 1996-10-29 | Trustees Of The Univ. Of Penna | Method of treating inflammatory bowel disease with tributyrin |
US5792795A (en) | 1995-05-15 | 1998-08-11 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
US5711964A (en) | 1995-06-07 | 1998-01-27 | United States Of America | Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D |
US5889028A (en) | 1996-02-09 | 1999-03-30 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5834016A (en) | 1996-04-04 | 1998-11-10 | Cilag Ag | Liposome-based topical vitamin D formulation |
US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6074859A (en) | 1997-07-08 | 2000-06-13 | Kikkoman Corporation | Mutant-type bioluminescent protein, and process for producing the mutant-type bioluminescent protein |
WO2000042072A2 (en) | 1999-01-15 | 2000-07-20 | Genentech, Inc. | Polypeptide variants with altered effector function |
WO2001027160A1 (en) | 1999-10-14 | 2001-04-19 | Applied Molecular Evolution, Inc. | Methods of optimizing antibody variable region binding affinity |
US20030120044A1 (en) | 1999-10-14 | 2003-06-26 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
US20040002587A1 (en) * | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
WO2004063351A2 (en) * | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
Non-Patent Citations (49)
Title |
---|
"Molec. Biology and Biotechnology: A Comprebensive Desk Reference", VCH PUBLISHER |
"Remington's Pharmaceutical Sciences", 1980 |
; HUSTON ET AL., CELL BIOPHYSICS, vol. 22, 1993, pages 189 - 224 |
AKOBOVITS ET AL., NATURE, vol. 362, 1993, pages 255 - 258 |
BERG ET AL., PNAS, vol. 88, 1991, pages 4723 - 4727 |
BURMEISTER ET AL., NATURE, vol. 342, 1994, pages 379 - 383 |
CARTER ET AL., NUCLEIC ACIDS RES., vol. 13, 1985, pages 4431 - 4443 |
CARTER ET AL., PROC. NATL. ACAD. SCI., vol. 89, 1992, pages 4285 |
CARTRON ET AL., BLOOD, vol. 99, 2002, pages 754 |
CHARNOW ET AL., J. IMMUNOL., vol. 153, 1994, pages 4268 |
CHOTHIA ET AL., J. MOL. BIOL., vol. 196, 1987, pages 901 |
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628 |
CLYNES ET AL., NAT. MED., vol. 6, no. 4, April 2000 (2000-04-01), pages 443 - 6 |
CLYNES ET AL., PNAS, vol. 95, 1998, pages 652 - 656 |
CLYNES RA ET AL., NAT MED, vol. 6, 2000, pages 443 |
DAY, E.D.: "Advanced Immunochemistry", 1990, WILEY-LISS, INC. |
DEISENHOFER, BIOCHEMISTRY, vol. 20, no. 9, 1981, pages 2361 - 2370 |
DEISENHOFER, BIOCHEMISTRY, vol. 28;20, no. 9, April 1981 (1981-04-01), pages 2361 - 70 |
ELLMAN ET AL., METH. ENZYM., vol. 202, 1991, pages 301 - 336 |
GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163 |
HARLOWE; LANE: "Antibodies: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY |
HOOGENBOOM ET AL., J. MOL. BIOL., vol. 227, 1991, pages 381 |
JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI., vol. 90, 1993, pages 2551 |
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991 |
KABAT, J. BIOL. CHEM., vol. 252, 1977, pages 6609 - 6616 |
KOZBOR, J. IMMUNOL., vol. 133, 1984, pages 3001 |
KUNKEL, PROC. NATL. ACAD. SCI., vol. 82, 1987, pages 488 |
MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783 |
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554 |
MENDEZ, MJ ET AL., NATURE GENETICS, vol. 15, 1997, pages 146 |
MILLSTEIN ET AL., NATURE, vol. 305, 1983, pages 537 - 539 |
MORRISON ET AL., PROC. NAT. ACAD. SCI, vol. 81, 1984, pages 6851 |
PLUCKTHUN; SKERRA, METH. ENZYMOL., vol. 178, 1989, pages 497 - 515 |
PRESTA ET AL., J. IMMUNOL., vol. 151, 1993, pages 2623 |
REFF ET, BLOOD, vol. 83, 1994, pages 435 - 445 |
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 327 |
SIMS ET AL., J. IMMUNOL., vol. 151, 1993, pages 2296 |
SONDERMANN ET AL., NATURE, vol. 406, 2000, pages 267 |
TRAUNECKER ET AL., EMBO J., vol. 10, 1991, pages 3655 - 3659 |
VALLETTE ET AL., NUC. ACIDS RES, vol. 17, 1989, pages 723 - 733 |
VAUGHAN, NATURE BIOTECH, vol. 14, 1996, pages 309 |
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536 |
WATERHOUSE ET AL., NUC. ACIDS. RES, vol. 21, 1993, pages 2265 - 2266 |
WELLS ET AL., GENE, vol. 34, 1985, pages 315 - 323 |
WOLFENSTEIN-TODEL C ET AL: "THE AMINO-ACID SEQUENCE OF HEAVY CHAIN DISEASE PROTEIN ZUC STRUCTURE OF THE FC FRAGMENT OF IMMUNO GLOBULIN G-3", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 71, no. 4, 1976, pages 907 - 914, XP009046941, ISSN: 0006-291X * |
ZUCKERMAN ET AL., CRC CRIT REV MICROBIOL, vol. 7, no. 1, 1978, pages 1 - 26 |
Cited By (505)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10233247B2 (en) | 1999-04-09 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Method of modulating the activity of functional immune molecules |
US8679491B2 (en) | 1999-04-09 | 2014-03-25 | Kyowa Hakko Kirin Co., Ltd. | Method of modulating the activity of functional immune molecules |
US8895266B2 (en) | 2000-10-06 | 2014-11-25 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US9409982B2 (en) | 2000-10-06 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US8367407B2 (en) | 2000-10-06 | 2013-02-05 | Kyowa Hakko Kirin Co., Ltd. | Cells with altered fucosylation and producing antibodies therefrom |
US8329443B2 (en) | 2000-10-06 | 2012-12-11 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US8110195B2 (en) | 2000-10-06 | 2012-02-07 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody |
US10233475B2 (en) | 2000-10-06 | 2019-03-19 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell |
US8067232B2 (en) | 2000-10-06 | 2011-11-29 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase |
US8158760B2 (en) | 2000-10-06 | 2012-04-17 | Kyowa Hakko Kirin Co., Ltd | Glycoengineered, recombinant antibody |
US8039595B2 (en) | 2000-10-06 | 2011-10-18 | Kyowa Hakko Kirin Co., Ltd. | Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation |
US8101185B2 (en) | 2000-10-06 | 2012-01-24 | Kyowa Hakko Kirin Co., Ltd. | Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation |
US8124731B2 (en) | 2002-03-01 | 2012-02-28 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8734791B2 (en) | 2002-03-01 | 2014-05-27 | Xencor, Inc. | Optimized fc variants and methods for their generation |
US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8946387B2 (en) | 2002-08-14 | 2015-02-03 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8968730B2 (en) | 2002-08-14 | 2015-03-03 | Macrogenics Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8809503B2 (en) | 2002-09-27 | 2014-08-19 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9353187B2 (en) | 2002-09-27 | 2016-05-31 | Xencor, Inc. | Optimized FC variants and methods for their generation |
US8858937B2 (en) | 2002-09-27 | 2014-10-14 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8383109B2 (en) | 2002-09-27 | 2013-02-26 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8039592B2 (en) | 2002-09-27 | 2011-10-18 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US10184000B2 (en) | 2002-09-27 | 2019-01-22 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8093359B2 (en) | 2002-09-27 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9193798B2 (en) | 2002-09-27 | 2015-11-24 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
US10183999B2 (en) | 2002-09-27 | 2019-01-22 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US9028815B2 (en) | 2003-01-09 | 2015-05-12 | Macrogenics, Inc. | Identification and engineering of antibodies with variant FC regions and methods of using same |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US8951517B2 (en) | 2003-01-09 | 2015-02-10 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US9663582B2 (en) | 2003-03-03 | 2017-05-30 | Xencor, Inc. | Optimized Fc variants |
US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
US10584176B2 (en) | 2003-03-03 | 2020-03-10 | Xencor, Inc. | Fc variants with increased affinity for FcγRIIc |
US10113001B2 (en) | 2003-03-03 | 2018-10-30 | Xencor, Inc. | Fc variants with increased affinity for FcyRIIc |
US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
US8735545B2 (en) | 2003-03-03 | 2014-05-27 | Xencor, Inc. | Fc variants having increased affinity for fcyrllc |
US9657106B2 (en) | 2003-03-03 | 2017-05-23 | Xencor, Inc. | Optimized Fc variants |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
US11168125B2 (en) | 2003-05-06 | 2021-11-09 | Bioverativ Therapeutics Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
US8318917B2 (en) | 2003-08-22 | 2012-11-27 | Biogen Idec Ma Inc. | Nucleic acids encoding antibodies having altered effector function and methods for making the same |
US7863419B2 (en) | 2003-08-22 | 2011-01-04 | Biogen Idec Ma Inc. | Antibodies having altered effector function and methods for making the same |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
US8618252B2 (en) | 2003-11-12 | 2013-12-31 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
US8133982B2 (en) | 2004-05-10 | 2012-03-13 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
US8871907B2 (en) * | 2004-05-31 | 2014-10-28 | Korea Prime Pharm Co., Ltd | Glycosylated immunoglobulin and immunoadhesin comprising the same |
WO2006085967A3 (en) * | 2004-07-09 | 2007-02-15 | Xencor Inc | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
EP3342782A1 (en) * | 2004-07-15 | 2018-07-04 | Xencor, Inc. | Optimized fc variants |
WO2006019447A1 (en) * | 2004-07-15 | 2006-02-23 | Xencor, Inc. | Optimized fc variants |
US11820830B2 (en) | 2004-07-20 | 2023-11-21 | Xencor, Inc. | Optimized Fc variants |
US8961976B2 (en) | 2004-07-26 | 2015-02-24 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
WO2006020114A2 (en) * | 2004-08-04 | 2006-02-23 | Applied Molecular Evolution, Inc. | Variant fc regions |
WO2006020114A3 (en) * | 2004-08-04 | 2006-04-06 | Applied Molecular Evolution | Variant fc regions |
EA012464B1 (en) * | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Antibody against cd20 and use thereof |
US7740847B2 (en) | 2004-08-04 | 2010-06-22 | Applied Molecular Evolution, Inc. | Variant Fc regions |
US7659374B2 (en) | 2004-08-16 | 2010-02-09 | Medimmune, Llc | Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US8318907B2 (en) | 2004-11-12 | 2012-11-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US11198739B2 (en) | 2004-11-12 | 2021-12-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8324351B2 (en) | 2004-11-12 | 2012-12-04 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9803023B2 (en) | 2004-11-12 | 2017-10-31 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8338574B2 (en) | 2004-11-12 | 2012-12-25 | Xencor, Inc. | FC variants with altered binding to FCRN |
US8852586B2 (en) | 2004-11-12 | 2014-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8883973B2 (en) | 2004-11-12 | 2014-11-11 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
US10336818B2 (en) | 2004-11-12 | 2019-07-02 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2006105338A3 (en) * | 2005-03-31 | 2007-03-29 | Xencor Inc | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
US11254748B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9889197B2 (en) | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US11254747B2 (en) | 2005-04-15 | 2022-02-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US10093739B2 (en) | 2005-04-15 | 2018-10-09 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US10093738B2 (en) | 2005-04-15 | 2018-10-09 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US8697396B2 (en) | 2005-04-26 | 2014-04-15 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
US8008443B2 (en) | 2005-04-26 | 2011-08-30 | Medimmune, Llc | Modulation of antibody effector function by hinge domain engineering |
US8309690B2 (en) | 2005-07-01 | 2012-11-13 | Medimmune, Llc | Integrated approach for generating multidomain protein therapeutics |
US8697071B2 (en) | 2005-08-10 | 2014-04-15 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
US9040041B2 (en) | 2005-10-03 | 2015-05-26 | Xencor, Inc. | Modified FC molecules |
US9574006B2 (en) | 2005-10-06 | 2017-02-21 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US7973136B2 (en) | 2005-10-06 | 2011-07-05 | Xencor, Inc. | Optimized anti-CD30 antibodies |
US9567389B2 (en) | 2005-10-14 | 2017-02-14 | Medimmune, Llc | Cell display of antibody libraries |
US8409568B2 (en) | 2005-10-14 | 2013-04-02 | Medimmune, Llc | Mutant antibody Fc domains and fusion proteins thereof |
US10654940B2 (en) | 2005-11-15 | 2020-05-19 | Genentech, Inc. | Method for treating joint damage |
US10450379B2 (en) | 2005-11-15 | 2019-10-22 | Genetech, Inc. | Method for treating joint damage |
WO2007080274A1 (en) * | 2005-12-16 | 2007-07-19 | Lfb Biotechnologies | Antibody characterization test |
EP1991572A2 (en) * | 2006-02-17 | 2008-11-19 | Syntonix Pharmaceuticals, Inc. | Peptides that block the binding of igg to fcrn |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
EP2011870A4 (en) * | 2006-04-14 | 2010-09-15 | Medical & Biol Lab Co Ltd | Mutant polypeptide having effector function |
WO2007119796A1 (en) * | 2006-04-14 | 2007-10-25 | Medical And Biological Laboratories Co., Ltd. | Mutant polypeptide having effector function |
EP2011870A1 (en) * | 2006-04-14 | 2009-01-07 | Medical and Biological Laboratories Co., Ltd. | Mutant polypeptide having effector function |
JP5242382B2 (en) * | 2006-04-14 | 2013-07-24 | 株式会社医学生物学研究所 | Polypeptide variant having effector function |
US10100116B2 (en) | 2006-06-26 | 2018-10-16 | Macrogenics, Inc. | FcγRIIB-specific antibodies and methods of use thereof |
US11098125B2 (en) | 2006-06-26 | 2021-08-24 | Macrogenics, Inc. | FcγRIIB-specific antibodies and methods of use thereof |
US9737599B2 (en) | 2006-06-26 | 2017-08-22 | Macrogenics, Inc. | Combination of FcγRIIB-specific antibodies and CD20-specific antibodies and methods of use thereof |
WO2008008482A2 (en) * | 2006-07-13 | 2008-01-17 | Genentech, Inc. | Altered br3-binding polypeptides |
WO2008008482A3 (en) * | 2006-07-13 | 2008-06-19 | Genentech Inc | Altered br3-binding polypeptides |
US9803020B2 (en) | 2006-08-14 | 2017-10-31 | Xencor, Inc. | Optimized antibodies that target CD19 |
US11618788B2 (en) | 2006-08-14 | 2023-04-04 | Xencor, Inc. | Optimized antibodies that target CD19 |
US10626182B2 (en) | 2006-08-14 | 2020-04-21 | Xencor, Inc. | Optimized antibodies that target CD19 |
US8524867B2 (en) | 2006-08-14 | 2013-09-03 | Xencor, Inc. | Optimized antibodies that target CD19 |
JPWO2008032833A1 (en) * | 2006-09-14 | 2010-01-28 | 株式会社医学生物学研究所 | Antibody with enhanced ADCC activity and method for producing the same |
WO2008032833A1 (en) * | 2006-09-14 | 2008-03-20 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
US8394374B2 (en) | 2006-09-18 | 2013-03-12 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US9040042B2 (en) | 2006-09-18 | 2015-05-26 | Xencor, Inc. | Optimized antibodies that target HM1.24 |
US10711069B2 (en) | 2006-12-08 | 2020-07-14 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
US11787871B2 (en) | 2006-12-08 | 2023-10-17 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having fc regions with altered affinities for FcgammaRactivating and FegammaRinhibiting |
US9708408B2 (en) | 2006-12-08 | 2017-07-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc Regions with altered affinities for FcγRactivating and FcγRinhibiting |
EP2377527A1 (en) | 2007-01-22 | 2011-10-19 | Genentech, Inc. | Polyelectrolyte precipitation and purification of antibodies |
JP5071942B2 (en) * | 2007-01-24 | 2012-11-14 | 協和発酵キリン株式会社 | Recombinant antibody composition with enhanced effector activity |
EP2119780A1 (en) * | 2007-01-24 | 2009-11-18 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
EP2119780A4 (en) * | 2007-01-24 | 2010-08-25 | Kyowa Hakko Kirin Co Ltd | Genetically recombinant antibody composition having enhanced effector activity |
US8492526B2 (en) | 2007-01-24 | 2013-07-23 | Kyowa Hakko Kirin Co., Ltd. | Effector function enhanced recombinant antibody composition |
US7994290B2 (en) | 2007-01-24 | 2011-08-09 | Kyowa Hakko Kirin Co., Ltd | Effector function enhanced recombinant antibody composition |
EP2703011A2 (en) | 2007-05-07 | 2014-03-05 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2737907A2 (en) | 2007-05-07 | 2014-06-04 | MedImmune, LLC | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
JP2009095249A (en) * | 2007-10-12 | 2009-05-07 | Igaku Seibutsugaku Kenkyusho:Kk | Antibody improved in effector function |
WO2009054435A1 (en) | 2007-10-24 | 2009-04-30 | Otsuka Chemical Co., Ltd. | Polypeptide having enhanced effector function |
US11932685B2 (en) | 2007-10-31 | 2024-03-19 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8795667B2 (en) | 2007-12-19 | 2014-08-05 | Macrogenics, Inc. | Compositions for the prevention and treatment of smallpox |
EP2604628A2 (en) | 2007-12-21 | 2013-06-19 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4R) - 173 |
EP3211010A1 (en) | 2007-12-21 | 2017-08-30 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (il-4r) - 173 |
WO2009092011A1 (en) | 2008-01-18 | 2009-07-23 | Medimmune, Llc | Cysteine engineered antibodies for site-specific conjugation |
US8993730B2 (en) | 2008-04-02 | 2015-03-31 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US10479831B2 (en) | 2008-04-02 | 2019-11-19 | Macrogenics, Inc | BCR-complex-specific antibodies and methods of using same |
US9469692B2 (en) | 2008-04-02 | 2016-10-18 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US9695236B2 (en) | 2008-04-02 | 2017-07-04 | Macrogenics, Inc. | BCR-complex-specific antibodies and methods of using same |
US12024569B2 (en) | 2008-04-02 | 2024-07-02 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US11028183B2 (en) | 2008-04-02 | 2021-06-08 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US10131713B2 (en) | 2008-04-02 | 2018-11-20 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using same |
US9243069B2 (en) | 2008-04-02 | 2016-01-26 | Macrogenics, Inc. | HER2/neu-specific antibodies and methods of using the same |
US10472623B2 (en) | 2008-04-11 | 2019-11-12 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
US9868948B2 (en) | 2008-04-11 | 2018-01-16 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US9890377B2 (en) | 2008-04-11 | 2018-02-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11371039B2 (en) | 2008-04-11 | 2022-06-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
US11359194B2 (en) | 2008-04-11 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding two or more antigen molecules repeatedly |
WO2010001908A1 (en) | 2008-06-30 | 2010-01-07 | 協和発酵キリン株式会社 | Anti-cd27 antibody |
US9994642B2 (en) | 2008-09-16 | 2018-06-12 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
EP3747464A1 (en) | 2008-09-16 | 2020-12-09 | F. Hoffmann-La Roche AG | Methods for treating progessive multiple sclerosis using an anti-cd20 antibody |
EP3095463A2 (en) | 2008-09-16 | 2016-11-23 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
EP4364800A2 (en) | 2008-09-16 | 2024-05-08 | F. Hoffmann-La Roche AG | Methods for treating progressive multiple sclerosis |
US9683047B2 (en) | 2008-09-16 | 2017-06-20 | Genentech, Inc. | Methods for treating progressive multiple sclerosis |
WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
WO2010074266A1 (en) | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | Anti-cd4 antibody |
WO2010078526A1 (en) | 2008-12-31 | 2010-07-08 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
US9376672B2 (en) | 2009-08-24 | 2016-06-28 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US9758776B2 (en) | 2009-08-24 | 2017-09-12 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
US11401348B2 (en) | 2009-09-02 | 2022-08-02 | Xencor, Inc. | Heterodimeric Fc variants |
US9096877B2 (en) | 2009-10-07 | 2015-08-04 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
US11306297B2 (en) | 2009-11-02 | 2022-04-19 | University Of Washington | Therapeutic nuclease compositions and methods |
EP3202898A1 (en) | 2009-11-02 | 2017-08-09 | University of Washington | Therapeutic nuclease compositions and methods |
WO2011053982A2 (en) | 2009-11-02 | 2011-05-05 | University Of Washington | Therapeutic nuclease compositions and methods |
US9790479B2 (en) | 2009-11-02 | 2017-10-17 | University Of Washington | Therapeutic nuclease compositions and methods |
US8841416B2 (en) | 2009-11-02 | 2014-09-23 | University Of Washington | Therapeutic nuclease compositions and methods |
US10000745B2 (en) | 2009-11-02 | 2018-06-19 | University Of Washington | Therapeutic nuclease compositions and methods |
EP3460056A1 (en) | 2009-11-02 | 2019-03-27 | University Of Washington | Therapeutic nuclease compositions and methods |
US9475881B2 (en) | 2010-01-19 | 2016-10-25 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2011100403A1 (en) | 2010-02-10 | 2011-08-18 | Immunogen, Inc | Cd20 antibodies and uses thereof |
CN102782131A (en) * | 2010-03-02 | 2012-11-14 | 协和发酵麒麟株式会社 | Modified antibody composition |
JP5820800B2 (en) * | 2010-03-02 | 2015-11-24 | 協和発酵キリン株式会社 | Modified antibody composition |
JPWO2011108502A1 (en) * | 2010-03-02 | 2013-06-27 | 協和発酵キリン株式会社 | Modified antibody composition |
US10040861B2 (en) | 2010-03-02 | 2018-08-07 | Kyowa Hakko Kirin Co., Ltd. | Antibody variants composition |
US9556279B2 (en) | 2010-03-02 | 2017-01-31 | Kyowa Hakko Kirin Co., Ltd. | Antibody variants composition |
WO2011108502A1 (en) | 2010-03-02 | 2011-09-09 | 協和発酵キリン株式会社 | Modified antibody composition |
US9896508B2 (en) | 2010-03-04 | 2018-02-20 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9714295B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US10683364B2 (en) | 2010-03-04 | 2020-06-16 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9714296B2 (en) | 2010-03-04 | 2017-07-25 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
US9441049B2 (en) | 2010-03-04 | 2016-09-13 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and uses thereof |
US10730945B2 (en) | 2010-03-04 | 2020-08-04 | Macrogenics, Inc. | Antibodies reactive with B7-H3 and users thereof |
WO2012006633A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
WO2012006635A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Processable single chain molecules and polypeptides made using same |
EP3560962A1 (en) | 2010-07-09 | 2019-10-30 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
US9856468B2 (en) | 2010-07-09 | 2018-01-02 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
US10927362B2 (en) | 2010-07-09 | 2021-02-23 | Bioverativ Therapeutics Inc. | Processable single chain molecules and polypeptides made using same |
US10968442B2 (en) | 2010-07-09 | 2021-04-06 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
WO2012018771A1 (en) | 2010-08-03 | 2012-02-09 | Genentech, Inc. | Chronic lymphocytic leukemia (cll) biomarkers |
EP4029881A1 (en) | 2010-11-08 | 2022-07-20 | F. Hoffmann-La Roche AG | Subcutaneously administered anti-il-6 receptor antibody |
EP3351559A2 (en) | 2010-11-08 | 2018-07-25 | F. Hoffmann-La Roche AG | Subcutaneously administered anti-il-6 receptor antibody |
WO2012064627A2 (en) | 2010-11-08 | 2012-05-18 | Genentech, Inc. | Subcutaneously administered anti-il-6 receptor antibody |
EP2787007A2 (en) | 2010-11-08 | 2014-10-08 | F. Hoffmann-La Roche AG | Subcutaneously administered ANTI-IL-6 receptor antibody |
US11891434B2 (en) | 2010-11-30 | 2024-02-06 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly |
US11718678B2 (en) | 2011-02-25 | 2023-08-08 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
US10618965B2 (en) | 2011-02-25 | 2020-04-14 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
EP3415528A2 (en) | 2011-04-13 | 2018-12-19 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US9469676B2 (en) | 2011-04-13 | 2016-10-18 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
WO2012142515A2 (en) | 2011-04-13 | 2012-10-18 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
EP3896083A1 (en) | 2011-04-13 | 2021-10-20 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US10214579B2 (en) | 2011-04-13 | 2019-02-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
EP3144320A1 (en) | 2011-04-13 | 2017-03-22 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
US11578141B2 (en) * | 2011-04-20 | 2023-02-14 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
US11034944B2 (en) | 2011-04-29 | 2021-06-15 | University Of Washington | Therapeutic nuclease compositions and methods |
US8937157B2 (en) | 2011-04-29 | 2015-01-20 | University Of Washington | Therapeutic nuclease compositions and methods |
WO2012149440A2 (en) | 2011-04-29 | 2012-11-01 | University Of Washington | Therapeutic nuclease compositions and methods |
EP3449933A1 (en) | 2011-04-29 | 2019-03-06 | University of Washington | Therapeutic nuclease compositions and methods |
US10202588B2 (en) | 2011-04-29 | 2019-02-12 | The University Of Washington | Therapeutic nuclease compositions and methods |
US9376495B2 (en) | 2011-05-21 | 2016-06-28 | Macrogenics, Inc. | Deimmunized serum-binding domains and their use in extending serum half-life |
EP3527218A1 (en) | 2011-06-10 | 2019-08-21 | Bioverativ Therapeutics Inc. | Pro-coagulant compounds and methods of use thereof |
US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
WO2012176779A1 (en) | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | Anti-erbb3 antibody |
AU2017272140B2 (en) * | 2011-07-06 | 2019-09-26 | Genmab B.V. | Antibody variants and uses thereof |
WO2013004842A3 (en) * | 2011-07-06 | 2013-04-04 | Genmab A/S | Antibody variants and uses thereof |
EP3970746A3 (en) * | 2011-07-06 | 2022-08-03 | Genmab B.V. | Polypeptide variants and uses thereof |
US10759867B2 (en) | 2011-07-06 | 2020-09-01 | Genmab B.V. | Antibody variants and uses thereof |
AU2012280222B2 (en) * | 2011-07-06 | 2017-09-14 | Genmab B.V. | Antibody variants and uses thereof |
US12049512B2 (en) | 2011-07-06 | 2024-07-30 | Genmab B.V. | Antibody variants and uses thereof |
AU2012280222B8 (en) * | 2011-07-06 | 2017-12-07 | Genmab B.V. | Antibody variants and uses thereof |
AU2012280222A8 (en) * | 2011-07-06 | 2017-12-07 | Genmab B.V. | Antibody variants and uses thereof |
WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
US11186638B2 (en) | 2011-09-12 | 2021-11-30 | Genzyme Corporation | Anti-αβTCR antibody |
WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
US11827699B2 (en) | 2011-09-30 | 2023-11-28 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing antibodies promoting disappearance of antigens having plurality of biological activities |
EP3939996A1 (en) | 2011-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013047729A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule inducing immune response to target antigen |
WO2013047748A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
WO2013047752A1 (en) | 2011-09-30 | 2013-04-04 | 中外製薬株式会社 | Antigen-binding molecule for promoting loss of antigens |
EP3680251A1 (en) | 2011-09-30 | 2020-07-15 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules for promoting elimination of antigens |
US10793633B2 (en) | 2011-09-30 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US10253100B2 (en) | 2011-09-30 | 2019-04-09 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
AU2012313670B2 (en) * | 2011-09-30 | 2017-06-15 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance |
WO2013081143A1 (en) | 2011-11-30 | 2013-06-06 | 中外製薬株式会社 | Drug containing carrier into cell for forming immune complex |
US11820793B2 (en) | 2011-11-30 | 2023-11-21 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
EP3517550A1 (en) | 2011-11-30 | 2019-07-31 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
US11136398B2 (en) | 2011-12-05 | 2021-10-05 | X-Body, Inc. | PDGF receptor beta binding polypeptides |
WO2013085972A1 (en) | 2011-12-05 | 2013-06-13 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
EP3712173A1 (en) | 2011-12-05 | 2020-09-23 | X-Body, Inc. | Pdgf receptor beta binding polypeptides |
WO2013093809A1 (en) | 2011-12-23 | 2013-06-27 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
WO2013100120A1 (en) | 2011-12-28 | 2013-07-04 | 中外製薬株式会社 | Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient |
US11370827B2 (en) | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
EP3505179A1 (en) | 2012-01-12 | 2019-07-03 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
US11685771B2 (en) | 2012-02-15 | 2023-06-27 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
US10370430B2 (en) | 2012-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Recombinant factor VIII proteins |
US10421798B2 (en) | 2012-02-15 | 2019-09-24 | Bioverativ Therapeutics Inc. | Factor VIII compositions and methods of making and using same |
EP3246339A1 (en) | 2012-03-28 | 2017-11-22 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
WO2013148296A1 (en) | 2012-03-28 | 2013-10-03 | Sanofi | Antibodies to bradykinin b1 receptor ligands |
WO2013147153A1 (en) | 2012-03-29 | 2013-10-03 | 株式会社未来創薬研究所 | Anti-lamp5 antibody and utilization thereof |
WO2013169657A1 (en) | 2012-05-07 | 2013-11-14 | Sanofi | Methods for preventing biofilm formation |
US11827701B2 (en) | 2012-05-23 | 2023-11-28 | argenx BV | IL-6 binding molecules |
US11117959B2 (en) | 2012-05-23 | 2021-09-14 | Argenx Bvba | IL-6 binding molecules |
WO2013175427A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V. | Il-6 binding molecules |
WO2013175276A1 (en) | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
US10183995B2 (en) | 2012-05-23 | 2019-01-22 | Argen-X N.V. | IL-6 binding molecules |
EP3795215A1 (en) | 2012-05-30 | 2021-03-24 | Chugai Seiyaku Kabushiki Kaisha | Target tissue-specific antigen-binding molecule |
EP3892638A1 (en) | 2012-05-30 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
WO2013180200A1 (en) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | Target-tissue-specific antigen-binding molecule |
WO2013180201A1 (en) | 2012-05-30 | 2013-12-05 | 中外製薬株式会社 | Antigen-binding molecule for eliminating aggregated antigens |
WO2013185114A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Chimeric clotting factors |
EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
WO2013185113A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
US11261437B2 (en) | 2012-06-08 | 2022-03-01 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
EP3693000A1 (en) | 2012-06-08 | 2020-08-12 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
US11168316B2 (en) | 2012-06-08 | 2021-11-09 | Bioverativ Therapeutics, Inc. | Chimeric clotting factors |
US10287564B2 (en) | 2012-06-08 | 2019-05-14 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
EP3404105A1 (en) | 2012-07-06 | 2018-11-21 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
WO2014006217A1 (en) * | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) * | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
WO2014007303A1 (en) | 2012-07-06 | 2014-01-09 | 学校法人 聖マリアンナ医科大学 | Therapeutic method and remedy for htlv-1-associated myelopathy patients |
US11091534B2 (en) | 2012-07-11 | 2021-08-17 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
EP4269431A1 (en) | 2012-07-11 | 2023-11-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
EP3674410A1 (en) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc. | Factor viii complex with xten and von willebrand factor protein, and uses thereof |
US10919953B2 (en) | 2012-08-24 | 2021-02-16 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific Fc region variant |
US10836813B2 (en) | 2012-09-12 | 2020-11-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
EP4223783A2 (en) | 2012-09-12 | 2023-08-09 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
EP2925350B1 (en) | 2012-12-03 | 2019-01-30 | Bristol-Myers Squibb Company | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
WO2014088040A1 (en) | 2012-12-06 | 2014-06-12 | 国立大学法人 金沢大学 | Method for treating mesothelioma |
EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
WO2014097648A1 (en) | 2012-12-21 | 2014-06-26 | 中外製薬株式会社 | Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective |
EP3557260A1 (en) | 2012-12-21 | 2019-10-23 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
WO2014108198A1 (en) | 2013-01-10 | 2014-07-17 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
EP3744728A1 (en) | 2013-02-12 | 2020-12-02 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
WO2014126884A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP3617220A1 (en) | 2013-02-12 | 2020-03-04 | Bristol-Myers Squibb Company | High ph protein refolding methods |
WO2014126871A1 (en) | 2013-02-12 | 2014-08-21 | Bristol-Myers Squibb Company | Tangential flow filtration based protein refolding methods |
EP3299378A1 (en) | 2013-02-12 | 2018-03-28 | Bristol-Myers Squibb Company | High ph protein refolding methods |
EP4223772A2 (en) | 2013-02-15 | 2023-08-09 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
US11787851B2 (en) | 2013-02-15 | 2023-10-17 | Bioverativ Therapeutics Inc. | Optimized factor VIII gene |
WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
EP3889173A1 (en) | 2013-02-15 | 2021-10-06 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
US10370431B2 (en) | 2013-02-15 | 2019-08-06 | Bioverativ Therapeutics Inc. | Optimized factor VIII gene |
US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
US10214589B2 (en) | 2013-03-11 | 2019-02-26 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
EP3424956A1 (en) | 2013-03-11 | 2019-01-09 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
US11807690B2 (en) | 2013-03-11 | 2023-11-07 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
EP4063389A2 (en) | 2013-03-11 | 2022-09-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US10494439B2 (en) | 2013-03-11 | 2019-12-03 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
WO2014164503A1 (en) | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
EP4098663A1 (en) | 2013-03-11 | 2022-12-07 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
WO2014164534A2 (en) | 2013-03-11 | 2014-10-09 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
US11130816B2 (en) | 2013-03-11 | 2021-09-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US9580511B2 (en) | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
US10730947B2 (en) | 2013-03-14 | 2020-08-04 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
US11421031B2 (en) | 2013-03-14 | 2022-08-23 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
US9908938B2 (en) | 2013-03-14 | 2018-03-06 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof |
WO2014144791A2 (en) | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US11642398B2 (en) | 2013-03-15 | 2023-05-09 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
US10745483B2 (en) | 2013-03-15 | 2020-08-18 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
EP3666886A1 (en) | 2013-03-15 | 2020-06-17 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US11267868B2 (en) | 2013-04-02 | 2022-03-08 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
WO2014208482A1 (en) | 2013-06-24 | 2014-12-31 | 中外製薬株式会社 | Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma |
EP3875106A1 (en) | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
US10947269B2 (en) | 2013-08-08 | 2021-03-16 | Bioverativ Therapeutics Inc. | Purification of chimeric FVIII molecules |
US10344092B2 (en) | 2013-08-09 | 2019-07-09 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
US11384149B2 (en) | 2013-08-09 | 2022-07-12 | Macrogenics, Inc. | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof |
US9845363B2 (en) | 2013-08-13 | 2017-12-19 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (PAI-1) and uses thereof |
EP3620472A1 (en) | 2013-08-13 | 2020-03-11 | Sanofi | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
US9822181B2 (en) | 2013-08-23 | 2017-11-21 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof |
US9932400B2 (en) | 2013-08-23 | 2018-04-03 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
US10858430B2 (en) | 2013-08-23 | 2020-12-08 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
US10787521B2 (en) | 2013-08-23 | 2020-09-29 | Macrogenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof |
EP3903599A1 (en) | 2013-09-25 | 2021-11-03 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
US11578098B2 (en) | 2013-09-25 | 2023-02-14 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
WO2015066557A1 (en) | 2013-10-31 | 2015-05-07 | Resolve Therapeutics, Llc | Therapeutic nuclease molecules with altered glycosylation and methods |
US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
US10584147B2 (en) | 2013-11-08 | 2020-03-10 | Biovertiv Therapeutics Inc. | Procoagulant fusion compound |
EP3763813A1 (en) | 2013-12-04 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
WO2015083764A1 (en) | 2013-12-04 | 2015-06-11 | 中外製薬株式会社 | Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules |
WO2015085210A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
US10106611B2 (en) | 2013-12-06 | 2018-10-23 | Dana-Farber Cancer Institute, Inc. | Antibodies that bind to MHC class I polypeptide-related sequence A |
EP4389139A2 (en) | 2014-01-10 | 2024-06-26 | Bioverativ Therapeutics Inc. | Factor viii chimeric proteins and uses thereof |
US11192936B2 (en) | 2014-01-10 | 2021-12-07 | Bioverativ Therapeutics Inc. | Factor VIII chimeric proteins and uses thereof |
EP4176894A1 (en) | 2014-01-10 | 2023-05-10 | Bioverativ Therapeutics Inc. | Factor viii chimeric proteins and uses thereof |
WO2015106052A1 (en) | 2014-01-10 | 2015-07-16 | Biogen Ma Inc. | Factor viii chimeric proteins and uses thereof |
US10279021B2 (en) | 2014-03-14 | 2019-05-07 | Dana-Faber Cancer Institute, Inc. | Vaccine compositions and methods for restoring NKG2D pathway function against cancers |
US10995148B2 (en) | 2014-03-19 | 2021-05-04 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
EP4015535A1 (en) | 2014-03-19 | 2022-06-22 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
US11697690B2 (en) | 2014-03-19 | 2023-07-11 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
EP3712176A1 (en) | 2014-03-21 | 2020-09-23 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
WO2015143271A1 (en) | 2014-03-21 | 2015-09-24 | X-Body, Inc. | Bi-specific antigen-binding polypeptides |
US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
WO2015187835A2 (en) | 2014-06-06 | 2015-12-10 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EP3998079A1 (en) | 2014-06-06 | 2022-05-18 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
EP3610924A1 (en) | 2014-06-06 | 2020-02-19 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
WO2016046301A1 (en) | 2014-09-26 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
US10064952B2 (en) | 2014-10-09 | 2018-09-04 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
US11160874B2 (en) | 2014-10-09 | 2021-11-02 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
EP3799887A1 (en) | 2014-10-09 | 2021-04-07 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
US11584923B2 (en) | 2014-10-14 | 2023-02-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
US9969998B2 (en) | 2014-10-14 | 2018-05-15 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
WO2016061286A2 (en) | 2014-10-14 | 2016-04-21 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
EP3789399A1 (en) | 2014-11-21 | 2021-03-10 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
EP3725808A1 (en) | 2014-11-21 | 2020-10-21 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
EP4249066A2 (en) | 2014-12-23 | 2023-09-27 | Bristol-Myers Squibb Company | Antibodies to tigit |
EP3816179A2 (en) | 2015-02-05 | 2021-05-05 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant comprising a modified fcrn-binding domain |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2016196228A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
US10745680B2 (en) | 2015-08-03 | 2020-08-18 | Bioverativ Therapeutics Inc. | Factor IX fusion proteins and methods of making and using same |
WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
WO2017046994A1 (en) | 2015-09-18 | 2017-03-23 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
WO2017087678A2 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
WO2017136358A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
US11753461B2 (en) | 2016-02-01 | 2023-09-12 | Bioverativ Therapeutics Inc. | Optimized factor VIII genes |
EP4137570A1 (en) | 2016-02-01 | 2023-02-22 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
WO2017152085A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
EP4112641A1 (en) | 2016-03-15 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
WO2017161173A1 (en) | 2016-03-16 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Engineered trail for cancer therapy |
US10961311B2 (en) | 2016-04-15 | 2021-03-30 | Macrogenics, Inc. | B7-H3 binding molecules, antibody drug conjugates thereof and methods of use thereof |
US11591400B2 (en) | 2016-04-15 | 2023-02-28 | Macrogenics, Inc. | B7-H3 directed antibody drug conjugates |
US11767364B2 (en) | 2016-05-09 | 2023-09-26 | Bristol-Myers Squibb Company | TL1A antibodies and methods of treatment |
US10968279B2 (en) | 2016-05-09 | 2021-04-06 | Bristol-Myers Squibb Company | TL1A antibodies and uses thereof |
WO2017196663A1 (en) | 2016-05-09 | 2017-11-16 | Bristol-Myers Squibb Company | Tl1a antibodies and uses thereof |
WO2018005954A2 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
US11591392B2 (en) | 2016-07-14 | 2023-02-28 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
US10077306B2 (en) | 2016-07-14 | 2018-09-18 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US10533052B2 (en) | 2016-07-14 | 2020-01-14 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
US11858980B2 (en) | 2016-08-02 | 2024-01-02 | Visterra, Inc. | Engineered polypeptides and uses thereof |
WO2018044970A1 (en) | 2016-08-31 | 2018-03-08 | University Of Rochester | Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof |
US11667890B2 (en) | 2016-10-31 | 2023-06-06 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
US10415015B2 (en) | 2016-10-31 | 2019-09-17 | Iovance Biotherapeutics, Inc. | Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion |
WO2018098363A2 (en) | 2016-11-23 | 2018-05-31 | Bioverativ Therapeutics Inc. | Bispecific antibodies binding to coagulation factor ix and coagulation factor x |
WO2018101448A1 (en) | 2016-11-30 | 2018-06-07 | Kyowa Hakko Kirin Co., Ltd. | Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody |
WO2018102760A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
WO2018129336A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
WO2018139404A1 (en) | 2017-01-24 | 2018-08-02 | 協和発酵キリン株式会社 | Therapeutic or prophylactic agent and treatment or prevention method for radiation sickness |
WO2018146317A1 (en) * | 2017-02-10 | 2018-08-16 | Genmab B.V. | Polypeptide variants and uses thereof |
US11142570B2 (en) | 2017-02-17 | 2021-10-12 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
US11827695B2 (en) | 2017-02-17 | 2023-11-28 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
WO2018151821A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
WO2018159845A1 (en) | 2017-03-02 | 2018-09-07 | 学校法人 聖マリアンナ医科大学 | Preventive or therapeutic agent for htlv-1-associated myelopathy using low-dose anti-ccr4 antibody |
WO2018209115A1 (en) | 2017-05-10 | 2018-11-15 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2018213097A1 (en) | 2017-05-15 | 2018-11-22 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
WO2018218056A1 (en) | 2017-05-25 | 2018-11-29 | Birstol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
EP4098662A1 (en) | 2017-05-25 | 2022-12-07 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2019032898A1 (en) | 2017-08-09 | 2019-02-14 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
WO2019040674A1 (en) | 2017-08-22 | 2019-02-28 | Sanabio, Llc | Soluble interferon receptors and uses thereof |
WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019103857A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
WO2019118873A2 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
WO2019140229A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
WO2019152692A1 (en) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing factor viii |
WO2019160829A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
US11242393B2 (en) | 2018-03-23 | 2022-02-08 | Bristol-Myers Squibb Company | Antibodies against MICA and/or MICB and uses thereof |
WO2019191295A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
WO2019195126A1 (en) | 2018-04-02 | 2019-10-10 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
US11155618B2 (en) | 2018-04-02 | 2021-10-26 | Bristol-Myers Squibb Company | Anti-TREM-1 antibodies and uses thereof |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
US12030925B2 (en) | 2018-05-18 | 2024-07-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia A |
WO2019222682A1 (en) | 2018-05-18 | 2019-11-21 | Bioverativ Therapeutics Inc. | Methods of treating hemophilia a |
WO2019236417A1 (en) | 2018-06-04 | 2019-12-12 | Biogen Ma Inc. | Anti-vla-4 antibodies having reduced effector function |
WO2020010117A2 (en) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Fgf21 formulations |
WO2020014132A2 (en) | 2018-07-09 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to ilt4 |
WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
EP4378530A2 (en) | 2018-08-31 | 2024-06-05 | Iovance Biotherapeutics, Inc. | Use of tumor infiltrating lymphocytes for treating nsclc patients refractory for anti-pd-1 antibody |
WO2020096682A2 (en) | 2018-08-31 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
WO2020096989A1 (en) | 2018-11-05 | 2020-05-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
WO2020112781A1 (en) | 2018-11-28 | 2020-06-04 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
WO2020142740A1 (en) | 2019-01-04 | 2020-07-09 | Resolve Therapeutics, Llc | Treatment of sjogren's disease with nuclease fusion proteins |
WO2020154293A1 (en) | 2019-01-22 | 2020-07-30 | Bristol-Myers Squibb Company | Antibodies against il-7r alpha subunit and uses thereof |
US11919962B2 (en) | 2019-01-22 | 2024-03-05 | Bristol Myers-Squibb Company | Antibodies against IL-7R alpha subunit and uses thereof |
US11008395B2 (en) | 2019-01-22 | 2021-05-18 | Bristol Myers-Squibb Company | Antibodies against IL-7R alpha subunit and uses thereof |
WO2020180733A1 (en) | 2019-03-01 | 2020-09-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2020189748A1 (en) | 2019-03-19 | 2020-09-24 | 中外製薬株式会社 | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
WO2020206063A1 (en) | 2019-04-03 | 2020-10-08 | Genzyme Corporation | Anti-alpha beta tcr binding polypeptides with reduced fragmentation |
WO2020254197A1 (en) | 2019-06-18 | 2020-12-24 | Bayer Aktiengesellschaft | Adrenomedullin-analogues for long-term stabilization and their use |
WO2021011678A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Anti-trem-1 antibodies and uses thereof |
WO2021011681A1 (en) | 2019-07-15 | 2021-01-21 | Bristol-Myers Squibb Company | Antibodies against human trem-1 and uses thereof |
WO2021055698A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
WO2021067389A1 (en) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
WO2021158938A1 (en) | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
WO2021174034A1 (en) | 2020-02-28 | 2021-09-02 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
US11879004B2 (en) | 2020-02-28 | 2024-01-23 | Genzyme Corporation | Modified binding polypeptides for optimized drug conjugation |
WO2021202235A1 (en) | 2020-04-01 | 2021-10-07 | University Of Rochester | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
WO2021222935A2 (en) | 2020-04-28 | 2021-11-04 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies and methods of use thereof |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
WO2022006153A1 (en) | 2020-06-29 | 2022-01-06 | Resolve Therapeutics, Llc | Treatment of sjogren's syndrome with nuclease fusion proteins |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076952A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022098870A1 (en) | 2020-11-04 | 2022-05-12 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022133140A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
WO2022147196A2 (en) | 2020-12-31 | 2022-07-07 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2022155324A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
WO2022187741A2 (en) | 2021-03-05 | 2022-09-09 | Iovance Biotherapeutics, Inc. | Tumor storage and cell culture compositions |
WO2022198141A1 (en) | 2021-03-19 | 2022-09-22 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils |
WO2022204155A1 (en) | 2021-03-23 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2022204564A2 (en) | 2021-03-25 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Methods and compositions for t-cell coculture potency assays and use with cell therapy products |
WO2022212876A1 (en) | 2021-04-02 | 2022-10-06 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
WO2022225981A2 (en) | 2021-04-19 | 2022-10-27 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2022235867A2 (en) | 2021-05-06 | 2022-11-10 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
WO2022245754A1 (en) | 2021-05-17 | 2022-11-24 | Iovance Biotherapeutics, Inc. | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
WO2023004074A2 (en) | 2021-07-22 | 2023-01-26 | Iovance Biotherapeutics, Inc. | Method for cryopreservation of solid tumor fragments |
WO2023009716A1 (en) | 2021-07-28 | 2023-02-02 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors |
WO2023039488A1 (en) | 2021-09-09 | 2023-03-16 | Iovance Biotherapeutics, Inc. | Processes for generating til products using pd-1 talen knockdown |
WO2023049862A1 (en) | 2021-09-24 | 2023-03-30 | Iovance Biotherapeutics, Inc. | Expansion processes and agents for tumor infiltrating lymphocytes |
WO2023077015A2 (en) | 2021-10-27 | 2023-05-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023196877A1 (en) | 2022-04-06 | 2023-10-12 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
US11981921B2 (en) | 2022-04-15 | 2024-05-14 | Iovance Biotherapeutics, Inc. | TIL expansion processes using specific cytokine combinations and/or AKTi treatment |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023220608A1 (en) | 2022-05-10 | 2023-11-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist |
WO2024011114A1 (en) | 2022-07-06 | 2024-01-11 | Iovance Biotherapeutics, Inc. | Devices and processes for automated production of tumor infiltrating lymphocytes |
WO2024020579A1 (en) | 2022-07-22 | 2024-01-25 | Bristol-Myers Squibb Company | Antibodies binding to human pad4 and uses thereof |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024062074A1 (en) | 2022-09-21 | 2024-03-28 | Sanofi Biotechnology | Humanized anti-il-1r3 antibody and methods of use |
WO2024089609A1 (en) | 2022-10-25 | 2024-05-02 | Ablynx N.V. | Glycoengineered fc variant polypeptides with enhanced effector function |
WO2024098027A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection |
WO2024098024A1 (en) | 2022-11-04 | 2024-05-10 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
WO2024112571A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom |
WO2024112711A2 (en) | 2022-11-21 | 2024-05-30 | Iovance Biotherapeutics, Inc. | Methods for assessing proliferation potency of gene-edited t cells |
WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
Also Published As
Publication number | Publication date |
---|---|
DE602005015542D1 (en) | 2009-09-03 |
IL176674A0 (en) | 2006-10-31 |
UA86605C2 (en) | 2009-05-12 |
BRPI0506771A (en) | 2007-05-22 |
SI1706424T1 (en) | 2010-01-29 |
PT1706424E (en) | 2009-10-01 |
CN1918178A (en) | 2007-02-21 |
AU2005206473A1 (en) | 2005-08-04 |
NO20063624L (en) | 2006-10-03 |
CN1918178B (en) | 2012-08-22 |
KR101149242B1 (en) | 2012-05-25 |
EP1706424B1 (en) | 2009-07-22 |
JP4762156B2 (en) | 2011-08-31 |
CY1109382T1 (en) | 2014-07-02 |
EA200601313A1 (en) | 2007-02-27 |
NO339745B1 (en) | 2017-01-30 |
CA2552788C (en) | 2013-09-24 |
DK1706424T3 (en) | 2009-11-02 |
US20080089892A1 (en) | 2008-04-17 |
EA009746B1 (en) | 2008-04-28 |
EP2154157A3 (en) | 2010-04-28 |
EP1706424A1 (en) | 2006-10-04 |
JP2008502590A (en) | 2008-01-31 |
ATE437184T1 (en) | 2009-08-15 |
PL1706424T3 (en) | 2010-04-30 |
KR20060130604A (en) | 2006-12-19 |
EP2154157A2 (en) | 2010-02-17 |
ES2328369T3 (en) | 2009-11-12 |
AU2005206473B2 (en) | 2011-11-10 |
IL176674A (en) | 2016-08-31 |
CA2552788A1 (en) | 2005-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1706424B1 (en) | Fc region variants | |
AU2005274905B2 (en) | Variant Fc regions | |
US20070141052A1 (en) | Fc region variants | |
CA2323757C (en) | Antibody variants and fragments thereof | |
KR100887482B1 (en) | Polypeptide Variants with Altered Effector Function | |
US7741072B2 (en) | Polypeptide variants | |
CA2740948A1 (en) | Antibody variants and fragments thereof | |
AU2012211437B2 (en) | Polypeptide variants with altered effector function | |
MXPA06007791A (en) | Fc region variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005704868 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005206473 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3117/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006549330 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2005206473 Country of ref document: AU Date of ref document: 20050110 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005206473 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10584692 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 176674 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2552788 Country of ref document: CA Ref document number: PA/a/2006/007791 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067013897 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200601313 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580004924.8 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005704868 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067013897 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0506771 Country of ref document: BR |